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Summary
The increasing volume and availability of healthcare and biomedical data is opening
up new opportunities for the use of computational methods to improve health. However,
the data are diverse, multidimensional and sparse, posing challenges to the extraction of
clinically-meaningful relations and interactions. For example, the electronic health records
(EHRs) of patients contain time-stamped occurrences of diverse features (e.g., diagnoses,
medications, procedures) as well as information about relationships among different types
of features (e.g., identifying the subset of medications prescribed to treat a certain diagno-
sis). Such EHR data can be utilized to identify patient cohorts sharing common conditions
without expert supervision, a task known as unsupervised phenotyping. Tensors, which are
generalizations of matrices for higher orders, can naturally express the multidimensional
data relationships inherent in the EHR. Tensor factorization encompasses a set of tools
which can capture the latent correlation structure among diverse feature sets. For example,
in the context of phenotyping, tensor factorization can be utilized to identify clinically-
meaningful patient groups, along with succinct feature profiles distinguishing one group of
patients from another.
In this dissertation, we expose how tensor factorization can be leveraged to tackle sev-
eral important problems in healthcare and biomedicine. We also identify multiple signifi-
cant methodological challenges in fully harnessing the capacity of tensor factorization for
the problems at hand and develop algorithms to tackle them. In particular, we focus on the
following problems:
• Drug-perturbed, tissue-specific gene expression prediction, where we demonstrate how
tensor factorization can be used to model the interactions between drugs, genes and
tissues in an efficient manner.
• Unsupervised phenotyping through EHRs, in the context of which we advance existing
tensor factorization methods so that: a) they are fast and scalable to use for large patient
xix
cohorts of hundreds of thousands of patients; and b) they yield interpretable output, easy
to be communicated to a clinical expert.
• Automating understanding of physician desktop work. Therein, we demonstrate how
tensor factorization can be used to substantially compress audit EHR logs, offering an




Through this dissertation, we expose how tensors (i.e., generalizations of matrices
for higher orders) and tensor factorization (a set of methods capturing and organizing
the latent correlation structure in multidimensional data) can be applied and extended
to tackle several important problems in healthcare and biomedicine.
The first of the problems we consider is to accurately predict drug-perturbed and tissue-
specific gene expression values which reflect how drugs, genes and tissues interact with one
another. The expression values are indicative of whether the corresponding drug could po-
tentially treat a tissue-specific disease [1]. An accurate prediction of those expression val-
ues can be impactful for drug repurposing, by computationally identifying that an already-
approved drug may have previously-unknown therapeutic capabilities [2]. Then, focusing
on challenges in the healthcare domain, we tackle the EHR-based unsupervised phenotyp-
ing problem [3]. This problem refers to grouping patients sharing a similar condition with-
out expert supervision. Efficient unsupervised phenotyping can be impactful for several
downstream applications [4, 5]; one of them is clinical decision support, where physicians
would be able to quickly identify similar patients and make more informed decisions, when
a patient does not meet textbook treatment guidelines [4, 6, 7]. In the context of unsuper-
vised phenotyping, we improve integer-constrained tensor factorization so that it can scale
to hundreds of thousands of data samples, thus enabling the extraction of succinct and in-
terpretable feature summaries (i.e., phenotype definitions) along with the associated patient
subgroups from large cohorts. In order to extract insights which may lead to a better under-
standing of disease progression [8, 9], we further applied and extended tensor factorization
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to extract not only phenotype candidates (i.e., patient groups and associated feature sum-
maries), but also information about the timing and sequencing of those phenotypes over
time (a task we call as temporal phenotyping [10]). We also expose how such tensor-based
temporal phenotyping can be: a) applied to extract phenotypes of medically-complex chil-
dren; b) scaled up to hundreds of thousands of patients by exploiting the sparse nature of
EHR data; and c) extended to extract interpretable integer-based feature summaries indicat-
ing the phenotype definitions as well as real-valued temporal trends of phenotypes. Finally,
we tackle the problem of automating the understanding of physician desktop work. In this
context, we demonstrate how the EHR activity log file could be processed through tensor
factorization to derive an intuitive categorization of EHR user actions that can be used for
workflow analysis and improvement.
The data elements utilized in all the problems tackled as part of this thesis share several
important properties: a) they are diverse in the sense of being described by multiple differ-
ent sets of features (e.g., EHR data contain patient, diagnosis, medication, procedure and
other information); b) they are multidimensional, due to the existence of high-order inter-
connections among different sets of features (e.g., a subset of medications is prescribed to
treat a certain diagnosis for a given patient); and c) they are sparse (e.g., very few medical
features occur per patient encounter as compared to the total number of features).
Tensor factorization [11, 12, 13, 14] is a set of methods which has been successfully
used in diverse applications, such as social network analysis [15], text mining [16], image
processing [17], recommendation systems [18], brain data analysis [19, 20] and healthcare
analytics [21, 22], in order to extract the latent correlation structure in diverse, multidimen-
sional and oftentimes sparse input data. A common paradigm among tensor factorization
methods is the distillation of an input tensor to intuitive, low-dimensional representations.
For example, we can derive a patient × diagnosis × medication tensor through EHR data,
where the (i, j, k) cell reflects the number of times the i-th patient has been prescribed the
k-th medication to treat the j-th diagnosis. A popular tensor factorization model (CP [23])
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would distill this patient× diagnosis×medication tensor into low-dimensional representa-
tions which may be interpreted as: a) soft phenotype assignments, where patients can have
multiple phenotype assignments with different degrees of association; b) diagnosis and
medication-based definitions of candidate phenotypes in terms of ensembles of correlated
input features [24].
Tensor factorization belongs to the family of linear dimensionality reduction meth-
ods [25]. The advantage of those approaches over non-linear ones (e.g., autoencoders [26])
lies in that the output factors are linear transformations of the original input features, thus
enhancing the ability to interpret what those factors signify w.r.t. the known set of input
features (a property known as feature attribution [27]). On the other hand, simpler lin-
ear dimensionality reduction approaches such as matrix factorization (e.g., PCA) are not
as suitable either when modeling interconnected high-order (order > 2) relations among
different feature sets. Using matrix factorization for input data that can be most naturally
represented as a tensor would require reshaping the tensor to a matrix which leads to mix-
ing up the input features (e.g., a tensor of size I ×J ×K would be reshaped to a I ×J ∗K
matrix). As such, the effect of a single input feature (e.g., a particular diagnosis) would
be associated with multiple coordinates of an output factor matrix, which hinders inter-
pretability. Overall, for the problems we tackle in this dissertation, we argue that tensor
factorization strikes a proper balance between: a) model sophistication, in order to avoid
unnatural transformations that would turn the factorization into a simpler problem; and
b) model simplicity, in the sense that the linear relationship between the input and output
factors promotes an intuitive model interpretation.
Below, we provide a more detailed introduction for each one of the problems tackled as
part of this thesis by highlighting the motivation behind each one of them.
Drug-perturbed, cell-specific gene expression prediction
First, we are motivated by a challenge arising in the field of chemogenomics 1, that is
1Chemogenomics is defined as the study of the genomic and/or proteomic response of an intact biological
system to chemical compounds and is central in drug discovery [28].
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to identify new disease indications for approved drugs, also known as drug repositioning.
Repurposing existing, approved drugs is expected to reduce the cost of developing new
ones, which is estimated to be more than $1 billion [29] per drug. Repositioning can also
speed up the drugs’ adoption due to the fact that they have already undergone a rigorous
safety testing required by the Food and Drug Administration [2].
Gene expression measurements can be used to measure the molecular activity of a drug
in a biological system [30]. Differential gene expression measures the difference in gene
expression between the drug-perturbed tissues and the controls. Differential expression
values with large magnitude are indicative of significant change in the cells’ behavior,
meaning the drug could potentially treat the corresponding disease [1]. Despite the re-
cent expansion of publicly available chemogenomic data providing such expression values
over many drug-disease combinations [31], there still exist substantial amounts of missing
expression values in the combinatorial space across drugs and diseases [32]. Such missing
data exist mainly due to the high cost associated with producing expression values. To
computationally address this challenge, we need accurate methods filling those gaps, i.e.,
predicting the expression values for (drug, gene, tissue) triads. Another notable challenge is
provide accurate predictions for entirely new drugs, for which no measurement is available.
To do so, we could exploit domain knowledge reflecting the similarity of new drugs with
existing ones in the training set. In that way, instead of directly conducting many expen-
sive lab experiments measuring the expression for a new drug, we could try to estimate its
treatment effect first computationally. Then, we could focus on a small subset of targeted
drug trials and cut down the corresponding costs. Through Polyadic Regression [33], we
tackle the above challenges as described in Chapter 2. This work was presented at the 2017
SIAM International Conference on Data Mining (SDM).
Scalable unsupervised phenotyping through electronic health records
Next, we are focusing on the EHR-based unsupervised phenotyping problem, which is a
central topic of this dissertation. Phenotyping is defined as grouping patients together that
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have a similar condition whether this is defined within a specific disease (e.g., prediagnostic
heart failure) or for a group of related diseases. The notion of searching for phenotypes is
consistent with the recognition that people with the same named disease can differ substan-
tially by the underlying pathophysiology. Phenotyping based on EHRs refers to identifying
patients with specific, clinically-meaningful characteristics from large volumes of imper-
fect practice-based data [3]. The ability to quickly identify patients with particular traits
by using common definitions is fundamental for a variety of target tasks. We list a few
notable examples: clinical decision support, where a physician could instantaneously iden-
tify patients sharing common traits and interventions, enabling her to make more informed
decisions, in the absence of gold-standard evidence [34, 4]; automating epidemic surveil-
lance by estimating rates of a particular infection (e.g., the Centers for Disease Control and
prevention need to automatically and quickly find patients with particular traits across ge-
ographies) [35]; genetic research can be empowered by large sample sizes of well-defined
phenotypes, in order to identify genetic variations between cases and controls [36, 37];
phenotyping has the potential to streamline clinical trial recruitment as it may be used to
determine patient eligibility [5] (e.g., by pharmaceutical companies).
Manual patient phenotyping is impractical for large cohorts, since it requires labor-
intensive, time-consuming chart reviewing, which needs periodic revision [38]. Indica-
tively, the 2008 revision of the World Health Organization (WHO) classification of lym-
phoid neoplasms lasted more than a year, involving an eight-member steering committee
and over 130 pathologists and hematologists [39]. Also, only 1400 cases were reviewed
for this revision, which may result in substantial selection biases [22]. As such, automated,
scalable phenotyping approaches are fundamental in order to both remove substantial bur-
den from the domain experts and eliminate selection biases.
Even if they are not originally designed for research use, we are motivated to exploit
EHRs to fulfill an automated fulfillment of phenotyping due to the dramatic increase in the
EHR adoption [36]. As an example, 84% of the US hospitals had adopted a basic EHR
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system as of 2015 [40]. This adoption results in massive cohorts of both structured (e.g.,
diagnoses codes) and unstructured data, such as clinical notes, being readily available for
research purposes. Exploiting observational EHR data for phenotyping is arguably a more
cost-effective direction than setting up Randomized Control Trials (RCTs) to accumulate
cohorts of similar sizes [41].
Despite the aforementioned potential of exploiting EHRs for research purposes, EHR-
based phenotyping is still grounded on a secondary analysis of EHRs, which have been
originally designed for billing purposes [38]. As such, the purpose behind the design of
some of the codes may be biased towards satisfying some financial incentive [42], rather
than precisely describing a certain disease. An example is the existence of “unspecified”
codes (e.g., 041.9 stands for unspecified bacterial infections) in the International Classifi-
cation of Diseases [43], which is the most widespread approach of diagnosis coding in the
EHR. Another issue is that although the timing of a patient visit is an important and mean-
ingful feature (e.g., all diseases change over time), timing is an intricate feature to model
because all clinical visits are essentially unscheduled; unscheduled means that there is no
structure to the timing of clinical events other than that one follows another [44].
As a result of the above and other issues, EHR-based phenotyping is far more challeng-
ing than a simple code search and sophisticated methods which can distill heterogeneous
data into clinically-interpretable descriptions are needed [7]. Phenotyping based on expert-
defined rules is widely adopted, due to the simplicity of the resulting rules, which are often
expressed in form of a decision tree and boolean logic. Still, the effort and time for develop-
ing such algorithms is significant, requiring both clinical and informatics knowledge [45].
Also, expert-defined rules cannot identify novel phenotypes, which are not first envisioned
by a researcher; as such, they have limited scope for exploratory analysis [46]. Similar
issues are faced by supervised phenotyping approaches, where patient cases need to be
manually labeled through chart review [45, 47].
For the above reasons, we are motivated to study the unsupervised EHR-based pheno-
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typing problem, which tremendously reduces the time needed for manual chart review [45];
it also needs close clinical expert involvement in the phenotypes’ validation, as no clear
ground truth is given [7].
In Chapter 3, we focus on the unsupervised EHR-based phenotyping problem, where
a fixed observation window is considered for each patient (e.g., defined based on clinical
knowledge). For this window, we are interested in extracting succinct phenotype defini-
tions and associated patient clusters out of EHR data, which will be explainable and useful
to medical experts. A common way of forming input data for unsupervised phenotyping
is to produce co-occurrence count tensors. For example, a patient × diagnoses × medi-
cation tensor can be formed [24], where each (i, j, k) cell reflects the number of times the
i-th patient has been prescribed the k-th medication to treat the j-th diagnosis. In [48],
we observe that factorizing such a tensor into real-valued factors as done by prior work
(e.g., [24, 21, 49, 50, 51]) makes it hard to assess the relative importance or frequency
between different factor elements (e.g., different medical features). For example, it is hard
to understand how much more frequent is a certain diagnostic code over another within the
same phenotype. This is mostly due to the arbitrary possible ranges and relative differences
between real-valued elements. To tackle this interpretability issue in a scalable manner,
and inspired by clinical scoring systems 2, we propose SUSTain [48], an integer tensor
factorization framework for integer input tensors. The factor matrices are constrained to
a small integer set; due to the integer nature of input data, the factor scores can be inter-
preted as distinct frequency levels. Extracting such frequency levels for medical features is
crucial for phenotyping: a) increased frequency oftentimes hints increased severity of the
corresponding condition due to the inherent bias in EHRs towards recording more severe
patient conditions [52, 53, 54, 55, 56] and b) increased frequency boosts the confidence
regarding the existence of the corresponding condition in the associated patients’ records
(e.g., in rule-based phenotyping, one of the inclusion criteria is oftentimes the occurrence
2In MDCalc, one can find a vast amount of such scoring systems used in medicine.
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of at least 3 occurrences of a diagnostic code [57]). SUSTain [48] was presented at the
24th ACM SIGKDD International Conference on Knowledge Discovery and Data Mining
(KDD 2018).
In Chapter 4, we tackle the challenge of modeling and utilizing the longitudinal na-
ture of EHR data, in order to extract both the phenotype definitions and assignments to
patients, as well as information regarding when a phenotype occurred; such insights may
lead to a better understanding of disease progression [8, 9]. We call this task as temporal
unsupervised phenotyping [10]. For this task, we observe that the PARAFAC2 model [58]
is a great fit. PARAFAC2 can account for the folded structure of the input EHR data,
where each patient is represented by a sequence of encounters, each of which can be rep-
resented by a set of features recorded. In particular, it enables extracting information about
the timing and sequencing of phenotypes without requiring any ad-hoc collapsing or ag-
gregation of encounters over time which would align the events across different patients
but may also obfuscate the temporal ordering and structure of individual encounters. An-
other favorable property of PARAFAC2 is that it guarantees model uniqueness under mild
assumptions [59]. The issue with non-unique models lies in that there may exist many
arbitrarily rotated versions of a solution yielding the same approximation error and it is
unclear to the practitioner which one of those solutions provides the true latent factors.
An open challenge was that the standard algorithm fitting the PARAFAC2 model was es-
sentially designed for dense input data [60] and no scalable algorithm existed that could
exploit the sparse nature of EHR data towards scaling-up computations for large amount of
patients (e.g., hundreds of thousands). Our proposed SPARTan [51] method, described in
Chapter 4 addresses those challenges. This work was presented at the 23rd ACM SIGKDD
International Conference on Knowledge Discovery and Data Mining (KDD 2017).
In Chapter 5, we demonstrate how the PARAFAC2 factorization (as implemented in [51])
can be applied and extended to distill the EHR data of a cohort of patients facing com-
plex clinical manifestations (medically-complex children from Children’s Healthcare of
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Atlanta) into clinically-meaningful phenotype definitions, their temporal trends over time
and associated patient groups. We identify four phenotype definitions, validated by a clini-
cal expert. We also demonstrate the utility of the extracted patient representations towards
identifying groups of patients with significant survival variations. This work was published
in the Journal of Biomedical Informatics [61].
In Chapter 6, we propose the integer-constrained PARAFAC2 factorization and utilize
that to efficiently identify interpretable pre-diagnostic subtypes of heart failure (HF). Pre-
cisely identifying the various stages and progress of pre-diagnostic HF is important due
to the prevalence of the disease, its heterogeneity and the potential of developing adaptive
treatment strategies based on a better understanding of pre-diagnostic heart failure patient
progress. Through our proposed approach, we extract succinct integer-based phenotype
definitions and patient assignments to phenotypes, as well as real-valued factors indicating
the timing and sequencing of phenotypes. We quantitatively demonstrate the increased in-
terpretability of the resulting phenotypes based on integer constraints, as compared to the
corresponding real-valued model; to do so, we evaluate both in terms of model conciseness
and feature overlap across different phenotypes.
An automated way of understanding physician desktop work through EHR audit data
Finally, in Chapter 7, we explored how the EHR activity log file, a rich source of complex
time-stamped data on desktop activities, could be processed to derive scalable and quan-
tifiable physician level workflow measures. While substantial advances have been made to
improving the quality of care through the effective use of electronic health records (EHR)
data (e.g., [5]) a parallel advance has not evolved for use of log file data to understand
variability in how desktop work is done and the time required to do this work. Log files,
however, are voluminous and difficult to decipher. We explored how tensor factorization
and in particular PARAFAC2 [58] as implemented in [51] could be used to substantially
compress a log file so that it offers more intuitive and accessible data that could be used
for workflow analysis. To this end, we identified activity log record clusters that represent
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common physician tasks: 1) medications access, 2) notes access, 3) order entry access, and
4) diagnosis modification.
We also sought to determine if the same method could be used to identify variation in
how physicians completed tasks without the need of ground-truth label information. To
validate our approach, we selected documentation of notes as our focus, given that it is
well established that two dominant methods are used for this purpose when using Epic
EHR. That is, the means by which notes are accessed and documented is known. Our
results reveal two distinct clusters of physicians accessing notes by either using the Visit
Navigator or the Wrap-Up option, representing known workflows for this task. This work
was presented at the AMIA 2018 Informatics Summit.
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CHAPTER 2
POLYADIC REGRESSION AND ITS APPLICATION TO CHEMOGENOMICS
Summary
In this Chapter, we study a problem in the field of chemical genomics: in order
to identify new disease targets for already-approved drugs (aka drug repositioning),
we need to estimate the drugs’ effectiveness on several tissue-specific diseases, as
this is measured over various genes. We introduce Polyadic Regression, a method
exploiting tensor factorization to efficiently learn the interactions across different
drug, gene and tissue combinations. We demonstrate superior accuracy in predicting
drug-perturbed, cell-specific gene expression measurements over prior work model-
ing high-order interactions among diverse feature sets.
We study the problem of Polyadic Prediction, where the input consists of an ordered
tuple of objects, and the goal is to predict a measurement associated with them. Many tasks
can be naturally framed as Polyadic Prediction problems. In drug discovery, for instance,
it is important to estimate the treatment effect of a drug on various tissue-specific diseases,
as it is expressed over the available genes. Thus, we essentially predict the expression
value measurements for several (drug, gene, tissue) triads. To tackle Polyadic Prediction
problems, we propose a general framework, called Polyadic Regression, predicting mea-
surements associated with multiple objects. Our framework enables predictions in both of
the following important use cases: a) predicting missing measurements (e.g., expression
values for drug x1, gene y and tissue z), and b) predicting measurements for out-of-sample
objects (e.g., expression values involving a drug x2 which is not involved in any of the
training instances). Our model is expressive, exploring high-order, polyadic interactions in












Figure 2.1: Example use case of Polyadic Prediction. We predict a measurement (expres-
sion value) associated with drug i1, gene i2 and tissue i3, indicating whether the drug i1 is
effective in treating tissue i3, w.r.t. gene i2. Each drug is described by features capturing
its chemical structure, and each gene is described by features reflecting its similarity with
other genes.
fit our model. We perform an extensive evaluation using real-world chemogenomics data,
where we illustrate the superior performance of Polyadic Regression over the prior art. Our
method achieves an increase of 0.06 and 0.1 in Spearman correlation between the predicted
and the actual measurement vectors, for predicting missing polyadic data and predicting
polyadic data for new drugs, respectively.
2.1 Introduction
Dyadic data are measurements on dyads, i.e., ordered pairs, where each element of a pair
originates from a finite set (i.e., data domain) of objects [62]. Typically, those data are
represented in a matrix, where a measurement for a pair (i, j) represents some form of
relationship between the objects i and j (e.g., user i and movie j are two objects of user and
movie data domains, and the corresponding rating reflects a certain relationship between the
two objects). We generalize the notion of dyadic data to describe measurements associated
with multiple objects (not only pairs), and call the corresponding data polyadic.
We study the problem of Polyadic Prediction, that is, predicting polyadic data. This
problem covers many important use cases. For instance, in drug discovery, we are interested
in the treatment efficacy of drugs on various types of tissue-specific diseases (e.g., different
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types of cancer), as this is measured by the expression regarding all the available genes.
While thousands of gene expression profiles (i.e., expression values for accessible genes)
are available, substantial gaps remain in the combinatorial space across drugs and tissues.
The reason for that is mainly the cost associated with producing expression values. An
accurate prediction of missing expression values can empower a better understanding of
drug mechanisms, a more precise identification of drug targets (i.e., specific proteins), as
well as finding new uses for existing drugs (known as drug repositioning) [63].
We can naturally frame the challenge above as a Polyadic Prediction problem: our data
domains correspond to the sets of objects: drugs, genes, and tissues. Given the observed
measurements for triads involving a specific object from each data domain, we are inter-
ested in predicting unseen triadic data, i.e., unseen measurements for (drug x1, gene y,
tissue z) triads.
Another notable challenge is to provide accurate predictions for entirely new objects
from some data domains, which are unseen during the training phase (cold-start prob-
lem [64]). For example, we may not have any available triads involving a certain drug x2;
still, it may be useful to estimate how this drug would interact with certain (gene, tissue)
combinations. In particular, instead of directly conducting many expensive lab experiments
measuring the expression for a new drug, we could try to estimate its treatment effect first
computationally. Then, we could focus on a small subset of targeted drug trials and cut
down the corresponding costs.
To enable predictions for new objects, we need some form of external knowledge for
their data domain. We illustrate this use case in Figure 2.1, where we predict the mea-
surement yi1,i2,i3 involving drug i1, gene i2 and tissue i3. We assume that feature vectors
are available for the drug data domain (e.g., x1i1 is the feature vector for drug i1). Thus,
we try to provide a prediction for yi1,i2,i3 , even if the drug i1 was not part of any observed
measurement during training. In Figure 2.1, this holds accordingly for the genes’ data
domain.
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Finally, in target applications involving polyadic data, a standard assumption is that
significant interactions exist between objects across the data domains. For instance, we
assume that the treatment effect of each drug is varying for different gene-tissue combi-
nations. Regarding the example in Figure 2.1, this property is mathematically reflected
through the interactions between drug with gene features and tissue objects. Thus, it is
imperative to efficiently integrate those inter-domain interactions, which can be high-order
for general polyadic data.
Dyadic Prediction has been studied in recent literature (e.g., [65, 66, 67], also men-
tioned as bilinear prediction or pair-input/pairwise learning). Still, those works limit their
endeavors to dyadic data. Instead, we propose a new framework, which we call Polyadic
Regression, to address the challenges introduced above. Our main contributions are as
follows:
• We propose a general Polyadic Prediction framework, predicting measurements asso-
ciated with multiple objects. The fitting algorithm adapts to various tasks (continu-
ous/discrete) and constraints (e.g., sparse solutions via `1 norm).
• Our framework is inductive 1: it enables predictions for new objects which have not
been encountered during training, tackling the so-called cold-start problem.
• Our model is expressive to fit the needs of Polyadic Prediction: it explores all the high-
order interactions across different data domains. Its factorized version is designed to
reduce its complexity and prevent overfitting.
We apply the proposed framework to problems in chemogenomics (i.e., chemical ge-
nomics). This field is facing many challenges that can be naturally framed as Polyadic
Prediction problems, such as drug-induced, cell-specific gene expression prediction and
drug-protein interaction prediction of various types [2]. Thus, we conduct an extensive
evaluation on both synthetic and real, publicly-available chemogenomics data. The syn-
1Our distinction between the inductive and transductive settings follows the one provided in [66, 67].
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thetic data experiment establishes the recovery of relevant features, in the presence of inter-
actions. The real data case study on drug-induced, cell-specific gene expression prediction
showcases the superior accuracy of Polyadic Regression as compared to the prior art in
both of our target use cases. In particular, our approach improves the correlation (standard
metric in gene expression analysis [68]) between the predicted and the actual measurement
vectors by 0.06 and 0.1, in estimating missing polyadic data and predicting polyadic data
involving new drugs, respectively.
2.2 Background
Tensors are high-order generalizations of matrices. The order of a tensor denotes the
number of its modes (e.g., matrices are 2-order tensors). A fiber is a vector extracted
from a tensor by fixing all modes but one. Considering a d-order tensor S ∈ RI , where
I := I1 × · · · × Id, the index set of each individual mode µ is Iµ := {1, . . . , nµ}, µ ∈
{1, . . . , d}. Matricization, also called reshaping or unfolding, logically reorganizes tensors
into other forms without changing the values themselves. The index set without mode-µ is
I(µ) := I1×· · ·×Iµ−1×Iµ+1×· · ·×Id. Then, the µ-mode matricization is a mapping from
a tensor to a matrix: S(µ) : RI → RIµ×I(µ) . As a result, the mode-µ fibers of the tensor
become columns of a matrix. Given Uµ ∈ RJµ×Iµ , the µ-mode multiplication (or µ-mode
product) is defined by S×µUµ and its matricized version isUµS(µ) ∈ RJµ×I(µ) . Given ma-
trices Uv ∈ RJv×Iv , v = 1, . . . , d, we can generalize this operation for all the tensor modes
via the multi-linear multiplication, denoted as: S ×1U1×2U2 · · ·×dUd ∈ RJ1×···×Jd [11].
2.3 Problem & Model Formulation
First, we formally introduce the Polyadic Prediction problem and our proposed model in its
most general form. Next, we extend this model to cases when prior knowledge for certain
data domains is not available. Then, we present a more efficient, factorized version of it
which can easily handle high-order input (≥ 3-order).
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2.3.1 Problem Definition
Suppose our dataset consists ofN samples of the following form: {(i1, i2, . . . , iK) , yi1,i2,...,iK},
where yi1,i2,...,iK is an observed measurement involving theK objects i1, i2, . . . , iK . We fur-
ther assume that ik ∈ {1, 2, . . . , nk}, 1 ≤ k ≤ K, that is, the object ik takes values from
a finite set of objects with cardinality nk. We call this set the k-th data domain, since it
contains objects indexed in the k-th position of the ordered tuple (i1, i2, . . . , iK). The goal
of Polyadic Prediction is to learn a function to predict the value of unseen measurements
yi1,i2,...,iK , given the values of the observed ones.
First, in Section 2.3.2, we assume that external knowledge is available for all K data
domains. In that case, each object ik is described by a feature vector xkik ∈ Rdk , where
the superscript refers to the k-th data domain and dk is the size of its feature vectors. In
Section 2.3.3, we relax this assumption.
2.3.2 Core Model
Our core regression model is
f(x1i1 ,x
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Suvr ×1 xuiu ×2 xviv ×3 xrir
︸ ︷︷ ︸
triadic interactions
+ · · ·
+ S ×1 x1i1 ×2 x2i2 · · · ×K xKiK︸ ︷︷ ︸
general polyadic interactions
(2.1)
where b is a scalar offset,wk ∈ Rdk is the vector capturing the linear feature effects of each
k-th data domain, Suv ∈ Rdu×dv is the matrix capturing dyadic feature interaction effects
across the u, v data domains, S ∈ Rd1×d2×···×dK is a tensor capturing the K-way feature
interaction effects across all the data domains. Our core model is expressive enough to
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capture all the dyadic, triadic, and in general polyadic interactions emerging across features
of various data domains.
We assume the matrices/tensors capturing interaction effects are order-independent
w.r.t. the data domains, i.e., Suvij = S
vu
ji , Suvrijk = Survikj = Svurjik = Svrujki = Sruvkij = Srvukji
and so on for the higher-order terms. That is, we model the interactions of each group of
data domains with a single matrix/tensor, ignoring the rest possible data domain permuta-
tions.
2.3.3 Partial Induction
The model in Equation (2.1) implies that we have external knowledge available for all the
data domains. We call this setting complete induction. However, this setting may not hold
in practice. For example, we may have drug and gene features available, but no external
information describing each one of the tissues. This setting is henceforth referred as partial
induction.
First, consider a dyadic data example. In complete induction, the measurement for a
















We now assume that external knowledge is only available for the 1st data domain. In this
case, we can predict a measurement associated with any object belonging to the 1st data
domain (either it is included in the training set or not) and any (encountered during training)
object belonging to the 2nd data domain. One typical analogue for this case is multi-label
learning [69], where we have features describing the objects of the 1st, and a set of labels
as the objects of the 2nd data domain. We follow the idea proposed in [70] and assume
there are shared and individual components in each label predictor. More concretely, the
possibility of assigning the label i2 to object i1 can be defined as
fi2(x
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where w1 is shared across all label predictors, and s12i2 is distinct for each label predictor.
If we define S12 = [s121 , s
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where e2i2 ∈ Rn2 is a vector with only the i2-the element being 1, all other elements are
zeros (one-hot encoding) and n2 is the cardinality of the 2nd data domain (i.e., number of
distinct labels).
We generalize the idea above for the Polyadic Regression model as follows. Let K =
{1, 2, · · · , K} = KU
⋃KF be the set of data domains. KU is the set of data domains
without external knowledge, KF is the set of data domains with features describing their
corresponding objects. In order to adapt Equation 2.1 to the partial induction setting, we
define x̄kik as either the feature vector of object ik from the k-th data domain, when k ∈ KF ,





xkik ∈ Rdk , if k ∈ KF
ekik ∈ Rnk , if k ∈ KU
We also use w̄k to either denote the linear feature effects of the k-th data domain when
k ∈ KF , or a zero vector which eliminates those effects when features are not available





wk ∈ Rdk , if k ∈ KF
0nk ∈ Rnk , if k ∈ KU
Then, the model takes the form
f(x̄1i1 , x̄
2












S̄uvr ×1 x̄uiu ×2 x̄viv ×3 x̄rir + · · ·
+ S̄ ×1 x̄1i1 ×2 x̄2i2 · · · ×K x̄KiK (2.2)
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dk, if k ∈ KF
nk, if k ∈ KU
then S̄uv ∈ Rd̄u×d̄v , S̄uvr ∈ Rd̄u×d̄v×d̄r , S̄ ∈ R
∏
k d̄k .
2.3.4 Factorizing Polyadic Interactions
Below, we first assume a complete induction setting, and then extend the discussion for
the partial induction one. The core model presented in Equation 2.1 enjoys high expres-
sive power in capturing all high-order interactions across different data domains. However,
this approach suffers from high model complexity (O(dK) for K data domains and d fea-
tures per domain), which apart from efficiency issues, may result in a poor generalization
performance.
As the pioneering work on Factorization Machines [71] suggested, it is reasonable to
assume that feature interactions are not independent, and patterns are emerging among
them. Those patterns imply a low-rank structure of the corresponding matrix/tensor re-
flecting interactions. To incorporate such a structure, one could augment the objective with
a rank-minimizing constraint (e.g., trace norm minimization [72]). Still, this approach faces
a huge model size problem for high-order interactions and is not feasible for our model.
Instead, we explicitly replace the parameters capturing interaction effects with their
low-rank counterparts, i.e., products of sets of low-rank matrices or tensors. Moreover, we
take the idea of shared patterns among features [71] a step further: we consider that shared
structure also exists among interactions of different orders, so that, for instance, the low-
rank approximation of §uv has common terms with the one of Suvr. We mathematically
translate this assumption to having a basis matrix Fk ∈ Rdk×m capturing the low-rank
structure of features for each k-th data domain. In that case, we would approximate §uv as








where Fuj is the j-th column of F
u. The formulation above implies that each dyadic effect
(entries of §uv) is a result from aggregating the interactions (outer products) among the m
feature groups defined by the columns of Fu,Fv. It is equivalent to the bilinear model
proposed in [67].
However, a pure generalization of Equation (2.3) for our model is restrictive. It would
imply that the interactions between feature groups share the same contribution (i.e., weight-
ing factor) for various data domain pairs or different orders. For a triadic data example, the
weight of the interaction between Fu1 and F
v
1 towards §uv is restrained to be the same as the
one between Fu1 and F
r
1 towards §ur. Another restrictive assumption is that the subspaces
defined by all the basis matrices Fk share the same dimension (m).
To tackle the above issues, we incorporate a scalar weight for each feature group inter-
action, capturing its significance towards the specific pair, triplet or higher combination of
feature groups considered. We also permit a different dimension for the subspace corre-
sponding to each basis matrix. Thus, Relation 2.3 is transformed to











so that each dyadic interaction matrix §uv is approximated by a tri-factorization [16]. For
higher-order terms, we adopt the multi-way analogue of tri-factorization, which is the
Tucker decomposition [73]:
Suvr ≈ Cuvr ×u Fu ×v Fv ×r Fr
...
S ≈ C ×1 F1 ×2 F2 · · · ×K FK
where Cuvr ∈ Rmu×mv×mr , C ∈ Rm1×m2×···×mK are low-rank core tensors, and Fk ∈
Rdk×mk with mk  dk.
The discussion above implies a complete induction setting. Consider now that we have
no external knowledge for the u-th data domain. In that case, we no longer need to learn a
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low-rank representation of features Fu. However, it is still useful to learn how the objects
from the u-th data domain interact with features/objects from other domains. To model this
behavior, we fix Fu to be an identity matrix Iu ∈ Rnu×nu and Relation (2.4) becomes
§̄uv ≈ C̄uv(Fv)>
where §̄uv ∈ Rnu×dv , C̄uv ∈ Rnu×mv . This is trivially extended for higher-order terms.
2.4 Algorithm
2.4.1 Objective Formulation
For simplicity, we assume a complete induction setting and for notational convenience, we
use {Xi, yi}Ni=1 to represent the i-th data sample, where Xi = (x1i1 ,x2i2 , · · · ,xKiK ) and yi
is the ground truth measurement of the objects involved in Xi. We define our objective
function as the sum of a term minimizing the desired loss and another one intended to





`(f(Xi), yi)︸ ︷︷ ︸
J (u)
+λΩ({wk}Kk=1, {Suv}uv, · · · ,S)︸ ︷︷ ︸
R(u)
(2.5)
where `(f(Xi), yi) is the regression loss of function f , Ω is an aggregation of the regular-
izations imposed on the model parameters and N is the number of training samples.
2.4.2 Objective minimization
The most straightforward choice of a method minimizing the objective in Equation (2.5)
would be that of an alternating Gradient Descent (GD). Such a choice would suffice in
cases when the regularization function is smooth, such as the squared `2-norm.
However, this choice falls short for nonsmooth regularizers [74], such as the `1-norm
which is the standard method to induce sparsity in the solution. In those cases, we have to
handle the regularizer as a distinct entity, which can possibly be non-differentiable. To do
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so, we can adopt proximal gradient methods [75] in each alternating iteration, which aim
to solve optimization problems of the following form
min
u∈H
J (u) +R(u) (2.6)
where J is convex and differentiable with Lipschitz continuous gradient, R is a convex,
lower semi-continuous function which is possibly non-differentiable, and H is some set,
typically a Hilbert space. The correspondence between the objectives (2.5) and (2.6) is
clear: the loss function corresponds to J (u) and R(u) is considered as the function re-
flecting any regularizations.
In proximal methods, uminimizes J (u)+R(u) if and only if 0 ∈ ∂u(J (u)+R(u)),
where ∂ is the sub-differential operator. Given a convex function ψ : H → R, we can define
its proximal operator proxψ : H → H as proxψ(z) = arg minu∈H ψ(u) + 12‖u − z‖22,
which can be seen as a generalization of a projection [76]. Then, the Proximal Gradient
(PG) method [75] dictates the following update rule to solve the objective (2.6)
uk+1 := proxγR
(
uk − γk∇J (uk)
)
(2.7)
where k denotes the current iteration and γk > 0 is a step size, which can be found
through line search. In the Supplementary Material 2, we include details regarding both the
implementation and the various possible choices of losses and regularization functions.
2.5 Experimental Analysis
Due to space limitations, we include our synthetic data experiments in the Supplementary
Material. In the following, we address a real-world challenge arising in the field of chemical




First, we briefly present some background related to our target application. Differential
gene expression profiling of in vitro drug perturbations refers to the process of measuring
the difference in gene expression of a certain cell culture (e.g., cells from brain affected
with cancer) before and after treating it with a specific drug. A large differential expression
value is indicative of a significant change in the cells’ behavior, meaning that the drug could
potentially treat the corresponding disease. The methodology described above (known as
chemogenomic profiling) has provided powerful insights towards several important tasks,
such as better understanding of drug mechanisms [77] and drug repurposing [30]. At the
same time, we witness an expansion of the publicly available chemogenomic data through
the Library of Integrated Cellular Signatures (LINCS) program [31]: they provide drug-
induced and cell-specific gene expression measurements for roughly 1000 genes, which are
known to be maximally predictive of the expression of the rest of the available genes [31].
As we discussed in Section 2.1, the data mentioned above have inherently many missing
values, since drugs are often measured only for a subset of tissues. Thus, a significant
challenge is to estimate the missing expression values. Another important goal is to enable
predictions for new drugs, which are unseen during training. The experiments illustrating
the superiority of Polyadic Regression in terms of predicting missing values and expression
values for new drugs are provided in Sections 2.5.4 and 2.5.5, respectively.
2.5.2 Formulation for drug effect prediction
Next, we present our formulation towards drug-induced, cell-specific gene expression pre-
diction. Consider that we have n1 drug objects, n2 gene objects and n3 tissue objects.
We used external knowledge for the drug and gene data domains, but no knowledge is
available for the tissues (partial induction on the domains of drugs and genes). Thus,
x1i1 ∈ Rd1 ,x2i2 ∈ Rd2 are the feature vectors for drug i1 and gene i2 respectively. We
also incorporate the low-rank assumptions presented in Section 2.3.4. Thus, the expression
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+(C̄ ×1 F1 ×2 F2 ×3 I3)×1 x1i1 ×2 x2i2 ×3 e3i3 (2.8)
where F1 ∈ Rd1×m1 , F2 ∈ Rd2×m2 , C12 ∈ Rm1×m2 , C̄13 ∈ Rm1×n3 , C̄23 ∈ Rm2×n3 , C̄ ∈
Rm1×m2×n3 , I3 ∈ Rn3×n3 is an identity matrix and e3i3 ∈ Rn3 is the one-hot encoding of
tissue i3. Since our measurements are continuous, we select the squared loss and solve for
























where D stands for our dataset, N for the number of training samples, λ1 is the regular-
ization parameter corresponding to the linear feature effects and λ2 is the regularization
parameter targeting polyadic interactions.
2.5.3 Experiment Setup
The version of LINCS data we used comprise 22, 412 drugs applied to 56 different tissues
for 978 landmark genes. We followed a standard protocol for data pre-processing, which is
described in the Supplementary Material. We incorporate external features for the drug and
gene data domains. For drugs, we use the substructure fingerprints denoting the chemical
structure for each drug [78]. For genes, we use gene-gene similarity features computed
using the GOSemSim [79] package in R. In all our experiments, we used the 10 tissues
containing the most expression profiles. We also discarded 128 genes for which we did not
have any similarity information.
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We employ the holdout method to tune the hyper-parameters, so the available samples
are split to train, validation and test sets with an approximate ratio of 0.6 : 0.2 : 0.2.
The validation set was purely used to tune the hyper-parameters, which are found using
logarithmic grid search for each one of the methods. The hyper-parameters achieving the
best performance on the validation set were selected and the corresponding performance
on the test set is reported. We used `2-norm regularization for all the methods.
We used the Spearman’s ρ (Spearman rank correlation coefficient ranging from−1 to 1)
between the vector of predicted and that of true measurements, as the measure of accuracy.
This is a standard evaluation metric for gene expression analysis, where correlation metrics
are usually preferred over error measures [68].
Polyadic Regression was set to compete with the following approaches:
Ridge Regression. A linear regression with L2 regularization without considering inter-
action terms. We used the GLMNet package [80] (Matlab version) implementing Ridge
Regression.
Factorization Machines (FMs) [71]. FMs are efficiently exploring all the pairwise feature
interactions. We used the libFM package [81] (C++) implementing FMs and the Monte
Carlo Markov Chain (MCMC) fitting algorithm, which is recommended by the author as
the least prone to hyper-parameter selection. Thus, other than the rank parameter governing
the model size, we only had to tune the standard deviation of the initial distribution of
parameters. Note that the regularization-related parameters are automatically determined
in MCMC.
Multi-view machines (MVMs) [82]. This is another prior work which takes into account
both linear and inter-domain interaction terms, and factorizes all of them jointly. We used
the zen package implementing Multi-view Machines [83, 82] on top of Apache Spark (in
local mode) using Scala. The fitting algorithm in this case is Gradient Descent with adaptive
gradient (AdaGrad) [84], which is also recommended by the authors in [82], so that the
algorithm is insensitive to the choice of the learning rate. We verified the performance
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boost using AdaGrad and the insensitivity to the initial learning rate in our experiments
when using it. Thus, apart from the rank parameter defining the model size, the only
hyper-parameter we had to tune was the λ value corresponding to `2-norm regularization.
Note that due to the joint factorization of all the parameters in MVMs, there is a single
regularization value to cover the needs of both the linear and interaction terms.
To adapt to the supervised learning setting employed by Ridge Regression and FMs, for
each sample {(i1, i2, i3) , yi1,i2,i3}, we create a “concatenated” feature vector [x1i1 ;x2i2 ; e3i3 ] ∈
Rd1+d2+n3 .
Our method is implemented in Matlab R2015b and C++ with multi-threading capabil-
ities (OpenMP). We used the Mex interface to bridge Matlab and C++ implementation.
We also employed the Matlab package apg in [85], implementing an accelerated proximal
gradient method.
We set all methods other than Ridge Regression to run for a maximum of 2, 000 itera-
tions 3. We do employ early-stopping through cross-validation to avoid overfitting for all
methods.
In terms of hardware, we used a server running Ubuntu 14.04 with 251 GB of RAM
and 16 physical Intel(R) Xeon(R) E5-2630 CPU’s with a maximum clock frequency of
2.40GHz. Each one of the physical cores can exploit 2 threads with hyper-threading en-
abled.
2.5.4 Predicting missing polyadic data
In the following, we evaluate the accuracy of the methods under comparison in predicting
missing measurements. Besides picking the top-10 tissues containing the most data, we
sub-selected the drugs with measurements available in all of them. Thus, we have 81 drugs
for this setting. We can consider that the objects under consideration form a dense tensor
containing 81× 850× 10 elements denoting the combinations of drugs × genes × tissues.
3Ridge regression implementation does not require an iteration parameter.
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Figure 2.2: Predicting missing measurements: Spearman correlation between the predicted
and the true vector of measurements, as we vary the model size.
Those 688, 500 expression values are split into train, validation and test sets, as explained
in Section 2.5.3. Moreover, we cleaned the initial 881 drug structure features to remove the
ones without any variation among the drugs selected. Thus, for this setting, we have 497
drug features kept. The number of gene features is the same as the number of genes since
we construct a gene-gene similarity matrix.
We vary the number of parameters for each method (apart from Ridge Regression where
the number of parameters is fixed to be the number of features), by tuning the correspond-
ing rank-related parameters. Note that in Polyadic Regression, we have two parameters
governing the number of parameters (m1 and m2, as shown in Equation 2.8). We con-
sider that m1 = m2 and vary them in the range {2, 4, 6, 8, 10}. Accordingly, we vary the
rank-related parameters in FMs and MVMs to reach comparable model sizes.
We present the results of those experiments in Figure 2.2. We notice that the output
of Ridge Regression achieves almost zero correlation with the true measurements. This
indicates that the linear terms do not have high predictive towards the predicted outcomes.
This is perfectly reasonable considering for instance a specific drug feature (e.g., existence
of a certain chemical bond). This feature may target a specific tissue on a certain group
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of genes, but intuitively there are no drug features that have treating capabilities for every
condition. Moreover, the MVMs do not achieve high accuracy either. This approach comes
with an efficient model representation which has shown success in recommender systems
applications [82]. However, it assumes that the linear and interaction terms are factorized
jointly; thus, a single regularization parameter has to cover the needs of both the linear
and interaction terms, even if the former ones are almost irrelevant towards the predicted
measurements. We believe this is the reason behind the low accuracy of MVMs for this
task. Finally, the FMs are promising for this task and the correlation achieved between
the output and the measurements’ vector reaches a maximum of 0.44. However, they do
not take into account 3-order interactions, limiting the model expressiveness for Polyadic
Prediction problems.
Polyadic Regression achieves the best performance for all model sizes, reaching a max-
imum of 0.5 correlation between the output and the true measurements’ vector. Note that
maximum performance on the validation set was in most cases achieved by setting λ1 (in
equation 2.9) to be orders of magnitude larger than λ2, where the former shrinks the linear
and the latter regularizes the interaction effects. Thus, the flexibility of independent rep-
resentation (and regularization) between linear and interaction terms is crucial towards the
target task.
2.5.5 Predicting polyadic data for new drugs
We also tackle another important challenge in the field of chemogenomics: predicting ex-
pression values for new drugs, unseen during the training phase. First, we want to in-
corporate more drugs than the ones used in Section 2.5.4, so that the task becomes more
challenging. Thus, instead of constraining the drugs to have relevant data in all the 10 tis-
sues, we require that they have data in at least 2 out of them. This requirement is fulfilled by
2, 169 drugs, which we further randomly sub-sample to 500. The number of relevant drug
features (non-zero variation) is 612 in this case. In sum, for the current task, we consider
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Table 2.1: Predicting measurements for new drugs: for roughly the same model size,
Polyadic Regression achieves 0.1 increase in Spearman correlation between the predicted
and the true vector of measurements, against the best-performing competing method. Re-
sults are averaged over 5 runs and standard deviation is reported.
Method Spearman’s ρ #Parameters
Polyadic Regression 0.23025 ± 0.0063886 4471
Factorization Machines 0.1252 ± 0.0083942 4417
Multi-view Machines 0.0669 ± 0.017242 4425
Ridge Regression 0.0061 1473
500 drugs, 850 genes and 10 tissues. In contrast to Section 2.5.4, we only have ≈ 44%
of the measurements among the object combinations available, thus leading to 1, 870, 850
data samples. Since we are only interested in predictions for new drugs (predicting for new
genes is not a practical use case and we have no external knowledge for tissues), we follow
the holdout method by constraining though that the the train, validation and test sets have
no common drugs.
We evaluate the robustness of the competing approaches, thus we fixed Polyadic Re-
gression, FMs and MVMs to roughly the same model size and run the experiments 5 times,
reporting average performance and standard deviation. We provide the results in Table 2.1.
Polyadic Regression achieves 0.1 increase in correlation between the predicted and the true
vector of measurements, against the best-performing competing method. Moreover, we
remark its robustness in terms of different initialization of parameters.
2.5.6 Scalability
We assess the scalability properties of the methods under comparison w.r.t. varying sizes of
training data and input features. To do so, we used the data described in Section 2.5.5. Re-
garding the scalability for increasing number of training examples, we constructed smaller
sets of data, by including random subsets of 1/8, 1/4, 1/2 of the total samples. As concerns
the scalability for increasing number of input features, we fixed the number of training ex-
amples and removed an equal number of features from the drug and gene domains, so as
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Figure 2.3: The scalability in terms of training time per epoch with respect to increasing
training data size and input feature dimension.
to reach the desired total feature number. We measured the training time per epoch, as an
average over 100 epochs.
Note that the GLMNet package implementing Ridge Regression uses a cyclical coordi-
nate descent algorithm, updating a specific parameter in each iteration. This is in contrast
to the rest of the methods which update the whole space of parameters; thus, a comparison
in terms of time per epoch with Ridge Regression would not be meaningful and is not in-
cluded. However, we empirically remark that it is the fastest method, which is reasonable
considering it only takes into account linear feature effects.
We provide the results in Figure 2.3. We remark that all methods share similar (near-
linear) scalability properties. We would like to emphasize that a direct time comparison
between different methods would not be fair, since they are implemented using different
setup (single-threaded, multi-threaded).
2.6 Related Work
Polyadic Regression essentially tackles the general case of the Dyadic Prediction problem
which is studied in [65, 86, 66, 67]. The corresponding approaches though, only predict
dyadic and cannot generalize to predicting polyadic data. Other works that also model
only dyadic interactions are the Sparse Factorization Machine [87] and the Conditional
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High-Order Boltzmann Machine [88].
Multi-view Machines [82] (MVMs) is a recently proposed model, exhibiting success
in recommender systems’ applications. MVMs capture both linear and higher-order inter-
actions across features of different data domains, and jointly factorize all of them by a CP
tensor decomposition [89]. On one hand, this decision limits the number of parameters
to learn. However, it restricts to a target model where the linear and interaction terms are
composed from the same low-rank factors, and have to share the same regularization. This
may be a limiting factor when the interaction and linear terms have very different contri-
butions towards the predicted measurements. Our model is more flexible, allowing for a
different treatment among the linear and interaction terms.
As concerns other lines of work, the notion of multi-view learning, as it has been hith-
erto used in the literature [90], does not tackle the challenges we introduced in Section 2.1.
It is limited to models either accepting only two inputs [91] or learning correlations at the
view-level (as in multiple-kernel learning [92]) and not between features of different repre-
sentations, thus limiting the model’s expressiveness and interpretation potential. On a dif-
ferent note, while tensor regression methods (e.g., [93]) predict polyadic data by generally
exploring only the highest order of possible interactions, they cannot provide predictions
for new objects (e.g., new drugs in our target application), in the post-training phase.
2.7 Conclusions
We proposed Polyadic Regression, a general framework predicting measurements associ-
ated with multiple objects. Our framework enables predictions for new objects, unseen
during training, thus tackling the so-called cold-start problem. Our model is expressive
for addressing general Polyadic Prediction problems, by exploring all the high-order in-
teractions across different data domains, in an efficient, factorized, way. We evaluate our
approach with real chemogenomics data, demonstrating its superior accuracy over the prior





SUSTAIN: SCALABLE UNSUPERVISED SCORING FOR TENSORS AND ITS
APPLICATION TO PHENOTYPING
Summary
In this Chapter, we focus on extracting integer factors, out of co-occurrence input
tensors derived from EHR data, which can be interpreted to identify patient groups
sharing common traits (aka unsupervised phenotyping). Prior work applying and
extending tensor methods for phenotyping focuses on real-valued models, which
may need arbitrary hard thresholding to the ranked list of factor elements to achieve
concise results. Also, assessing the relative frequency between different real-valued
factor elements may be non-intuitive. To tackle these challenges, we introduce SUS-
Tain, an integer-constrained tensor factorization framework, which shows either sig-
nificantly better fit or orders of magnitude speedups for a comparable fit against
several baselines and can be used to extract concise and clinically-meaningful phe-
notype definitions (87% of them were validated as meaningful by a cardiologist).
This chapter introduces a new method, which we call SUSTain, that extends real-valued
matrix and tensor factorizations to data where values are integers. Such data are common
when the values correspond to event counts or ordinal measures. The conventional ap-
proach is to treat integer data as real, and then apply real-valued factorizations. However,
doing so fails to preserve important characteristics of the original data, thereby making
it hard to interpret the results. Instead, our approach extracts factor values from integer
datasets as scores that are constrained to take values from a small integer set. These scores
are easy to interpret: a score of zero indicates no feature contribution and higher scores
indicate distinct levels of feature importance.
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At its core, SUSTain relies on: a) a problem partitioning into integer-constrained sub-
problems, so that they can be optimally solved in an efficient manner; and b) organizing
the order of the subproblems’ solution, to promote reuse of shared intermediate results.
We propose two variants, SUSTainM and SUSTainT , to handle both matrix and tensor
inputs, respectively. We evaluate SUSTain against several state-of-the-art baselines on both
synthetic and real Electronic Health Record (EHR) datasets. Comparing to those baselines,
SUSTain shows either significantly better fit or orders of magnitude speedups that achieve
a comparable fit (up to 425× faster). We apply SUSTain to EHR datasets to extract patient
phenotypes (i.e., clinically meaningful patient clusters). Furthermore, 87% of them were
validated as clinically meaningful phenotypes related to heart failure by a cardiologist.
3.1 Introduction
Matrix and tensor factorization are among the most promising approaches to extracting
meaningful latent structure from multi-aspect data. They have been applied successfully
in diverse applications, including social network analysis [15], text mining [16], image
processing [17], recommendation systems [18], brain data analysis [19] and healthcare
analytics [21], to name a few. Factorization models decompose input data into real-valued
representatives revealing clusters with distinct interpretable feature profiles.
However, a significant problem arises when the input data are most naturally expressed
as integer values. Examples include event counts and ordinal data [94]. In such cases,
real-valued factors distort the original integer characteristics. For example, real values
might no longer be interpretable as counts or frequencies. Also, the possible ranges and
relative differences of elements in real-valued factors is arbitrary; this makes it hard to in-
tuitively compare the importance of different elements. Furthermore, in many applications,
practitioners are accustomed to interpreting integer-valued scores in standardized scales.
Real-valued factors might require arbitrary thresholding or other unnatural transformations
to convert into such scales, thereby inhibiting interpretation by domain experts.
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A specific motivating application for our methods is clinical phenotyping from Elec-
tronic Health Records (EHR) data. Consider that a disease, such as heart failure, is often
heterogeneous in that patients differ by underlying pathophysiology and needs. That is, a
disease is often comprised of distinct disease subtypes, or phenotypes, which vary by the
ensemble of causes, associations with other diseases, and treatment needs [38]. Phenotyp-
ing is intended to distinguish the latent structure among features that can, in turn, be used to
prevent disease subtypes and improve treatment development and management [95]. EHR
data offer a diverse and rich set of features (e.g., diagnostic, drug and procedure codes)
that can serve to improve disease phenotyping. But, these data must often be represented
in integer form (e.g., clinical event counts) to be utilized in unsupervised learning. For
example, we can construct a patient-disease matrix where the ij-th element represents the
number of times patient i had disease j documented in her records. Similarly, we can build
higher-order tensors such as a patient-disease-medication one. The goal of unsupervised
phenotyping is to identify patient clusters defined by unique feature sets, each one of which
aligns with a distinct and intuitive clinical profile; in this work, we tackle this challenge via
a scalable constrained integer tensor factorization.
Factorization methods have been successfully used for EHR-based unsupervised phe-
notyping [24, 21, 49, 50, 51]. In many of those settings, the problem can be formulated
via Nonnegative Matrix Factorization (NMF) [17] e.g., minimizing the squared Frobenius
norm of the error:
min
{
||X −UV T ||2F
∣∣ U ≥ 0,V ≥ 0
}
(3.1)
X ∈ ZM×N+ is a non-negative integer input matrix whose X(i, j) cell reflects the event
counts for the i-th (out of M ) patient with respect to the j-th (out of N ) features. Given an
input number R of desired phenotypes, the matrix U ∈ RM×R corresponds to a member-
ship matrix of the patients with respect to the R phenotypes. And the matrix V ∈ RN×R
provides the phenotypes’ definition: the non-zero elements of the r-th column V (:, r) re-
veal the potentially relevant features to the r-th phenotype.
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Figure 3.1: Fit (range [0, 1]) vs time trade-off for varying target number of phenotypes R =
{5, 10, 20, 40}, on a patients-by-diagnoses matrix formed of ≈ 260K patients from Sutter
Palo Alto Medical Foundation Clinics. SUSTainM is as accurate as the most accurate
baseline (based on [96, 97, 94]), but up to 425× faster (R = 5: ≈ 3 seconds by SUSTainM
vs. ≈ 22 minutes by AILS). Even for a larger target rank (e.g., R = 20), SUSTainM
is 110× faster (≈ 4 minutes by SUSTainM vs. ≈ 7 hours by AILS). As compared to a
carefully-designed heuristic that performs a scale-and-rounding of the real-valued solution,
SUSTainM achieves up to 16% higher fit. In summary, SUSTainM dominates all other
baselines in both time and fit.
Interpreting those factors is crucial in order to determine whether and to what extent a
patient exhibits a phenotype, as well as which set of candidate features should be considered
to compose each r-th phenotype so that it is clinically meaningful. However, this can
be challenging if the resulting factors contain arbitrary (nonnegative) real values. Real-
valued factors distort the count nature of input data; thus, identifying cases and controls
based on counts of relevant medical features [98, 57] is no longer possible. Also, the
possible ranges and relative differences of elements in real-valued factors is arbitrary, thus
impeding the practitioner’s assessment of their relative importance. In practice, ad hoc
heuristics have been introduced with limited success: a) hard thresholding to the ranked
list of factor elements, which is usually arbitrary and leads to poor model fit; b) the factor
values are hidden altogether and only the elements’ ranking is preserved, which omits
valuable information regarding the individual elements’ actual importance.
Contributions: To tackle these challenges, we propose Scalable Unsupervised Scoring
for Tensors (SUSTain), a framework extracting the factor values as scores, constrained to
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Table 3.1: Most prevalent phenotype (26% of patients) extracted via SUSTainT for a heart
failure cohort. The r-th phenotype prevalence is measured through the patient membership
vectors containing non-zero element in the r-th coordinate. The score of each feature in-
dicates its relative frequency. The prefix for each feature indicates whether it corresponds
to a medication (Rx) or a diagnosis (Dx). The cardiologist labeled the result as “hyperlipi-
demia” and confirmed that the two features are clinically connected to heart failure.
Hyperlipidemia Score
Rx HMG CoA Reductase Inhibitors 3
Dx Disorders of lipid metabolism 1
a small integer set. SUSTain offers a straightforward interpretation protocol: a score of
zero indicates no feature contribution and higher scores indicate distinct levels of feature
importance.
Our methodology relies on identifying a problem partitioning into integer-constrained
sub-problems so that each one of them can be solved optimally in an efficient manner; at
the same time, their solution order is organized so as to promote re-use of shared interme-
diate results. SUSTain can handle both matrix and tensor inputs, through SUSTainM and
SUSTainT methods, which we formulate in Sections 3.3.1 and 3.3.2 respectively.
SUSTain yields faster and more scalable approaches than baselines achieving compa-
rable fit, as evaluated on both synthetic (publicly-available) and real healthcare datasets.
For example, as shown in Figure 3.1, SUSTainM achieves the same level of accuracy as
the most accurate baseline up to 425× faster. SUSTainT can handle large-scale tensor
inputs for which the most accurate baseline fails and scales linearly with the number of
patients.
SUSTain’s interpretation protocol is particularly meaningful for unsupervised pheno-
typing: it is easily understood by medical experts who are used to simple and concise,
scoring-based descriptions of a patient’s clinical status (e.g., risk scores1). While recent
work derives risk scores for predictive modeling (supervised learning) [99], our application
of SUSTain extracts scores for unsupervised phenotyping based on unlabeled EHR data. In
1In MDCalc, one can find a vast amount of such scores used in medicine.
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Table 3.1, we provide a representative phenotype extracted through our method, as part of a
case study we performed on phenotyping heart failure patients. The meaningfulness of the
phenotype candidates extracted through this case study was confirmed by a cardiologist,
who annotated 87% of them as clinically meaningful phenotypes related to heart failure.
We summarize our contributions as:
• Scalable unsupervised scoring: We propose SUSTain, a fast and scalable approach
decomposing integer multi-aspect data into integer scores, preserving the original integer
characteristics.
• SUSTain can handle matrix and tensor input: We present SUSTain for both matrix
(Section 3.3.1) and tensor (Section 3.3.2) inputs, through SUSTainM and SUSTainT
methods, respectively.
• Evaluation on various datasets: We evaluate both the matrix and tensor versions on
both synthetic (publicly-available) and real healthcare datasets.
• Phenotyping heart failure patients: The interpretability of the extracted scoring-based
phenotypes was confirmed by a cardiologist, who annotated 87% of them as clinically
meaningful.
To promote reproducibility, our code is open-sourced and publicly available at: https:
//github.com/kperros/SUSTain.
3.2 Background
In Table 3.2 we summarize the notations used throughout this work. Let x0 ∈ Rn. The eu-
clidean projection ofx0 to a setC ⊆ Rn is defined as ΠC(x0) = argmin {||x− x0||22 | x ∈ C};
thus, it is the problem of determining the vector x∗ among all x ∈ C which is the closest to
x0 w.r.t. the Euclidean distance [100]. A matrixX is called rank-1 if it can be expressed as
the outer product of 2 non-zero vectors: X = x◦y. The Khatri-Rao Product (KRP) [101] is
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the “matching column-wise” Kronecker product: for two matricesU ∈ RM×R,V ∈ RN×R
their KRP is as follows: U  V = [U(:, 1)⊗ V (:, 1) U(:, 2)⊗ V (:, 2) . . . U(:, R)⊗ V (:, R)] ∈
RMN×R
A tensor is a multi-dimensional array. The tensor’s order denotes the number of its
dimensions, also known as ways or modes (e.g., matrices are 2-order tensors). A d-order
tensor X is called rank-1 if it can be expressed as the outer product of d non-zero vec-
tors: X = a1 ◦ a2 ◦ · · · ◦ ad. A fiber is a vector extracted from a tensor by fixing all
modes but one. For example, a matrix column is a mode-1 fiber. A slice is a matrix ex-
tracted from a tensor by fixing all modes but two. Matricization, also called reshaping
or unfolding, logically reorganizes tensors into other forms without changing the values
themselves. The mode-n matricization of a d-order tensor X ∈ RI1×I2×···×Id is denoted by
X(n) ∈ RIn×I1I2...In−1In+1...Id and arranges the mode-n fibers of the tensor as columns of
the resulting matrix. The Matricized-Tensor Times Khatri-Rao Product (MTTKRP) [102]
w.r.t. mode-n is the matrix multiplication X(n) A
(−n)
 , where A
(−n)
 corresponds to the
Khatri-Rao product of all the modes except the n-th. MTTKRP is the bottleneck operation
in many sparse tensor algorithms.
Table 3.2: Notations used throughout this work.
Symbol Definition
X ,X,x, x Tensor, matrix, vector, scalar
vec(X) Vectorization operator for matrixX
ΠC(x) Euclidean projection of x to a set C
X(:, i) Spans the entire i-th column ofX
diag(x) Diagonal matrix with vector x on the diagonal
X(n) mode-n matricization of tensor X






 Khatri-Rao product of all the factor matrices expectA
(n)
M (n) the MTTKRP corresponding to mode-n
∗ Hadamard (element-wise) product
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3.3 The SUSTain framework
First we present SUSTain for matrix input. Then, we describe how SUSTain can be ex-
tended for general high-order tensor input. Finally, we provide our interpretation protocol
of SUSTain for unsupervised phenotyping.
3.3.1 SUSTain for matrix input
Model: For an integer input matrix X ∈ ZM×N+ and a certain target rank R, the problem
can be defined as:
min
{
||X −U Λ V T ||2F
∣∣∣ U ∈ ZM×Rτ ,V ∈ ZN×Rτ ,Λ ∈ ZR×R+
}
(3.2)
where Zτ = {0, 1, . . . , τ} is the set of nonnegative integers up to τ , Z+ = {1, 2, . . . ,∞} is
the set of positive integers and Λ is a diagonal R-by-R matrix. The above problem can be
also formulated as ||X−∑Rr=1 λ(r)U(:, r) V (:, r)T ||2F where λ(r) = Λ(r, r). The reason
for having λ(r) is to absorb any scaling of each r-th rank-1 component, since the entries
of U and V factors are upper bounded by τ . Note that the λ(r) values cannot be simply
obtained through normalization as in the corresponding real-valued models (e.g., NMF [17,
103]), due to the integer constraints. Finally, note that the integer set Zτ can easily vary
for different factor matrices and even allow negative integers; this can also happen for the
input matrix X . The formulation in Problem (3.2) favors simplicity of presentation and
matches the need of phenotyping applications.
Fitting Algorithm: We employ an alternating updating scheme to tackle the non-convex
optimization Problem (3.2). Our scheme leads to optimal solutions to each one of the sub-
problems in an efficient manner, while organizing the order of updates so as to promote
re-use of already computed intermediate results.
We follow the intuition behind the Hierarchical Alternating Least Squares (HALS)
framework, which enables isolating and solving for each k-th rank-1 component separately.
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λ(r) U(:, r) V (:, r)T
︸ ︷︷ ︸
Rk
−λ(k) U(:, k) V (:, k)T ||2F (3.3)
| U ∈ ZM×Rτ ,V ∈ ZN×Rτ ,Λ ∈ ZR×R+ }
where Rk corresponds to the “residual matrix” and is considered fixed when solving for
the k-th rank-1 component. The objective can be written as [104]:
J = ||Rk||2F + λ2(k) ||U(:, k)||22 ||V (:, k)||22 − 2 λ(k) U(:, k)T Rk V (:, k)
We set:
∂J/∂λ(k) = 2 λ(k) ||U(:, k)||22 ||V (:, k)||22 − 2 U(:, k)T Rk V (:, k) = 0
and obtain:
λ∗k :=
U(:, k)T Rk V (:, k)
||U(:, k)||22 ||V (:, k)||22
If U(:, k)T Rk V (:, k) > 0 then the minimum value of J for λ(k) ∈ Z+ is obtained at
max(1, round(λ∗k)) where round() rounds to the nearest integer. IfU(:, k)
T Rk V (:, k) ≤
0, then the minimum objective value for λ(k) ∈ Z+ is attained at λ(k) = 1. Combining





U(:, k)T Rk V (:, k)
||U(:, k)||22 ||V (:, k)||22
))
(3.4)
In practice,Rk may be large (M ×N ) and dense, even if the input is sparse (as happens in
our main motivating application); thus its explicit materialization should be avoided [105,
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Next, solving Problem (3.3) for V (:, k) gives:
min
{
||Rk − λ(k) U(:, k) V (:, k)T ||22
∣∣ V (:, k) ∈ ZNτ
}
(3.6)
To solve the above, we apply the Optimal Scaling Lemma [106] for the integer constraint.
This Lemma states that for any set C of constraints imposed on b, it holds that:
min
{
||Y − x bT ||22
∣∣ b ∈ C
}
= ΠC(β)
where β = x
T Y
xT x
is the unconstrained solution to the above problem. This means that the
optimal solution of the constrained problem is simply the projection of the unconstrained
solution onto the constraint set C. Thus, the optimal solution of Problem (3.6) is:
V (:, k)← ΠZNτ
(
RTk U(:, k)
[UT U ]k,k λ(k)
)
(3.7)
Since ZNτ is the Cartesian product of subsets of the real line, i.e., ZNτ = Zτ × Zτ × · · · × Zτ︸ ︷︷ ︸
N times
we can take
ΠZNτ (V (:, k)) = [ΠZτ (V (1, k)), . . . ,ΠZτ (V (N, k))] (3.8)
thus project each scalar coordinate individually. For a real-valued scalar α, projecting onto
Zτ gives [107]:
ΠZτ (α) = min (max (round (α) , 0) , τ) (3.9)
Finally, expandingRk in Expression (3.7), combining with (3.8), (3.9) and setting:
b← V (:, k) + [X
T U ]:,k − V Λ [UT U ]:,k
[UT U ]k,k λ(k)
(3.10)
gives the optimal solution for Problem (3.6):
V (:, k)← min (max (round (b) , 0) , τ) (3.11)
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where min(),max(), round() are taken element-wise.
Having derived the updates for λ(k),V (:, k), in Relations (3.5) and (3.11) respectively,
we remark that the computationally expensive intermediate results [XT U ] and [UT U ]
are shared between them. To exploit that, we choose to successively update λ(k) and
V (:, k) during the same iteration and iterate ∀k ∈ {1, . . . , R}. As a result of the proposed
update order, the only non-negligible additional operation in order to compute both λ(k)
and V (:, k) is to re-compute t := V Λ [UT U ]:,k after having updated λ(k).
Re-computing t can be further optimized by observing that only the contribution of the
k-th component tk := V (:, k) ∗ λ(k) [UT U ]k,k has to be adjusted. Thus, we can store t
and tk, compute λ′(k), and then adjust t as: t← t− tk +
(
V (:, k) ∗ λ′(k) [UT U ]k,k
)
.
Updating U(:, k) can be executed in symmetric fashion to V (:, k). In Algorithm 1, we
present our main procedure to update both the factor matrices U and V and λ values in an
alternating fashion. In Algorithm 2, we provide the definition of SUSTain Update Factor
which updates a single factor (denoted as F ) and the vector λ.
Algorithm 1 SUSTainM
Input: X ∈ RM×N , target rank R and upper bound τ
Output: U ∈ ZM×Rτ ,V ∈ ZN×Rτ ,λ ∈ ZR+
1: Initialize U ,V ,Λ
2: while convergence criterion is not met do
3: F ← U ,M ←X V ,C ← V T V
4: [U ,λ] = SUSTain Update Factor(F ,M ,C,λ, R, τ)
5: F ← V ,M ←XT U ,C ← UT U
6: [V ,λ] = SUSTain Update Factor(F ,M ,C,λ, R, τ)
7: end while
Computational Complexity: The asymptotic cost of executing Algorithm 2 is 2R2I flops
(i.e., floating-point operations), ∀R > 5. This step costs 2R2N when updating V and
2R2M when updatingU . In Algorithm 1, assuming the inputX is sparse, the cost of each
one of X V and XT U is 2 nnz(X) R flops. Also, computing V T V and UT U cost
2R2N and 2R2M flops respectively. Thus, the total cost is: 4R (nnz(X) + (M +N)R)
flops.
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Algorithm 2 SUSTain Update Factor(F ,M ,C,λ, R, τ)
Input: F ∈ Zτ I×R,M ∈ RI×R,C ∈ RR×R,λ ∈ ZR+, target rank R and upper bound τ
Output: F ∈ Zτ I×R,λ ∈ ZR+
1: for k = 1, . . . , R do
2: t← F (λ ∗C(:, k))
3: tk ← F (:, k) ∗ λ(k) C(k, k)
4: α← λ(k) + F (:,k)T (M(:,k) − t)
C(k,k) [F T F ]k,k
5: λ(k)← max (1, round (α))
6: t← t− tk + (F (:, k) ∗ λ(k) C(k, k))
7: b← F (:, k) + M(:,k) − tC(k,k) λ(k)
8: F (:, k)← min (max (round (b) , 0) , τ)
9: end for
3.3.2 SUSTain for tensor input
Model: For a tensor X ∈ RI1×I2×...Id of order d and a certain target rank R, the problem




λ(r)A(1)(:, r) ◦ . . . ◦ A(d)(:, r)||2F
| A(n) ∈ ZIn×Rτ ,λ(r) ∈ Z+} (3.12)
where n = {1, . . . , d},Zτ = {0, 1, . . . , τ} is the set of nonnegative integers up to τ
and Z+ = {1, 2, . . . ,∞} is the set of positive integers. Our model is an extension of
SUSTainM presented in Section 3.3.1 for high-order tensors. It can be viewed as a con-
strained version of the CP tensor model [23, 89, 108].
Fitting Algorithm: Similarly to the matrix case, we set:
Rk := X −
R∑
r=1,r 6=k
λ(r)A(1)(:, r) ◦ . . . ◦ A(d)(:, r)
Thus, Problem (3.12) becomes:
min{||Rk − λ(k)A(1)(:, k) ◦ . . . ◦ A(d)(:, k)||2F
| A(n) ∈ ZIn×Rτ ,λ(k) ∈ Z+} (3.13)
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We matricize the above expression w.r.t. mode-n and utilize the fact that the mode-n matri-
cization of a rank-1 tensor b1 ◦ · · · ◦ bd can be expressed as bn (bd ⊗ · · · ⊗ bn+1 ⊗ bn−1 ⊗ · · · ⊗ b1)T [109]:
min{||Rk(n) − λ(k)A(n)(:, k)
(A(d)(:, k)⊗ · · · ⊗A(n+1)(:, k)⊗A(n−1)(:, k)⊗ · · · ⊗A(1)(:, k))T ||2F
| A(n) ∈ ZIn×Rτ ,λ(k) ∈ Z+} (3.14)
We setA(−n) := A(d)  · · · A(n+1) A(n−1)  · · · A(1) as the Khatri-Rao Product of
all the factor matrices except the n-th and
C(−n) := A(d)
T
A(d) ∗ · · · ∗A(n+1)T A(n+1) ∗A(n−1)T A(n−1) ∗ · · · ∗A(1)T A(1) (3.15)
as the Hadamard product of the Gram matrices of all the factor matrices except the n-th.
Then, Objective (3.14) becomes
min{||Rk(n) − λ(k)A(n)(:, k)A(−n) (:, k)T ||2F | A(n) ∈ ZIn×Rτ ,λ(k) ∈ Z+} (3.16)
Solving the above for λ(k) can be handled equivalently to the corresponding matrix case











By exploiting that [11]:











 ]k,k = C
(−n)(k, k)
and expanding:
Rk(n) A(−n) (:, k) = M (n)(:, k)−A(n) Λ C(−n)(:, k) + λ(k) C(−n)(k, k)A(n)(:, k) (3.18)
where M (n)(:, k) is the Matricized-Tensor Times Khatri-Rao Product (MTTKRP) [102]
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Next, we transpose the Objective (3.16) and solving forA(n)(:, k) can be handled as in the
matrix case (Relation (3.7)) through the Optimal Scaling Lemma [106]. Thus, the optimal
A(n)(:, k) ∈ ZInτ is given by:
A(n)(:, k)← ΠZInτ
(












Note the direct correspondence of the above formulations for λ(k),A(n)(:, k) with the core
update Algorithm 2 we used for the matrix case. If we setF ← A(n),M ←M (n),C ← C(−n)
then we can simply use Algorithm 2 to update a single factor A(n) and the λ values. Also,
we can exploit the development of existing scalable software libraries computing the bot-
tleneck MTTKRP kernel for sparse data efficiently [102]. In Algorithm 3, we summarize
the operations of our methodology for tensor input.
Algorithm 3 SUSTainT
Input: X ∈ RI1×I2×...Id , target rank R and upper bound τ
Output: A(n) ∈ ZIn×Rτ , with n ∈ {1, . . . , d},λ ∈ ZR+
1: InitializeA(n),λ
2: while convergence criterion is not met do
3: for n = 1, . . . , d do
4: M (n) ← X(n) A(−n) // MTTKRP
5: Compute C(−n) as in Relation (3.15)
6: [A(n),λ] = SUSTain Update Factor(A(n), M (n), C(−n),λ, R, τ)
7: end for
8: end while
Computational Complexity: Updating the n-th mode in Algorithm 3 requires: 3Rnnz(X )
flops to compute the MTTKRP using state-of-the-art libraries for sparse tensors [102],
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2 R2 In flops to compute A(n)
T
An and (d − 1) R2 flops to update C(−n) as in Equa-
tion (3.15). As discussed in the matrix case, the dominant cost of Algorithm 2 is 2 R2 In
flops. Overall, Algorithm 3 requires: 3 d R nnz(X ) + 4 R2 ∑dn=1 In + d (d− 1) R2 flops.
In our experiments, the first term, thus the computation of MTTKRP, dominates the total
cost.
3.3.3 Interpretation for phenotyping
Given the EHRs of a certain cohort, we form a patient-by-diagnoses matrix X , whose
X(i, j) cell is the number of encounters of patient i where encounter diagnosis j was
recorded. In that case, the patient membership vector U (i, :) of SUSTainM provides the
distinct levels of frequency of each one of theR phenotypes throughout the medical history
of the i-th patient. Likewise, each column V (:, r) indicates the frequency levels of each
medical feature w.r.t. the r-th phenotype. Table 3.1 summarizes a phenotype example that
accounts for the largest share of heart failure patients. Finally, due to the integer box (i.e.,
{0, . . . , τ}) constraints employed on the factor matrices, we can interpret the integer λ(r)
values as scaling up the input encounter counts for the r-th phenotype. Thus, phenotypes
with higher λ(r) values are expected to describe more persistent medical conditions, with
higher number of associated encounters.
The above interpretation can be extended to the tensor case. Consider a tensor X whose
X (i, j, k) cell defines the count of encounters of patient i where medication k was or-
dered for the patient with diagnosis j as the order indication. Factorizing this tensor using
SUSTainT yields a patient factor A(1) which can be interpreted similarly to the U factor
in the matrix case. Also, the factor matrices A(2),A(3) corresponding to diagnosis and
medication or procedure phenotypes can be interpreted similarly to the V factor in the





Table 3.3 summarizes statistics for the datasets used.
Sutter: This dataset corresponds to EHRs from Sutter Palo Alto Medical Foundation
(PAMF) Clinics. The patients are 50 to 80 years old adults chosen for a heart failure
study [110]. To form a patient-by-diagnosis matrix input, we extracted the number of
encounter records with a specific diagnosis for each patient. To form a patient-diagnosis-
medication tensor input, we used the medication orders, reflecting the ordered medications
and the indicated diagnosis. We adopt standard medical concept groupers to group the
available ICD-9 diagnosis codes [43] into Clinical Classification Software (CCS) [111] di-
agnostic categories (level 4). We also group the normalized drug names (i.e., combining
all branded names and the generic name for a medication) based on unique therapeutic
subclasses using the Anatomical Therapeutic Chemical Classification System [112].
CMS: We used a publicly-available CMS Linkable 2008-2010 Medicare Data Entrepreneurs’
Synthetic Public Use File (DE-SynPUF) 2 that contains three years of claim records syn-
thesized (i.e., to protect privacy) from 5% of the 2008 Medicare population. CMS creates
twenty 5% subsamples of the claims data. We used the carrier claims data available from
DE-SynPUF for the patients belonging to Samples 1 & 2. We increase the number of sam-
ples (i.e., number of patients) considered for the experiments related to assessing scalabil-
ity. We used the diagnostic code information to build the input matrix and the diagnoses
and procedures recorded to build the input tensor. In particular, we group the available
ICD-9 diagnosis codes [43] into CCS [111] diagnostic categories (level 4) and use the CCS
flat code grouper [111] to transform the CPT procedure codes available into procedure




Table 3.3: For each dataset used, we list its name, nature of input modes, their sizes and
the approximate number of non-zeros. Pat refers to patients, Dx to diagnoses, Rx to medi-
cations and Proc to procedures.
dataset modes size of modes #nnz (≈Millions)
Sutter-matrix Pat-Dx 259,999× 576 5.7
Sutter-tensor Pat-Dx-Rx 248,347× 552× 555 5.4
CMS-matrix Pat-Dx 197,212× 583 10.9
CMS-tensor Pat-Dx-Proc 197,143× 583× 239 23.4
categories.
Baselines
Below, we describe our efforts to design competitive baseline methods producing the tar-
get models in Problems 3.2 and 3.12, for the matrix and the tensor cases respectively.
Round: This baseline rounds the factor matrices from nonnegative matrix/tensor factoriza-
tion. In the matrix case, we used the implementation of Nonnegative Matrix Factorization
(NMF) [12, 113] and projected all the entries of the resulting factor matrices to Zτ . We
also set λ to an all-ones vector as NMF typically does not have the diagonal matrix Λ. A
typical issue of naively rounding NMF solutions is that values that are lower than 0.5 are
rounded to 0, so a potentially large part of model information can be lost.
In the tensor case, we used the CP-ALS algorithm as in the Tensor Toolbox [114],
adjusted to impose non-negativity constraints [113] on the factor matrices. Also, in contrast
to the NMF case, CP-ALS produces a λ vector of nonnegative real values. In order to
alleviate the effect of zeroing out values less than 0.5 we compute the cube root of the
λ vector element-wise and form a vector λ̂. Then, we absorb this scaling in the factor
matrices by multiplyingA(n) diag(λ̂), ∀n = {1, . . . , d} where d is the input tensor’s order.
Finally, we set λ to an all-ones vector and project all the entries of the resulting factor
matrices to Zτ .
Scale-and-round: We design a more sophisticated scale-and-rounding heuristic which
scales the factor matrices of the real-valued solutions before performing the rounding. This
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step further alleviates the problem of zeroing out values less than 0.5.
In the matrix case, we define the scaling factor γ2(j) = τ/max(V (:, j)). Then, Ṽ (:, j)
= round (γ2(j)V (:, j)). Similarly, we define γ1(j) = τ /max(U(:, j)). Then, Ũ(:, j)
= round (γ1(j)U(:, j)). Those steps scale-up the maximum value of each factor matrix
column to reach the upper bound τ . Then, this excess scaling is absorbed into λ as:
λ = round(1/γ1γ2).
In the tensor case, we absorb the scaling of the λ output of the real-valued solution
into the factor matrices as in “Round”, and extend the Scale-and-round matrix approach
accordingly.
AILS: Alternating Integer Least Squares approach: We used the Integer Least Squares
(ILS) with box constraints approach which is proposed in [97, 96]. This approach was
recently unified within an Integer Matrix Factorization framework [94]. We exploit the re-
dundancy among ILS problems targeting the same factor matrix, so that the QR factoriza-
tion in the reduction phase is only computed once. Note that solving general ILS problems
is NP-hard [94], which is reflected in the runtime of this method in the experiments. We
enabled the extraction of the integer λ values through an ILS by noticing that vectorizing
the original problem as
min
{
||vec(U Λ V T )− vec(X)||2F
∣∣∣ Λ ∈ ZR×R+
}
can be transformed to [115]: min
{
||(V U)λ− vec(X)||2F
∣∣ λ ∈ ZR+
}
which gives the
ILS to solve for. Note that we attempted to extend this approach for tensor input; however,
the materialization of the Khatri-Rao product of all the factor matrices failed due to out
of memory problems even for the smallest target rank for both of the datasets used. To
illustrate the magnitude of this issue, the size needed for the Khatri-Rao product of all
factor matrices for Sutter data and R = 5 is: 248347∗552∗555∗5∗8 bytes≈ 3 Terabytes.
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Evaluation metrics
We evaluate the methods under comparison in terms of the trade-off between execution
time and accuracy for various target ranks considered (R = {5, 10, 20, 40}). Accuracy is
measured in terms of fit: 1 − ||X − X̂||F/||X||F , where X̂ is the re-constructed input
through the model factors (this extends trivially to the tensor case); fit can be considered as
the the proportion of data explained by the model.
Initialization details
In all experiments, when we compare SUSTain and AILS, we provide them with the same
initialization.
Regarding the accuracy-time trade-off evaluation, we initialize with several schemes
and for each method we choose the one providing the highest fit. The schemes are the fol-
lowing: a) round heuristic, b) scale-and-round heuristic, c) random: random initialization
with integers within the required range and λ set to all-ones vector, d) random & sampling:
random initialization of the patients factor and sampling from the input data to populate
the rest of the factors. In the matrix case, we initialize each j-th column of V by random
sampling of input patient vectors and scaling them to lie on Zτ if needed. In the tensor
case, for each sampled slice X (i, :, :), we populate each j-th component of A(2),A(3) by
sampling the row and column of X (i, :, :) with the maximum sum. Note that when we
measure execution time for each approach, we do take into account the time spent for its
initialization.
In the scalability evaluation, we initialize each method with the random & sampling
scheme (d) described above; this provided better starting points than using pure random
initialization. For this experiment, we ignore the initialization time, since we want to focus
on the methods’ scalability behavior.
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Implementation details
We used MatlabR2017b for our implementations, along with functionalities for sparse ten-
sors from the “Tensor Toolbox” [114] and for nonnegative matrix factorization from the
“nonnegfac-matlab” [12] toolbox. The ILS solver we use for the AILS baseline is included
in the state-of-the-art MILES software [116].
The zero-lock problem refers to the case when a single column is zeroed out, thus
zeroing out an entire rank-1 component of the solution. To avoid that in our scheme, we
add the smallest perturbation possible (+1) to a randomly-chosen coordinate of the vector
zeroed out.
In both SUSTain and AILS, we break the iterations when the successive difference of
the objective drops below 1e− 4. Finally, the parameter τ is set to 5 driven by discussions
with medical experts and similarity to many medical scoring systems.
Hardware
We conducted our experiments on a server running Ubuntu 14.04 with 1TB of RAM and
four Intel E5-4620 v4 CPU’s with a maximum clock frequency of 2.10GHz. Each of the
processors contains 10 cores with 2 threads each.
3.4.2 Matrix case experiments
Accuracy-Time trade-off: In Figure 3.1, we showcase the accuracy-time trade-off regard-
ing the Sutter PAMF dataset. SUSTainM is at least 60× faster (R = 40) than the most
accurate baseline (AILS). For R = 5, SUSTainM achieves 425× speedup over AILS: as
compared to the ≈ 22 minutes spent by AILS, our approach executes in ≈ 3 seconds for
the same level of accuracy. Even for R = {10, 20} SUSTainM achieves 98× and 110×
faster computations than AILS. At the same time, SUSTainM achieves up to 16% higher
fit than the scale-and-round heuristic, operating on comparable running times. Note that for
R = 5, our approach is even faster (and more accurate) than the scale-and-round baseline
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Figure 3.2: Fit (range [0, 1]) vs time trade-off for varying target number of phenotypes R =
{5, 10, 20, 40} for the CMS matrix input. SUSTainM is at least an order of magnitude
faster than the most accurate baseline (up to 38× faster for R = 20), while achieving the
same level of accuracy. Also, SUSTainM achieves up to 14% higher fit over scale-and-
rounding heuristics.
Table 3.4: Running time (seconds) of one iteration for increasingly larger number of pa-
tients considered from the CMS data. Matrix case, R = 10.
#patients (≈Thousands) 246 493 739 985
#nnz (≈Millions) 14 27 41 55
SUSTainM 0.71 0.95 1.66 2.82
Round / Scale-and-round 4.4 8.9 12.9 19.5
AILS 339 514 940 1254
as well, since initializing with random factors provided a better final fit than initializing
with the scale-and-round result. We also remark that the naive round heuristic achieves a
fit of zero, which is a by-product of zeroing out the majority of the model factor elements.
In Figure 3.2, we provide the results of the same experiment regarding the CMS dataset.
For the same level of accuracy, SUSTainM is at least an order of magnitude faster than
AILS, and up to 38× faster for R = 20. It also achieves up to 14% higher fit over the
scale-and-rounding heuristic for comparable execution time.
Scaling for larger number of patients: In Table 3.4, for fixed R = 10, we measure a
single iteration’s time for increasing subsets of CMS patients. The NMF execution time
is considered for Round and Scale-and-round heuristics, since their post-processing cost is
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Figure 3.3: Fit (range [0, 1]) vs time trade-off for varying target number of phenotypes
R = {5, 10, 20, 40} for the Sutter and the CMS tensor input. SUSTainT achieves up to
9% and 12% higher fit respectively over scale-and-rounding heuristics.
Table 3.5: Running time (seconds) of one iteration for increasingly larger number of pa-
tients considered from the CMS data. Tensor case, R = 10.
#patients (≈Thousands) 246 493 739 985
#nnz (≈Millions) 29 58 88 117
SUSTainT 38.5 76.9 115 151
Round / Scale-and-round 39.6 78 117 157
negligible. SUSTainM can execute very fast (a single iteration in ≈ 3 seconds) even for
≈ 985 thousand patients.
3.4.3 Tensor case experiments
Accuracy-Time trade-off: In Figure 3.3, we provide the fit-time trade-off for varying
target rank of our input tensor datasets. As discussed in Section 3.4.1, the extension of
AILS approach to tensors cannot scale for any dataset or target rank considered. Overall,
SUSTainT achieves up to 9% and 12% increase in fit over the scale-and-round heuristic
w.r.t. the Sutter PAMF and CMS datasets respectively. Note that the fit of the scale-and-
round approach decreases for successively increasing target rank values (e.g., transitioning
from R = 20 to R = 40 for CMS data). This indicates that heuristic approaches which
simply post-process real-valued solutions may not fully exploit the available target rank.
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Scaling for larger number of patients: In Table 3.5, we report the time spent for one
iteration of increasingly larger subset of patients considered from the CMS data, with fixed
target rank (R = 10). The time measured for the heuristic approaches corresponds to the
execution time of CP-ALS, since the post-processing cost is negligible. We observe that
SUSTainT achieves linear scale-up w.r.t. increasing number of patients. We also remark
that the dominant cost in both SUSTainT and the CP-ALS is the MTTKRP computation,
which explains the comparable running time.
3.4.4 Case study on Phenotyping HF patients
Cardiovascular disease (CVD) is the leading cause of death worldwide and heart failure
(HF) is a dominant cause of morbidity and mortality. HF is traditionally characterized by
reduced ejection fraction (HFrEF) and preserved ejection fraction (HFpEF). But, recent
evidence suggests that HF is more heterogeneous than is reflected by ejection fraction. We
used SUSTain to explore this heterogeneity in an incident HF cohort.
Cohort and data selection: We select only the HF case patients from the Sutter PAMF
dataset. For each incident HF case, we extracted data in the 12-months before and the 12-
months after the initial HF diagnosis date, which resulted in 70, 531 clinical encounters. We
used all the data modalities available, i.e., medication orders and indications and encounter
diagnoses. The size of the resulting (patient-by-diagnosis-by-medication) tensor is 3, 497×
396× 367; the tensor contains a total of 92, 662 non-zero elements.
Choosing the number of phenotypes: We use the stability-driven criterion introduced
in [117]. The intuition behind this criterion is in promoting a target rank for which several
runs with different initial points return reproducible factors. We choose the diagnosis factor
matrix as the factor under assessment. Let D1 and D2 be the diagnosis factor matrix for 2
different runs with the same target rank. Then, the cross-correlation matrix C ∈ RR×R is
computed between the columns ofD1,D2 and the dissimilarity between them is computed
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Table 3.6: SUSTainT achieves ≈ 8.6% increase in fit than a Nonnegative CP-ALS model
truncated to achieve the same level of sparsity. The result refers to the HF case study for
R = 15.
method #nnz(A(1)) #nnz(A(2)) #nnz(A(3)) fit
SUSTainT 3, 438 54 88 0.261















Note that whenD1 can be transformed toD2 by column permutation, then diss(D1,D2) =
0. If B is the number of repetitions for each target rank, then the following relation com-







We used the “staNMF” toolbox 3 to compute the above score for each target rank on the
range {5, . . . , 20}. The input to SUSTainT were B = 20 initial points of the round
heuristic. R = 15 phenotypes were selected based on the above criterion. For the target
rank chosen, we pick the solution yielding the highest fit.
SUSTain provides concise and accurate solutions: We observed that besides preserving
the input data properties and providing a natural interpretation for medical experts, SUS-
Tain implicitly imposes sparse factors. To assess the factors’ conciseness, we compare their
fit with the achieved fit of the real-valued model (NN CP-ALS), which is post-processed to
achieve factor sparsity (as would be done by a practitioner). For each of the feature factors
(diagnosis and medication) of the real-valued model, we only consider the top-k elements
for each column (i.e., most important elements of each phenotype). For the patient factor,
we consider the top-k elements for each row (i.e., most important phenotypes for each pa-
3https://github.com/bdgp/staNMF
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Table 3.7: Representative phenotypes extracted by SUSTainT for our HF case study. The
score of each feature indicates its relative frequency within the phenotype. The prefix for
each feature indicates whether it corresponds to a medication (Rx) or a diagnosis (Dx). A
cardiologist provided phenotype annotations and validated that: the top-most phenotype is
aligned to guideline-based management of HF with reduced LVEF (HFrEF), the next one
corresponds to typical hypertensive patients (common risk factor of HF) and the last one
corresponds to hypertensive patients being more difficult to control.
HF with reduced LVEF (HFrEF) Score
Rx Loop Diuretics 3
Dx Congestive heart failure 1
Rx ACE Inhibitors 1
Rx Alpha-Beta Blockers 1
Rx Potassium 1
Hypertension Score
Rx ACE Inhibitors 3
Dx Essential hypertension 1
Rx Alpha-Beta Blockers 1
Rx Beta Blockers Cardio-Selective 1
Rx Calcium Channel Blockers 1
Rx HMG CoA Reductase Inhibitors 1
Rx Loop Diuretics 1
Rx Thiazides and Thiazide-Like Diuretics 1
Hypertension (more difficult to control) Score
Rx Angiotensin II Receptor Antagonists 2
Rx Beta Blockers Cardio-Selective 2
Rx Calcium Channel Blockers 2
Dx Essential hypertension 1
Rx Antiadrenergic Antihypertensives 1
Rx Loop Diuretics 1
Rx Potassium 1
tient). In each case, the value of k is chosen so that the sparsity level is close to the one
achieved by SUSTainT . We provide the results in Table 3.6, where we notice that for
the same level of sparsity, SUSTainT achieves ≈ 8.6% increase in fit. Thus, the integer
factors of SUSTainT decompose the input more accurately for the same level of sparsity
than the real-valued counterpart.
Phenotype discovery: In Table 3.1 and Table 3.7, we provide representative phenotypes
extracted through our method. A subset of annotations provided by the cardiologist are as
follows: hyperlipidemia (the one in Table 3.1), HF with reduced LVEF (HFrEF), hyperten-
sion (HTN), HTN which is more difficult to control, persistent and chronic atrial fibrilla-
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tion, depression, diabetes, comorbidities of aging, prior pulmonary embolism. Overall, 13
out of 15 phenotype candidates were annotated as clinically meaningful phenotypes related
to heart failure.
3.5 Related Work
Discrete factorization-based approaches: Dong et al. [94] proposed an Integer Matrix
Factorization framework via solving Integer Least Squares subproblems. As we experimen-
tally evaluated, this approach is orders of magnitude slower than SUSTain while achieving
the same level of accuracy. Kolda and O’Leary [118, 104] proposed a Semidiscrete Ma-
trix Decomposition into factors containing ternary values ({−1, 0, 1}). Despite its demon-
strated success for compression purposes, a direct application of this approach would in-
troduce negative values into the factors, thus hurting interpretability for nonnegative input.
Finally, several prior works target binary factorization (e.g., [119, 120, 121, 122, 123, 124,
125]). In contrast to strictly binary factors, SUSTain captures the quantity embedded in the
input data, which reveals important information (e.g., relative phenotype prevalence and
associated feature frequencies).
Unsupervised Phenotyping: Extensive prior work applies factorization techniques for
unsupervised phenotyping (e.g., [24, 21, 49, 50, 51, 126]). However, no work considered
extracting scoring-based phenotypes to facilitate their interpretation by domain experts.
HALS fitting algorithms: Our fitting algorithms follow the intuition of Hierarchical Al-
ternating Least Squares (HALS) framework [127] (aka rank-one residue iteration [128]),
which enables formulating the solution for each k-th rank-1 component separately. How-
ever, plain HALS does not tackle the challenges involved with either imposing integer
constraints or solving for the vector λ.
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3.6 Conclusions
The accuracy and scalability of SUSTain on “native” integer data derives from two key
insights. One is expected: just rounding or applying related transformations to real-valued
solutions is inherently limited. The second may be more surprising: while discrete con-
straints might appear to make the problem more challenging, in fact, a careful organiza-
tion of the problem into subparts can mitigate that complexity. In our case, we identify a
problem partitioning of integer-constrained subproblems that leads to an optimal and effi-
cient solution; and, we also define the order of alternating updates so as to enable reuse of
shared intermediate results. Consequently, SUSTain outperforms several baselines on both
synthetic (publicly-available) and real EHR data, showing either a better fit or orders-of-
magnitude speedups at a comparable fit.
Moving forward, there are many other sources of integer values in real-world data.
These include, for instance, ordinal values. Thus, whereas this work targets event counts,
extensions for other cases is a ripe target for future work.
Lastly, to enable reproducibility of our work, we open-source our implementations and
make them publicly available at: https://github.com/kperros/SUSTain.
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CHAPTER 4
SPARTAN: SCALABLE PARAFAC2 FOR LARGE & SPARSE DATA
Summary
Aggregating event occurrences over time for unsupervised phenotyping purposes,
as done in Chapter 3, may not be appropriate when disease states are evolving, as it
obfuscates the temporal ordering and structure of individual EHR encounter records.
In this Chapter, we expose how PARAFAC2 can account for the folded structure of
EHRs and augment phenotype candidates with information about their timing and
sequencing across different patients, which may in turn lead to a better understand-
ing of disease progression. To enable scalable PARAFAC2 computations for large
EHRs, we propose SPARTan, which exploits the inherent sparsity of input EHR data
and shows both faster (up to 22×) and more memory-efficient performance than
prior work.
A common problem in unsupervised learning is how to extract the latent correlation
structure among a set of variables, measured across a set of subjects whose observations
do not align naturally. For example, when modeling features derived from EHRs across a
set of patients, the number and duration of treatments may vary widely in time, meaning
there is no meaningful way to align their clinical records across time points. This renders
the extraction of high-order relationships among observations, patients and features a chal-
lenging task, e.g., extracting correlated sets of features indicating clinical manifestations,
the corresponding subset of patients exhibiting those features, as well as when these are ex-
hibited across observations for different patients. Extracting those high-order relationships
from large-scale EHR data may offer a scalable way to better understand the progression
of diseases and disease subtypes. We expose how the PARAFAC2 model can be utilized
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Table 4.1: Running time comparison: Time in minutes of one iteration for increasingly
larger datasets (63m to 500m) and fixed target rank (two cases considered: R = {10, 40}).
The mode sizes for the datasets constructed are: 1Mil. subjects, 5K variables and a maxi-
mum of 100 observations per subject. OoM (Out of Memory) denotes that the execution
failed due to the excessive amount of memory requested. Experiments are conducted on a
server with 1TB of RAM.
Target Rank 10 40
#nnz(Millions) 63 125 250 500 63 125 250 500
SPARTan 7.4 8.9 11.5 15.4 14 18.4 61 114
Sparse PARAFAC2 24.4 60.1 72.3 194.5 275.2 408.1 OoM OoM
to tackle this challenge, yielding interpretable and robust output. However, the standard
algorithm fitting the PARAFAC2 model expects dense data as input; designing an efficient
algorithm which can exploit the inherent sparsity of EHR data and can handle large-scale
EHR datasets has been an open challenge.
In this work, we develop a scalable method to compute the PARAFAC2 model for
large and sparse input data. Our method, called SPARTan, exploits special structure of
intermediate data arising within the PARAFAC2 model fitting, leading to a novel algorithm
that is both faster and more memory-efficient than prior work. We evaluate SPARTan on
both synthetic and real datasets, showing 22× performance gains over the best previous
implementation and also handling larger problem instances for which the baseline fails.
4.1 Introduction
This work concerns tensor-based analysis and mining of multi-modal data where obser-
vations are difficult or impossible to align naturally along one of its modes. A concrete
example of such data is electronic health records (EHR), our primary motivating applica-
tion. An EHR dataset contains longitudinal patient information, represented as an event
sequence of multiple modalities such as diagnoses, medications, procedures, and lab re-
sults. An important characteristic of such event sequences is that there is no simple way to
align observations in time across patients. For instance, different patients may have varying
length records between the first admission and the most recent hospital discharge; or, two
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patients whose records’ have the same length may still not have a sensible chronological
alignment as disease stages and patient progress vary.
For tensor methods, such data poses a significant challenge. Consider the most popu-
lar tensor analysis method in data mining, the canonical polyadic (CP) factorization (also
known as PARAFAC or CANDECOMP) [23, 89, 108]. A dataset with three modes might
be stored as an I × J ×K tensor X , which CP then decomposes into a sum of multi-way
outer (rank-one) products, X ≈ ∑Rr=1 ur ◦ vr ◦wr, where ur,vr,wr are column vectors
of size I, J,K, respectively, that effectively represents latent data concepts. Its popularity
owes to its intuitive output structure and uniqueness property that makes the model reliable
to interpret [129, 130, 11, 131, 132], as well as the existence of scalable algorithms and
software [102, 133, 114]. In the context of our main motivating application, tensor meth-
ods, such as CP, may offer a scalable way to better understand disease and disease subtype
progression; this may be achieved through the extraction of disease and treatment patterns,
the corresponding subsets of patients exhibiting those patterns, as well as their temporal
trends indicating when each of those patterns is expressed across observations for different
patients. However, in order to extract the latent correlation structure among variables, pa-
tients and time from EHR data, it would require finding some way to align time. This fact
is an inherent limitation of applying the CP model: any preprocessing to aggregate across
time may lose temporal patterns [24, 134, 135], while more sophisticated temporal feature
extraction methods typically need continuous and sufficiently long temporal measures to
work [136]. Other proposed methods specific to healthcare applications may give some
good results [137, 138, 139] but lack the uniqueness guarantee; thus, it becomes harder to
reliably extract the actual latent concepts as an equivalent arbitrary rotation of them will
provide the same fit. All of these weaknesses apply in the EHR scenario outlined above.
In fact, the type of data in the motivating example are quite general: consider that we
haveK subjects, for which we record J variables and we permit each k-th subject to have Ik
observations, which are not necessarily comparable among the different subjects. For this
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type of data, Harshman proposed the PARAFAC2 model [58]. It is a more flexible version of
CP: while CP applies the same factors across a collection of matrices, PARAFAC2 instead
applies the same factor along one mode and allows the other factor matrix to vary [11]. At
the same time, it preserves the desirable properties of CP, such as uniqueness [140, 141, 59,
142]. As shown in Figure 4.1, PARAFAC2 approximates each one of the input matrices as:
Xk ≈ Uk Sk V T , whereUk is of size Ik×R,Sk is a diagonal R-by-R, V is of size J ×R
and R is the target rank of the decomposition.
Despite its applicability, the lack of efficient PARAFAC2 decomposition algorithms has
been cited as a reason for its limited popularity [143, 144]. Overall, PARAFAC2 has been
mostly used for dense data (e.g., [59]) or sparse data with a small number of subjects [144].
To our knowledge, no work has assessed PARAFAC2 for large-scale sparse data, as well as
the challenges arising by doing so.
In this work, we propose SPARTan (abbreviated from Scalable PARafac Two) to fill
this gap, with a focus on achieving scalability on large and sparse datasets. Our method-
ological advance is a new algorithm for scaling up the core computational kernel arising in
the PARAFAC2 fitting algorithm. SPARTan achieves the best of both worlds in terms of
speed and memory efficiency: a) it is faster than a highly-optimized baseline in all cases
considered for both real (Figures 4.5, 4.6, 4.7) and synthetic (Table 4.1) datasets, achieving
up to 22× performance gain; b) at the same time, SPARTan is more scalable, in that it
can execute in reasonable time for large problem instances when the baseline fails due to
excessive memory consumption (Table 4.1). We summarize our contributions as:








Figure 4.1: Illustration of the PARAFAC2 model.
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PARAFAC2 model on large and sparse data.
• Evaluation on various datasets: We evaluate the scalability of our approach using
datasets originating from two different application domains, namely a longitudinal EHR
and a time-evolving movie ratings’ dataset, which is also publicly available. Addition-
ally, we perform synthetic data experiments.
• Real-world case study: We performed a case study of applying SPARTan on temporal
phenotyping over medically complex pediatric patients in collaboration with Children’s
Healthcare of Atlanta (CHOA). The phenotypes and temporal trends discovered were
endorsed by a clinical expert from CHOA.
To promote reproducibility, our code is open-sourced and publicly available at: https:
//github.com/kperros/SPARTan.
4.2 Background
Next we describe the necessary terminology and operations regarding tensors. Then, we
provide an overview of the CP model and relevant fitting algorithm. In Table 4.2, we
summarize the notations used throughout this work.
Table 4.2: Notations used throughout this work.
Symbol Definition
X ,X,x, x Tensor, matrix, vector, scalar
X† Moore-Penrose pseudoinverse
X(:, i) Spans the entire i-th column ofX (same for tensors)
X(i, :) Spans the entire i-th row ofX (same for tensors)
diag(x) Diagonal matrix with vector x on the diagonal
diag(X) Extract diagonal of matrixX
Xk shorthand forX(:, :, k) (k-th frontal slice of tensor X )
{Xk} the collection ofXk matrices, for all valid k




∗ Hadamard (element-wise) product
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4.2.1 Tensors and Tensor Operations
The order of a tensor denotes the number of its dimensions, also known as ways or modes
(e.g., matrices are 2-order tensors). A fiber is a vector extracted from a tensor by fixing
all modes but one. For example, a matrix column is a mode-1 fiber. A slice is a matrix
extracted from a tensor by fixing all modes but two. In particular, the X(:, :, k) slices of a
third-order tensor X are called the frontal ones and we succinctly denote them asXk [11].
Matricization, also called reshaping or unfolding, logically reorganizes tensors into other
forms without changing the values themselves. The mode-n matricization of a N -order
tensor X ∈ RI1×I2×···×IN is denoted by X(n) ∈ RIn×I1I2...In−1In+1...IN and arranges the
mode-n fibers of the tensor as columns of the resulting matrix.
4.2.2 CP Decomposition
The CP decomposition [23, 89, 108] of a third-order tensor X ∈ RI×J×K is its approxima-




ur ◦ vr ◦wr (4.1)
where ur ∈ RI ,vr ∈ RJ and wr ∈ RK are column vectors. If we assemble the column
vectors ur,vr,wr as: U = [u1 u2 . . . uR] ∈ RI×R,V = [v1 v2 . . . vR] ∈ RJ×R,W =
[w1 w2 . . . wR] ∈ RK×R, then U ,V ,W are called the factor matrices. Interpretation
of CP is very intuitive: we consider that the input tensor can be summarized as R latent
concepts. Then, for each r-th concept, the vectors (ur,vr,wr) are considered as soft-
clustering membership indicators, for the corresponding I, J and K elements of each mode.
An equivalent formulation of Relation (4.1) w.r.t. the frontal slices Xk of the input tensor
X is [145]:
Xk ≈ U Sk V T (4.2)
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where k = 1, 2, . . . , K and S ∈ RR×R×K is an auxiliary tensor. Each frontal slice Sk of
S contains the row vectorW (k, :) along its diagonal: Sk = diag(W (k, :)). Relation (4.2)
provides another viewpoint of interpreting the CP model, through its correspondence to
the Singular Value Decomposition (SVD): each slice Xk is decomposed to a set of factor
matrices U ,V (similar to the singular vectors) which are common for all the slices, and
a diagonal middle matrix (similar to the singular values) which varies for each k-th slice.
Note, however, that no orthogonality constraints are imposed on U ,V of the CP model, as
in the SVD [144].
Uniqueness. A fundamental property of CP is uniqueness [129, 130]. The issue with
non-uniqueness can be exemplified via matrix factorization as follows [11, 131]: If a ma-
trix X is approximated by the product of ABT , then it can also be approximated with
the same error by AQQ−1BT = ÃB̃T , for any invertible Q. Thus, we can easily con-
struct two completely different sets of rank-one factors that sum to the original matrix.
Inevitably, this hurts interpretability, since we cannot know whether our solution is an ar-
bitrarily rotated version of the actual latent factors. In contrast to matrix factorization or
Tucker decomposition [11], Kruskal [129] proved that CP is unique, under the condition:
kU + kV + kW ≥ 2R + 2, where kU is the k-rank of U , defined as the maximum value
k such that any k columns are linearly independent. The only exception is related to ele-
mentary indeterminacies of scaling and permutation of the component vectors [11, 132]. In
sum, the CP decomposition is pursuing the true underlying latent information of the input
tensor and provides reliable interpretation for unsupervised approaches.
Fitting the CP model. Perhaps the most popular algorithm for fitting the CP model is
the CP-Alternating Least Squares (CP-ALS) [108, 89], listed in Algorithm 4. The main
idea is to solve for one factor matrix at a time, by fixing the others. In that way, each
subproblem is reduced to a linear least-squares problem. In case the input tensor contains
non-negative values, a non-negative least-squares solver (e.g., [146]) can be used instead
of an unconstrained one, to further improve the factors’ interpretability [143].
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Due to the ever increasing need for CP decompositions in data mining, the parallel
CP-ALS for sparse tensors has been extensively studied in the recent literature for both
single-node and distributed settings (e.g., [102, 147, 148, 149, 150, 151]). A pioneer-
ing work in addressing scalability issues for sparse tensors was provided by Bader and
Kolda [102] 1. The authors identified and scaled up the algorithm’s bottleneck, which is
the materialization of the Matricized-Tensor-Times-Khatri-Rao-Product (MTTKRP). For
example, in Algorithm 4, the MTTKRP corresponds to the computation of X(1)(W  V )
when solving for U . For large and sparse tensors, a naive construction of the MTTKRP
requires huge memory (which might not even be available) and computational cost and has
to be avoided.
Algorithm 4 CP-ALS
Input: X ∈ RI×J×K and target rank R
Output: λ ∈ RR,U ∈ RI×R,V ∈ RJ×R,W ∈ RK×R
1: Initialize V ,W
2: while convergence criterion is not met do
3: U ←X(1)(W  V )(W TW ∗ V TV )†
4: Normalize columns of U
5: V ←X(2)(W U)(W TW ∗UTU)†
6: Normalize columns of V
7: W ←X(3)(V U)(V TV ∗UTU)†
8: Normalize columns ofW and store norm in λ
9: end while
4.3 PARAFAC2 Overview & Challenges
4.3.1 Model
As we introduced in Section 4.1, the PARAFAC2 model [58] can successfully deal with
an incomparable mode of each slice Xk [59]. It does so, by introducing a set of Uk ma-
trices replacing the U matrix of the CP model in Relation (4.2). Thus, each slice Xk is
1The contributions of [102], among others, are summarized as the Tensor Toolbox [114], which is widely
acclaimed as the state-of-the-art package for single-node sparse tensor operations and algorithms.
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decomposed as shown in Figure 4.1:
Xk ≈ Uk Sk V T (4.3)
where k = 1, . . . , K,Uk ∈ RIk×R,Sk ∈ RR×R is diagonal and V ∈ RJ×R. To preserve
uniqueness, Harshman [58] imposed the constraint that the cross productUTk Uk is invariant
regardless which subject k is involved [11, 144]. In that way, the CP model’s invariance
of the factor Uk itself (or U given its invariance to k), is relaxed [152]. For the above
constraint to hold, each Uk factor is decomposed as:
Uk = QkH (4.4)
whereQk is of size Ik×R and has orthonormal columns, andH is anR×R matrix, which
does not vary by k [11]. Then, the constraint that UTk Uk is constant over k is implicitly
enforced, as follows: UTk Uk = H
TQTkQkH = H
TH = Φ.
There have been several results regarding the uniqueness property of PARAFAC2 [140,
141, 59]. The most relevant [140] towards our large-scale data scenario (i.e., the num-
ber of K subjects can easily reach the order of hundreds of thousands) is that a rank-R
PARAFAC2 model is unique if Φ and V have rank R, Φ has no zero entries and the num-
ber of K subjects is at least: R (R+ 1) (R+ 2) (R+ 3) / 24 [153]. Note that this bound on
the number of K subjects is sufficient but not necessary to achieve uniqueness; it is conjec-
tured (as evaluated through simulation studies) that PARAFAC2 provides unique solutions
as long as K ≥ 4 [59, 153, 142].
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4.3.2 Classical Algorithm for PARAFAC2
Below, we overview the classical algorithm for fitting PARAFAC2, proposed by [59]. Their





||Xk −UkSkV T ||2F
subject to: Uk = QkH , QTkQk = I and Sk to be diagonal. Algorithm 5 follows an
Alternating Least Squares (ALS) approach, divided in two distinct steps: first (lines 3-6),
the set of column-orthonormal matrices {Qk} is computed by fixingH ,V , {Sk}. This step
can be derived by examining the pursuit of eachQk as an individual Orthogonal Procrustes
Problem [109] of the form:
min
Qk
||Xk −QkHSkV T ||2F (4.5)
subject to QTkQk = I . Given the SVD of HSkV
TXTk as PkΣkZk, the minimum of
objective (4.5) over column-orthonormalQk is given byQk = ZkP Tk [59, 109].






||QTkXk −HSkV T ||2F (4.6)
where Sk is diagonal. Note the equivalence of the above objective with the CP “slice-wise”
formulation of Relation (4.2). This equivalence implies that minimizing the objective (4.6)
is achieved by executing the CP decomposition on a tensor Y ∈ RR×J×K with frontal
slices Yk = QTkXk (lines 7-10). In order to avoid executing all the costly CP iterations,
Kiers et al. [59] propose to run a single CP-ALS iteration, since this suffices to decrease
the objective.
The PARAFAC2 model can be extended so that non-negative constraints are imposed
on {Sk},V factors [145]. This is a property inherited by the CP-ALS iteration, where we
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can constrain the factors V andW to be non-negative, as discussed in Section 4.2.2. Note
that constraining the {Uk} factors to be non-negative as well is not as simple, and a naive
approach would violate the model properties [154].
Algorithm 5 PARAFAC2-ALS [59]
Input: {Xk ∈ RIk×J} for k = 1, . . . ,K and target rank R
Output: {Uk ∈ RIk×R}, {Sk ∈ RR×R} for k = 1, . . . ,K, V ∈ RJ×R
1: InitializeH ∈ RR×R,V , {Sk} for k = 1, . . . ,K
2: while convergence criterion is not met do
3: for k = 1, . . . ,K do
4: [Pk,Σk,Zk]← truncated SVD ofHSkV TXTk at rank R
5: Qk ← ZkP Tk
6: end for
7: for k=1, . . . , K do
8: Yk ← QTkXk // construct slice Yk of tensor Y
9: end for
10: Run a single iteration of CP-ALS on Y to computeH,V ,W
11: for k = 1, . . . ,K do
12: Sk ← diag(W (k, :))
13: end for
14: end while
15: for k = 1, . . . ,K do
16: Uk ← QkH // Assemble Uk
17: end for
4.3.3 Challenges of PARAFAC2 on sparse data
Next, we summarize a set of crucial observations regarding the computational challenges,
when executing Algorithm 5 on large, sparse data:
Bottleneck of Algorithm 5. Regarding the 1st step (lines 3-6), in practice for sparse
Xk, each one of the K sub-problems scales as O(min(RI2, R2I)), due to the SVD in-
volved [155], where I is an upper bound for Ik. Note that this computation can be trivially
parallelized for all K subjects. On the other hand, the 2nd step (lines 7-10) is dominated
by the MTTKRP computation (which as we discussed in Section 4.2 is the bottleneck of
sparse CP-ALS). Thus, it scales as 3R nnz(Y) [150], using state-of-the-art sparse tensor li-
braries for single-node [102]. Given that none of the input matricesXk is completely zero,
then: 3R nnz(Y) ≥ 3KR2. As a result, this step becomes the bottleneck of Algorithm 5
for large and sparse “irregular” tensors, since it cannot be parallelized w.r.t. the K subjects,
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as trivially happens with the 1st one.
Imbalance of mode sizes of Y . The size of the intermediate tensor Y formed isR×J×K.
For large-scale data, we expect that R << K, J since R corresponds to the target rank of
the overall PARAFAC2 decomposition. Note that this property of “size imbalance” may
not hold for a general large tensor, thus generic CP-ALS solvers (e.g., [102]) cannot exploit
it.
Structured sparsity of {Xk}. First, we observe that even if the input slices {Xk ∈ RIk×J}
are very sparse, all their Ik rows will contain at least one non-zero element. If this is not
the case, we can simply filter the zero ones, without affecting the result. However, this does
not hold for the J columns of each Xk, which have to be aligned across all K subjects. A
direct consequence of that in real datasets is that very few variables (relative to their total
number) are typically recorded for each subject. For example, in the EHR data use case
introduced in Section 4.1, very few medical features are recorded for each patient.
Driven by this observation, we are motivated to computationally exploit any column
sparsity (i.e., cases where many columns will be completely zero) of each one of the input
matricesXk.
4.4 The SPARTan approach
4.4.1 Overview
Motivated by the challenges presented in Section 4.3, we propose a specialized version of
the Matricized-Tensor-Times-Khatri-Rao-Product (MTTKRP) kernel, specifically target-
ing the intermediate tensor Y ∈ RR×J×K formed within the PARAFAC2-ALS algorithm.
We first provide an overview of the properties that our approach exhibits:
• It is fully parallelizable w.r.t. the K subjects. This property is crucial towards scaling up
for large-scale “irregular” tensors.

















Figure 4.2: SPARTan computations for the MTTKRP w.r.t. the 1st mode. For each k-th
partial result of Equation (4.8), we only use the rows of V factor matrix corresponding to
the non-zero columns of Yk. For each of the R rows of the resulting matrix, we compute
the Hadamard product with W (k, :), which is the k-th row of the factor matrix W . The
described computations fulfill all of the desirable properties presented in Section 4.4.1.
to the observation that the k-th frontal slice Yk = QTkXk of Y follows precisely the
column sparsity pattern of Xk. In particular, if ck is the number of columns of Xk
containing at least one non-zero element, then Yk will contain R ck non-zero elements
located in the positions of the non-zero columns of Xk. Exploiting structured sparsity is
indispensable towards minimizing intermediate data and computations to the absolutely
necessary ones.
• As a by-product of the above, SPARTan avoids unnecessary data re-organization (tensor
reshaping/permutations), since all operations are formulated w.r.t. the frontal slices Yk
of tensor Y . In fact, our approach never forms the tensor Y explicitly and directly utilizes
the available collection of matrices {Yk} instead.
4.4.2 Methodology
In the following, we describe the design of our MTTKRP kernel for each one of the tensor
modes. We use the notation M (i) to denote the MTTKRP corresponding to the i-th tensor
mode. Note that our factor matrices are: H ∈ RR×R,V ∈ RJ×R and W ∈ RK×R as in
Line 10 of Algorithm 5.
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Mode-1 MTTKRP. First, we re-visit the MTTKRP equation:
M (1) = Y(1) (W  V ) , (4.7)
where M (1) ∈ RR×R,Y(1) ∈ RR×KJ . In order to attempt to parallelize the above compu-
tation w.r.t. the K subjects, we define the matrix T (k) ∈ RJ×R to denote the k-th vertical
block of the Khatri-Rao ProductW  V ∈ RKJ×R:









We then remark that Y(1) (i.e., mode-1 matricization of Y) consists of an horizontal con-
catenation of the tensor’s frontal slices Yk. Thus, we exploit the fact that the matrix multi-
plication in Equation (4.7) can be expressed as the sum of outer products or more generally,






Through Equation (4.8), the computation can be easily parallelized over K independent
sub-problems and then sum the partial results. This directly utilizes the frontal slices Yk
without further tensor organization. However, it constructs the whole Khatri-Rao Product
(in the form of blocks T (k)). In order to avoid that, we first state an expression for each i-th
row of T (k), which is a direct consequence of the Khatri-Rao Product definition:
T (k)(i, :) = V (i, :) ∗W (k, :), (4.9)
where ∗ stands for the Hadamard (element-wise) product. Then, we express the j-th row
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of each partial result of Equation (4.8) as follows:
[Yk T















= (Yk(j, :) V ) ∗W (k, :), (4.10)
where (a) stems from the associative property of the Hadamard product and the fact that
W (k, :) is independent of the summation and (b) from the calculation of matrix multipli-
cation as a sum of outer-products (in particular, we encounter the sub-case of vector-matrix
product).
Equation (4.10) suggests an efficient way to compute the partial results of Equation (4.8),
which we illustrate in Figure 4.2. First, we compute the matrix product YkV and for each
row of the intermediate result of size R × R, we compute the Hadamard product with
W (k, :). Note that, as we discussed in Section 4.3, Yk is expected to be column-sparse
in practice, thus multiplying by V uses only those rows of V corresponding to the non-
zero columns of Yk. Thus, we avoid the redundant and expensive computation of the full
Khatri-Rao Product. Overall, the methodology described above enjoys all of the properties
described in Section 4.4.1.
Mode-2 MTTKRP. The methodology followed for the Mode-2 case is similar to the one
described for the 1st case. We state the corresponding MTTKRP equation:
M (2) = Y(2) (W H) (4.11)
whereM (2) ∈ RJ×R,Y(2) ∈ RJ×RK . The main remark is thatY(2) consists of an horizontal
concatenation of the transposed frontal slices {Yk} of the intermediate tensor Y . Thus, if















Figure 4.3: SPARTan computations for the MTTKRP w.r.t. the 2nd mode. For each k-th
partial result of Equation (4.12), we perform the vector-matrix multiplications for each non-
zero row of Y Tk . Then, for each intermediate vector, the Hadamard product withW (k, :) is
computed. Finally, we distribute the vectors to their corresponding positions inY Tk T
(k). As
in the case w.r.t. the 1st mode, we limit computations to the necessary ones corresponding to
the non-zero columns of Yk and all the properties presented in Section 4.4.1 are preserved.






Given the above, it is easy to extend Equation (4.10) for this case, so as to compute a single







∗W (k, :) (4.13)
The corresponding operations are illustrated in Figure 4.3. A crucial remark is that we
can focus on computing the relevant intermediate results only for the non-zero rows of
Y Tk , since the rest of the rows of the result Y
T
k T
(k) will be zero. In sum, we again avoid
redundant computations of the full Khatri-Rao Product and preserve all of the properties
described in Section 4.4.1.
Mode-3 MTTKRP. First, we state the equation regarding the Mode-3 case:
M (3) = Y(3) (V H) (4.14)
















Figure 4.4: SPARTan computations for the MTTKRP w.r.t. the 3rd mode. We compute
each row of the resultM (3)(k, :) independently of others, enabling parallelization w.r.t. the
K subjects. As in mode-1, mode-2 cases, we exploit the column sparsity of Yk. In this case,
we also leverage thatH is a smallR-by-Rmatrix in practice (due to the “size imbalance” of
the intermediate tensor Y). Thus, it is efficient to delay any computations onH until theR-
by-R product of YkV is formed, and then take column-wise inner products between those
two matrices. The described operations fulfill all the properties outlined in Section 4.4.1.
TKRP of the mode corresponding to the K subjects. Thus, an entirely different approach
than the Mode-1, Mode-2 cases is needed so that we construct efficient independent sub-
problems for each one of them. In particular, we need to design each k-th subproblem so
that it computes the k-th row of M (3). In addition, we want to operate only on {Yk} with-
out forming and reshaping the tensor Y , as well as to exploit the frontal slices’ sparsity. To
tackle the challenges above, we leverage the fact that [148]:
M (3)(:, r) =


H(:, r)T Y1 V (:, r)
...




Then, we remark that in order to retrieve a certain element of the matrixM (3), we have:
M (3)(k, r) =H(:, r)T Yk V (:, r)
=H(:, r)T [YkV ](:, r)
The last line above reflects the inner product between the corresponding r-th columns ofH
and [Yk V ], respectively. Thus, in order to retrieve a row M(k, :), we can simply operate
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as:
M (3)(k, :) = dot (H ,YkV ) (4.16)
where the dot() function extracts the inner product of the corresponding columns of its two
matrix arguments. We illustrate this operation in Figure 4.4. Since H is a small R-by-R
matrix (due to the tensor’s “size imbalance”), it is very efficient to delay any computations
on H until the R-by-R intermediate matrix is formed as a product of Yk V . Then, we
simply take the column-wise inner products between those two R-by-R matrices. In that
way, all the desirable properties we mentioned in Section 4.4.1 are also fulfilled.
In Algorithm 6, we list the pseudocode corresponding to the methodology proposed.
Note that in lines 8,16, we can accumulate over the partial results in parallel, since the
summation is independent of the iteration order.
Algorithm 6 MTTKRP for SPARTan
Input: {Yk ∈ RR×J} for k = 1, . . . ,K, H ∈ RR×R,V ∈ RJ×R,W ∈ RK×R, the target rank R
and the mode n for which we are computing the MTTKRP
Output: M (n)
1: InitializeM (n) with zeros
2: if n == 1 then
3: for k = 1, . . . ,K do
4: temp← YkV
5: for r = 1, . . . , R do
6: temp(r, :)← temp(r, :) ∗W (k, :)
7: end for
8: M (1) ←M (1) + temp // sum in parallel ∀k = 1, . . . ,K
9: end for
10: else if n == 2 then
11: for k = 1, . . . ,K do
12: Initialize temp ∈ RJ×R with zeros








16: M (2) ←M (2) + temp // sum in parallel ∀k = 1, . . . ,K
17: end for
18: else if n == 3 then
19: for k = 1, . . . ,K do




Table 4.3: Summary statistics for the real datasets of our experiments. K is the number of
subjects, J is the number of variables, Ik is the number of observations for the k-th subject
and #nnz corresponds to the total number of non-zeros.
Dataset K J max(Ik) #nnz
CHOA 464,900 1,328 166 12.3 Mil.
MovieLens 25,249 26,096 19 8.9 Mil.
4.5 Experiments
4.5.1 Setup
Real Data Description. Table 4.3 provides summary statistics regarding the real datasets
used.
The CHOA (Children Healthcare of Atlanta) dataset corresponds to EHRs of pediatric
patients with at least 2 hospital visits. For each patient, we utilize the diagnostic codes
and medication categories from their records, as well as the provided age of the patient (in
days) at the visit time. The available International Classification of Diseases (ICD9) [43]
codes are summarized to Clinical Classification Software (CCS) [111] categories, which
is a standard step in healthcare analysis improving interpretability and clinical meaning-
fulness. We aggregate the time mode by week and all the medical events over each week
are considered as a single observation. The resulting data are of 464,900 subjects by 1,328
features by maximum 166 observations with 12.3m non-zeros.
MovieLens 20M is another real dataset we used, which is publicly available 2. We are
motivated to use this dataset, because of the importance of the evolution of user preferences
over time, as highlighted in recent literature [156]. For this dataset, we consider that each
year of ratings corresponds to a certain observation; thus, for each user, we have a year-by-
movie matrix to describe her rating activity. We consider only the users having at least 2
years of ratings.
Implementation details. We used MatlabR2015b for our implementations, along with
2https://grouplens.org/datasets/movielens/
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functionalities for sparse tensors from the Tensor Toolbox [114] and the Non-Negative
Least Squares (NNLS) approach [146] from the N-way Toolbox [157] 3. In both the
SPARTan and the baseline implementations, we adjust the CP-ALS iteration arising in the
PARAFAC2-ALS, so that non-negative constraints are imposed on the {Sk},V factors, as
discussed in Section 4.3.2.
The baseline method corresponds to the standard fitting algorithm for the PARAFAC2
model [59] adjusted for sparse tensors as in [144]. We utilized the implementation from
the most recent version of the Tensor Toolbox [114] regarding both the manipulation of
sparse tensors, as well as the CP-ALS iteration arising in the PARAFAC2-ALS.
Parallelism. We exploit the capabilities of the Parallel Computing Toolbox of Matlab,
by utilizing its parallel pool in both SPARTan and the baseline approach, whenever this
is appropriate. Regarding the size of the parallel pool, the number of workers of all the
experiments regarding a certain dataset is fixed. For the movie-rating dataset we used the
default of 12 workers. For the synthetic and the CHOA datasets, we increased the number
of workers to 20 because of the data size increase.
Hardware. We conducted our experiments on a server running Ubuntu 14.04 with 1TB
of RAM and four Intel E5-4620 v4 CPU’s with a maximum clock frequency of 2.10GHz.
Each one of the processors contains 10 cores, and each one of the cores can exploit 2 threads
with hyper-threading enabled.
4.5.2 SPARTan is fast and memory-efficient
Synthetic Data. We assess the scalability of the approaches under comparison for sparse
synthetic data. We considered a setup with 1, 000, 000 subjects, 5, 000 variables and a
maximum of 100 observations for each subject. The number of observations Ik for each
subject is dependent on the number of rows of Xk containing non-zero elements; thus, Ik
increases with the dataset density. Indicatively, the mean number of observations Ik for the
3We also accredit the dense PARAFAC2 implementation by Rasmus Bro, from where we have adapted
many functionalities.
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sparsest dataset created (≈ 63 mil.) is 46.9 and for the densest (≈ 500 mil.) dataset, the
mean Ik is 99.3. We randomly construct the factors of a rank-40 (which is the maximum
target rank used in our experiments) PARAFAC2 model. Based on this model, we construct
the input slices {Xk}, which we then sparsify uniformly at random, for each sparsity level.
The density of the sparsification governs the number of non-zeros of the collection of input
matrices.
We provide the results in Table 4.1. First, we remark that SPARTan is both more scal-
able and faster than the baseline. In particular, the baseline approach fails to execute in
the two largest problem instances for target rank R = 40, due to out of memory problems,
during the creation of the intermediate sparse tensor Y . Note that as we discussed in Sec-
tion 4.4, SPARTan avoids the additional overhead of explicitly constructing a sparse tensor
structure, since it only operates directly on the tensor’s frontal slices {Yk}. Regarding the
baseline’s memory issue, since the density of Y may grow (e.g., ≈ 10% in the densest
case), we also attempted to store the intermediate tensor Y as a dense one. However, this
also failed, since the memory requested for a dense tensor of size 40-by-5K-by-1Mil. ex-
ceeded the available RAM of our system (1TB). Overall, it is clear that the baseline ap-
proach cannot fully exploit the input sparsity. On the contrary, SPARTan properly executes
for all the problem instances considered in a reasonable amount of time. In particular, for
R = 40, SPARTan is up to 22× faster than the baseline. Even for a lower target rank of
R = 10, SPARTan achieves up to 13× faster computation.
Real Data. We evaluate the scalability of the proposed SPARTan approach against the
baseline method for the real datasets as well. In Figures 4.5, 4.6, 4.7, we present the results
of the corresponding experiments. First, we target the full datasets and vary the pursued
target rank (Figure 4.5). Note that for both datasets considered, the time per iteration of the
baseline approach increases dramatically as we increase the target rank. On the contrary,
the time required by SPARTan increases only slightly. Overall, our approach achieves up
to over an order of magnitude gain regarding the time required per epoch for both datasets.
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Figure 4.5: Time in minutes for one iteration (as an average over 10) for varying target rank
for both the real datasets used. SPARTan achieves up to 12× and 11× speedup over the
baseline approach for the CHOA and the MovieLens datasets respectively.
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(a) Target Rank R = 10
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(b) Target Rank R = 40
Figure 4.6: CHOA dataset: Time in minutes for one iteration (as an average over 10)
for varying number of subjects (K) included and fixed target rank (two cases considered:
R = {10, 40}).
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(b) Target Rank R = 40
Figure 4.7: MovieLens dataset: Time in minutes for one iteration (as an average over 10)
for varying number of variables (J) included and fixed target rank (two cases considered:
R = {10, 40}).
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We also evaluate the scalability of the methods under comparison as we vary the sub-
jects and the variables considered. Since the CHOA dataset (Figure 4.6) contains more
subjects than variables, we vary the number of subjects for this dataset for two fixed target
ranks (10, 40). In both cases, SPARTan scales better than the baseline. As concerns the
MovieLens dataset (Figure 4.7), since it contains more variables than subjects, we examine
the scalability w.r.t. increasing subsets of variables considered. In this case as well, we re-
mark the favorable scalability properties of SPARTan, rendering it practical to use for large
and sparse “irregular” tensors.
4.5.3 Phenotype discovery on CHOA EHR Data
Motivation. Next we demonstrate the usefulness of PARAFAC2 towards temporal pheno-
typing of EHRs. Phenotyping refers to the process of extracting meaningful patient clusters
(i.e., phenotypes) out of raw, noisy Electronic Health Records [45]. An open challenge in
phenotyping is to capture temporal trends or patterns regarding the evolution of those phe-
notypes for each patient over time. Below, we illustrate how SPARTan can be used to
successfully tackle this challenge.
Model Interpretation: We propose the following model interpretation towards the target
challenge:
• The common factor matrixV reflects the phenotypes’ definition and the non-zero values
of each r-th column indicate the membership of the corresponding medical feature to
the r-th phenotype.
• The diagonal Sk provides the importance membership indicators of the k-th subject to
each one of the R phenotypes/clusters. Thus, we can sort the R phenotypes based on
the values of vector diag(Sk) and identify the most relevant phenotypes for the k-th
subject.
• EachUk factor matrix provides the temporal signature of each patient: each r-th column
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of Uk reflects the evolution of the expression of the r-th phenotype for all the Ik weeks
of her medical history. Note that since allXk,Sk,V matrices are non-negative, we only
consider the non-negative elements of the temporal signatures in our interpretation.
Temporal Phenotyping of Medically Complex Patients (MCPs) In order to illustrate
the use of PARAFAC2 towards temporal phenotyping, we focus our analysis on a subset
of pediatric patients from CHOA, which are classified by them as Medically Complex.
These are the patients with high utilization, multiple specialty visits and high severity.
Conceptually, those patients suffer from chronic and/or very severe conditions that are hard
to treat. As a result, it becomes a very important challenge to accurately phenotype those
patients, as well as provide a temporal signature for each one of them, which summarizes
their phenotypes’ evolution.
The number of MCPs in the CHOA cohort is 8, 044, their diagnoses and medications
sum up to 1, 126, and the mean number of weekly observations for those patients is 28.
We ran SPARTan for target rank R = 5 and the phenotypes discovered are provided in Ta-
ble 4.4 (phenotypes’ definition matrix). The labels for each group are the definitions of the
phenotypes provided by the medical expert, who endorsed their clinical meaningfulness.
In Figure 4.8, we provide part of the real EHR, as well as the temporal signature pro-
duced by SPARTan, for a certain medically complex patient. Regarding the EHR, we vi-
sualize the subset of diagnoses and medications for which the sum of occurrences for the
whole patient history is above a certain threshold (e.g., 5 occurrences). This step ensures
that the visualized EHR will only contain the conditions exhibiting some form of temporal
evolution. For the patient example considered, we identify the top-2 relevant phenotypes
through the importance membership indicator matrix Sk as discussed above. For those
top-2 phenotypes, we present the resulting temporal signature, from which we easily de-
tect intricate temporal trends of the phenotypes involved. Those trends were confirmed by
the clinical expert as valuable towards fully understanding the phenotypic behavior of the
MCPs.
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Table 4.4: Phenotypes discovered by PARAFAC2. The title annotation for each phenotype is pro-





Immunity disorders [57.] 0.23
HEPARIN AND RELATED PREPARATIONS 0.6
ANTIEMETIC/ANTIVERTIGO AGENTS 0.34
SODIUM/SALINE PREPARATIONS 0.32
TOPICAL LOCAL ANESTHETICS 0.19
ANTIHISTAMINES - 1ST GENERATION 0.16
Sickle Cell Anemia (SCA) Weight
Sickle cell anemia [61.] 0.73
NSAIDS, CYCLOOXYGENASE INHIBITOR - TYPE 0.31
ANALGESICS NARCOTICS 0.26
FOLIC ACID PREPARATIONS 0.2
BETA-ADRENERGIC AGENTS 0.18
SODIUM/SALINE PREPARATIONS 0.16
Neurological System Disorders Weight
Other nervous system symptoms and disorders 0.56
Rehabilitation care; fitting of prostheses; and adjustment of devices [254.] 0.5
Residual codes; unclassified; all E codes [259. and 260.] 0.46
Other connective tissue disease [211.] 0.33
Other and unspecified metabolic; nutritional; and endocrine disorders 0.18
Gastrointestinal Disorders Weight
Residual codes; unclassified; all E codes [259. and 260.] 0.2
Other and unspecified metabolic; nutritional; and endocrine disorders 0.15








ANALGESICS NARCOTIC ANESTHETIC ADJUNCT AGENTS 0.18
NSAIDS, CYCLOOXYGENASE INHIBITOR - TYPE 0.16
IRRIGANTS 0.16
LAXATIVES AND CATHARTICS 0.15
GENERAL INHALATION AGENTS 0.15
Liver/Kidney System Disorders Weight
Other aftercare [257.] 0.8
hronic kidney disease [158.] 0.39
Other and unspecified liver disorders 0.3
Immunity disorders [57.] 0.16
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Figure 4.8: Upper part: Part of real EHR data of a Medically Complex Patient (MCP). For
each week, it contains the occurrences of a diagnosis/medication in the patient’s records.
Lower part: Temporal signature of the patient created by SPARTan. PARAFAC2 captures
the stage where cancer treatment is initiated (week 65). At that point, indications of cancer
treatment and diagnosis, such as cancer of brain, chemotherapy, heparin and antineoplastic
drugs start to get recorded in the patient history. PARAFAC2 also captures the presence of
neurological disorders during the first weeks of the patient history. The definition for each
phenotype as produced by PARAFAC2 can be found in Table 4.4.
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4.6 Discussion & Conclusions
PARAFAC2 has been the state-of-the-art model for mining “irregular” tensors, where the
observations along one of its modes do not align naturally. However, it has been highly
disregarded by practitioners, as compared to other tensor approaches. Bro [143] has sum-
marized the reason for that as:
The PARAFAC2 model has not yet been used very extensively maybe because
the implementations so far have been complicated and slow.
The methodology proposed in this work renders this statement no longer true for large
and sparse data. In particular, as tested over real and synthetic datasets, SPARTan is both
fast and memory-efficient, achieving up to 22× performance gains over the best previous
implementation and also handling larger problem instances for which the baseline fails due
to insufficient memory.
The key insight driving SPARTan’s scalability is the pursuit and exploitation of special
structure in the data involved in intermediate computations; prior art did not do so, instead
treating those computations as a black-box.
The capability to run PARAFAC2 at larger scales is, in our view, an important en-
abling technology. As shown in our evaluations on EHR data, the clinically meaningful
phenotypes and temporal trends identified by PARAFAC2 reflect the ease of the model’s
interpretation and its potential utility in other application domains.
Future directions include, but are not limited to: a) development of PARAFAC2 al-
gorithms for alternative models of computation, such as distributed clusters [147], or su-
percomputing environments; b) extension of the methodology proposed for higher-order
“irregular” tensors with more than one mismatched mode.
Finally, to enable reproducibility and promote further popularization of the PARAFAC2




TEMPORAL PHENOTYPING OF MEDICALLY COMPLEX CHILDREN VIA
PARAFAC2 TENSOR FACTORIZATION
Summary
How tensor factorization can be applied and extended to distill the EHR data of a
cohort of patients facing complex clinical manifestations into clinically-meaningful
phenotype definitions, their temporal trends over time and associated patient groups?
In this Chapter, we demonstrate how the PARAFAC2 model, as implemented in
Chapter 4, can be applied and extended to extract phenotype definitions of medically-
complex children from Children’s Healthcare of Atlanta. We identified 4 phenotypes
which are validated by a clinical expert, as well as significant survival variations
among different phenotypes.
Objective: Our aim is to extract clinically-meaningful phenotypes from longitudinal elec-
tronic health records (EHRs) of medically-complex children. This is a fragile set of patients
consuming a disproportionate amount of pediatric care resources but who often end up with
sub-optimal clinical outcome. The rise in available electronic health records (EHRs) pro-
vide a rich data source that can be used to disentangle their complex clinical conditions
into concise, clinically-meaningful groups of characteristics. We aim at identifying those
phenotypes and their temporal evolution in a scalable, computational manner, which avoids
the time-consuming manual chart review.
Materials and Methods: We analyze longitudinal EHRs from Children’s Healthcare of
Atlanta including 1,045 medically complex patients with a total of 59,948 encounters over
2 years. We apply a tensor factorization method called PARAFAC2 to extract: a) clinically-
meaningful groups of features b) concise patient representations indicating the presence of
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a phenotype for each patient, and c) temporal signatures indicating the evolution of those
phenotypes over time for each patient.
Results: We identified four medically complex phenotypes, namely gastrointestinal disor-
ders, oncological conditions, blood-related disorders, and neurological system disorders,
which have distinct clinical characterizations among patients. We demonstrate the utility
of patient representations produced by PARAFAC2, towards identifying groups of patients
with significant survival variations. Finally, we showcase representative examples of the
temporal phenotypic trends extracted for different patients.
Discussion: Unsupervised temporal phenotyping is an important task since it minimizes
the burden on behalf of clinical experts, by relegating their involvement in the output phe-
notypes validation. PARAFAC2 enjoys several compelling properties towards temporal
computational phenotyping: a) it is able to handle high-dimensional data and variable num-
bers of encounters across patients, b) it has an intuitive interpretation and c) it is free from
ad-hoc parameter choices. Computational phenotypes, such as the ones computed by our
approach, have multiple applications; we highlight three of them which are particularly use-
ful for medically complex children: 1) integration into clinical decision support systems,
2) interpretable mortality prediction and 3) clinical trial recruitment.
Conclusion: PARAFAC2 can be applied to unsupervised temporal phenotyping tasks where
precise definitions of different phenotypes are absent, and lengths of patient records are
varying.
5.1 Objective
Medically complex or fragile children need intensive medical care due to multisystem dys-
function, technology dependence, or complex medication needs.[158] It has been estimated
that children with special healthcare needs constitute about 18% (near 12.6 millions) of all
the US children. [159] Their population is also growing at approximately 5% annually,
outpacing the rate of growth of typically developing children (1-2%).[160] Given the large
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portion of complex children in consumption of hospital resources,[161] the Institute of
Medicine has identified Children with Special Health Care Needs (CSHCN) as a priority
population for study.[162] Medically complex patients consume significant disproportion-
ate amount of care resources in hospitals.[161] For example, the Children’s Hospital Asso-
ciation reported that among the 33 million children in Medicaid in 2013, the 2 million with
medical complexity were in need of approximately 10 times the costs per year, on average,
compared to other children.[163]
Important ongoing research is on how to improve the outcome such as survival and
decrease the healthcare costs of medically complex children. In order to achieve such
advancements, there have been several efforts reported in predicting hospital readmis-
sion [164] as well as exposing the increase in medically complex children population. [158]
With the advent and availability of EHRs, it is possible to extract computational phenotypes
to group medically complex children based on their underlying heterogeneity. Each one of
the groups is described by a clinically-meaningful set of features, i.e., the phenotype defi-
nitions.
Phenotyping based on manual chart review is time-consuming and not scalable to large
patient cohorts. [38, 37] There have been several efforts to extract computational pheno-
types based on rule-based algorithms, separating patients based on carefully crafted feature
sets and their possible ranges. The eMERGE network [165] is such a leading effort and the
PheKB repository contains algorithms from eMERGE and other sources. [166] The main
drawback of such approaches is the substantial burden and effort on both medical informat-
ics experts and clinicians to develop specialized criteria for each individual phenotype. As
such, these approaches are notoriously hard to scale for increasing number of patients and
heterogeneous patient cohorts. [167]
To tackle the above challenges, it is imperative to establish accurate and efficient meth-
ods for computational phenotyping through readily available EHR data. Computational
phenotypes can then be used in multiple applications [7], such as in clinical decision sup-
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port [37], clinical predictive modeling [24] and automatically determining eligibility for
clinical trial recruitment [5]. In this work, in the absence of expert-annotated labels for
medically-complex children, we focus on unsupervised computational phenotyping. We
are additionally interested in extracting information revealing when a certain phenotype
occurred; such insights may lead to a better understanding of complex disease progression
(a task we call as temporal phenotyping [10]). To do so, we have to overcome the following
challenges, pertaining to the nature of the EHRs:
• High-dimensionality and incompleteness of EHR records. EHRs are typically high-
dimensional event sequences, including information from different modalities, such
as diagnoses, medications and procedures. Moreover, the recording of EHRs is very
far from the rigorous data collection employed in formal experiments, [168] since
records only occur during patient encounters at the hospital; thus, sparsity and dis-
continuities of clinical features are a commonplace.[169]
• Variable number of medical encounters across patients. Another important charac-
teristic of EHRs is the variable number of observations across patients. This renders
any temporal alignment for analysis purposes an intricate task. In fact, even if two
patients share the same length of records, their temporal alignment is not necessarily
meaningful for many reasons, such as: a) disease stages and progression vary, and b)
more records are present when a patient is undergoing a more severe condition, thus
we should not consider the observations as random samples over time.[170]
To successfully tackle these challenges, we apply and extend the PARAFAC2 tensor
factorization in order to extract phenotype descriptions from medically complex children,
associated patient groups and temporal trends of phenotypes. PARAFAC2 [58] can handle
high-dimensional, sparse and irregular input data. It can also accept a variable number of
observations for each patient and provides a great match for using sequence time as the
time parameterization of EHR data. [53, 170] To frame the input for PARAFAC2, we use a
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binary occurrence matrix of size Ik × J reflecting the k-th patient’s medical history, where
Ik corresponds to the k-th patient’s number of encounters and J to the number of medical
features. Then, we apply PARAFAC2 [58] to the collection of matrices {Xk ∈ RIk×J}
which leads to the following approximation:
Xk ≈ Uk Sk V T
where k = 1, . . . , K,Uk ∈ RIk×R,Sk ∈ RR×R is diagonal and V ∈ RJ×R. Through this
model, we extract: a) the definition of the R phenotypes (V matrix in the model), b) a per-
sonalized phenotype membership indicator for each patient reflecting the existence/absence
of each phenotype within her medical history (Sk matrix in the model), c) a personalized
profile for each patient reflecting the phenotypic evolution across her encounters (Uk matrix
in the model). In contrast to other methodologies proposed to tackle temporal phenotyping,
PARAFAC2 preserves uniqueness of the output model. [59] In non-unique models, there
may be many arbitrarily rotated versions of a solution yielding the same approximation er-
ror and it is unclear to the practitioner which one of those solutions provides the true latent
factors. Unique models avoid such rotational ambiguities, thus boosting interpretability.
In addition to recent work proposing advancements on the scalability of PARAFAC2
for EHR data [51], in this work we illustrate an automatic way of determining the number
of phenotypes. To do so, we apply the Core Consistency Diagnostic (CORCONDIA) to
automatically discover the number of phenotypes required to succinctly summarize the
different phenotypes of medically complex patients. [171] This step makes PARAFAC2
free from ad-hoc parameter choices. We also present how patients can be grouped based
on the learned model parameters.
With PARAFAC2, we identified four medically complex phenotypes, namely gastroin-
testinal disorders, oncological conditions, blood-related disorders, and neurological system
disorders, which have distinct clinical characterizations among patients. We demonstrate
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the utility of patient representations produced by PARAFAC2, towards identifying groups
of patients with significant survival variations. Finally, we showcase representative exam-
ples of the temporal phenotypic trends extracted for different patients.
5.2 Background and Significance
Below, we review previous approaches related to unsupervised temporal phenotyping. For
a broader discussion on phenotyping based on EHRs, including rule-based and supervised
phenotyping approaches, we refer to existing survey papers. [7, 172]
Probabilistic Approaches
Lasko et al. study the temporal phenotyping problem from a probabilistic perspective (us-
ing Gaussian Processes).[173] In contrast to our application, they focus on continuous vari-
ables (e.g. uric acid concentration over time). The sparsity and irregularities of medical
codes make their approach difficult to handle high-dimensional discrete event sequences
(e.g., diagnoses and medications). Wang et al. use a Markov Jump Process to model the
stage transitions of a certain disease, as reflected by a set of comorbidities.[8] Their method-
ology targets a single disease and requires a homogeneous cohort as input (sharing the tar-
get disease). Also, their modeling assumes a certain set of hidden disease stages which is
shared among all the comorbidities; this assumption may be restrictive for medically com-
plex patients who often share multiple different evolving phenotypes. Similar specialized
modeling of a single conditions progression has been studied in [174], where the authors
focus on extracting temporal trajectories of individual input variables, rather than the trajec-
tories of clinically-meaningful feature groups. Another probabilistic approach is proposed
by Ghassemi et al.,[175] where Multi-Task Gaussian Processes are used to model the tem-
poral evolution of clinical concepts. The main limitations of that approach are the high
computational cost and the multi-modal hyper-parameter space to be tuned; in contrast,
our approach does not require any ad-hoc parameter search. Static probabilistic pheno-
typing approaches have also been proposed (e.g., the UPhenome model [176]). However,
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those do not encode any temporality about the patient records.
Non-unique Factorization-Based Temporal Phenotyping
The idea of factorizing temporally-evolving matrices of clinical features has already ap-
peared in the literature. Wang et al. propose a convolutional framework of matrix factor-
ization to capture temporal phenotypic trends.[138] In other prior art, matrices of clinical
features over time are jointly factorized to capture phenotypes and their evolution.[139,
177, 178] In contrast to those works, our PARAFAC2 application provides model unique-
ness; thus, reliable interpretation of the resulting phenotypes and phenotypic trends is pos-
sible, avoiding rotational ambiguities of the output model.
Static Matrix/Tensor Phenotyping
Static computational phenotyping involving tensors [134, 135, 179, 180, 48] and matri-
ces [46, 181] has also been an active subject of interest. However, those works often avoid
modeling time directly via temporal aggregation. However, as we show in this work, the
temporal evolution of phenotypes can provide crucial insights regarding disease progres-
sion.
Clustering Approaches
There do exist other unsupervised approaches, such as k-means or hierarchical clustering,
which can be used to group patients based on a set of clinical features. [182] However,
such approaches only provide the patient clusters, without the corresponding definitions
of the phenotypes that could explain the reasoning behind the groupings, as happens in
PARAFAC2. At the same time, PARAFAC2 provides a temporal signature indicating the
evolution of phenotypes for each patient. Simpler clustering approaches preserve none of
the above properties. They may additionally require preprocessing of the input longitudinal
data into segments, so that those are comparable across patients. [183, 184] Our approach
based on PARAFAC2 enables avoiding such potentially-limiting assumptions, which are
usually disease-dependent and may obfuscate the extracted temporal patterns.
Embedding-based approaches
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The idea of word embeddings [185] has been used to extract vector representations of
medical concepts (e.g., diagnostic codes) and patients. The success of word embeddings
is attributed to the fact that contextually similar terms have their corresponding vectors
close to each other in the embedding space. There do exist extensions of word embeddings
extracting medical concept and visit, [186] as well as patient vector representations. [167]
However, these works do not focus on extracting the phenotype trajectories over time.
Careflow mining
Approaches based on sequential pattern mining have also been proposed to model the tem-
porality of care provided. [10, 187] However, those approaches extract sequences of indi-
vidual events which capture a certain flow of care, rather than evolving phenotypic defini-
tions based on shared groups of features among different visits and patients. Also, pattern
mining methods do not provide computable low-dimensional patient representations based
on the extracted phenotypes; these can be further used for clustering and prediction tasks.
Association analysis
Finally, there do exist works which conduct association analysis of diagnostic codes and
visualize the resulting association patterns. [188] However, these methods only provide a
high-level understanding of diagnostic code associations over time, without neither provid-
ing precise phenotypic definitions nor identifying the importance of different phenotypes
for every patient.
5.3 Materials and Methods
Input Data Formulation
First, we formally describe the input data representation. A natural way to represent the
EHR of each k-th patient is to use a binary matrix Xk of size IK × J to model the Ik
encounters from patient k about J clinical features. If we observe the j-th clinical feature
(e.g., diagnosis of respiratory disorders) recorded during the i-th encounter of the patient
















Figure 5.1: Input data representation before temporal phenotyping: each slice Xk repre-
sents the data from k-th patient, each row corresponds to one encounter from that patient,
each column represents a particular clinical feature (e.g., whether diagnosis of brain cancer
is present or not). All patients shared the same set of clinical features (i.e., the same number

















Figure 5.2: PARAFAC2 Decomposition example for temporal phenotyping with R=2 phe-
notypes pursued
ization of the input data. Note that we are modeling three input modes: patients, clinical
features, patient encounters. Given such unique input representation, the most popular ten-
sor methods such as Canonical Polyadic (CP) [23] and Tucker [73] have to assume the
same number of encounters across all patients, which is not true in practice. Note that an
attempt to collapse the patient mode by vertically concatenating all the encounters into a
single matrix would result in abandoning the patient-level information; as we will demon-
strate in the experiments, this information is crucial in identifying patient sub-groups with
similar phenotypic characteristics. We next describe how PARAFAC2 [58] can tackle this
challenge.
Figure 5.2 provides an overview of the PARAFAC2 decomposition [58] towards tem-
poral phenotyping. PARAFAC2 approximates a collection of matrices {Xk ∈ RIk×J} as:
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Xk ≈ Uk Sk V T (5.1)
where k = 1, . . . , K,Uk ∈ RIk×R,Sk ∈ RR×R is diagonal and V ∈ RJ×R.
Intuitively, the output components from PARAFAC2 model provide the key towards
temporal phenotyping: a) the definition of the R phenotypes (V matrix in the model),
b) a personalized phenotype membership indicator for each patient reflecting the exis-
tence/absence of each phenotype within her medical history (Sk matrix in the model), c) a
personalized profile for each patient reflecting the phenotypic evolution across her encoun-
ters (Uk matrix in the model).
The model can be extended so that non-negative constraints are imposed on {Sk},V
factors.[189] To further enhance interpretability, we employ this constraint in our experi-
ments and given that the input data are non-negative (binary), we elaborate our interpreta-
tion in more details:
• The common factor matrixV reflects the phenotypes’ definition and the non-zero values
of each r-th column indicate the membership of the corresponding medical feature to
the r-th phenotype.
• The diagonal Sk provides the importance membership indicators of the k-th subject to
each one of the R phenotypes/clusters. Thus, we can sort the R phenotypes based on
the values of vector diag(Sk) and identify the most relevant phenotypes for the k-th
subject.
• EachUk factor matrix provides the temporal signature of each patient: each r-th column
of Uk reflects the evolution of the expression of the r-th phenotype for all the Ik daily
encounters of her medical history.
Model and algorithm details
PARAFAC2 preserves uniqueness of the model output, by imposing the constraint that the
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cross product UTk Uk is invariant regardless which k is involved. [58] This implies that the
correlations between the phenotypes are kept constant, for all the encounters. [60] Preserv-
ing uniqueness means that the model is pursuing the actual latent factors, rather than an
arbitrary rotation of them.[131] The issue with non-unique models is that many arbitrarily
rotated decompositions may yield equivalent solutions in terms of the approximation error.
As a result, it is unclear to the practitioner which one of those solutions does provide the
true latent factors. Overall, in applications where we care about model interpretation (as
happens in temporal phenotyping) and not merely about compressing the input data, unique
models have a clear advantage over non-unique ones.[131]
The state-of-the-art framework for fitting the PARAFAC2 model uses the Alternating
Least Squares (ALS).[60] This corresponds to optimizing a least-squares criterion, in an
alternating fashion, where we solve for a subset of factors by fixing all others. Due to the
sparse nature of our EHR input data, we use the algorithm proposed by Perros et al., which
also follows the ALS framework, but is optimized for sparse datasets.[51]
Automatic identification of the number of phenotypes
Up to now we assume the number of phenotypes R are given but in practice it is unknown
and should be learned by the algorithm. Next we describe an extension to [51] for auto-
matically determining R. [190]
Consider that we have computed the factor matrices U ,V ,W of the CP model with R
components for a tensor X ∈ RI×J×K . A simple and intuitive way of assessing the quality
of the CP model is described in [145, 191]: assuming thatU ,V ,W are the factor matrices
of a Tucker model for X , retrieve the corresponding core tensor G. As mentioned above,
the CP is a restricted version of the Tucker model, where the core tensor G is assumed
to be super-diagonal. The core consistency diagnostic (CORCONDIA) [145, 191] essen-
tially assesses the validity of this assumption, by examining whether there are significant
deviations from a super-diagonal core tensor. This would imply that the decomposition is
somehow flawed (either the pursued rank is not appropriate or the model cannot describe
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the data well enough).
Thus, the least-squares problem to retrieve the core tensor G can be posed as [192]:
min
G
||vec(X )− (U ⊗ V ⊗W ) vec(G)||2F (5.2)
with solution: vec(G) = (U ⊗ V ⊗W )† vec(X ), where⊗ stands for the Kronecker prod-
uct and † stands for the matrix pseudoinverse. Then, if T is defined as a super-diagonal








(G(p, q, r)− T (p, q, r))2
R
(5.3)
Computing the CORCONDIA measure for CP models is useful for PARAFAC2, be-
cause the CP decomposition arises as an intermediate step of the workhorse PARAFAC2
fitting algorithm. [59, 51] Thus, a practical way of estimating the validity of PARAFAC2
model is to estimate the validity of its intermediate CP decomposition which provides a
subset of the resulting PARAFAC2 model factors. We refer to [190] for further details of
this process.
We summarize the process of extracting the most appropriate model as follows: we
define a range to search for the number of phenotypes (in the experiments, we have used
R = {2, 3, . . . , 7}). For each one of the candidate values of R, we run the PARAFAC2
fitting algorithm 20 times with random initialization of factors, and also with the Singular
Value Decomposition (SVD)-based initialization suggested in [193]. This step increases
our chances of avoiding local minima. Then, for each candidate target rank R, we choose
the solution with the minimum cost function error. [145] Finally, we choose the solution
with the highest possible target rank, which still provides a well-specified model with re-
spect to the core consistency diagnostic. The reasoning is that models with larger target
rank explain more of the input data variation (i.e., lower approximation error), so we prefer
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them, given the fact that the model is well-specified w.r.t. the CORCONDIA measure. We
use the standard threshold of 90% to define a well-specified model. [171]
Identification of patient groups with similar phenotypic behavior
Since the diagonal Sk matrix provides personalized phenotype indicators based on the ex-
tracted phenotypes, it can be used to extract meaningful groups of patients with similar
phenotypic behavior. To do so, we build a patient-by-phenotypes matrix W ∈ RK×R,
where the k-th row W(k, ) contains the diagonal of Sk. The resulting matrix is essen-
tially a low-dimensional representation of patients; a key property though is that all the
patient representations are directly interpretable based on the extracted phenotypes. To
visually identify clusters of users with similar utilization profiles, we use the well-known
tSNE [194] software, which can reduce the R-dimensional vectors to the 2-dimensional
space.
Table 5.1: Summary of dataset statistics. We consider that the k-th patient exhibits a certain
phenotype (e.g., Gastrointestinal disorders) based on the coordinate of the diagonal Sk
(phenotype indication output vector) with the maximum value.
Summary statistics value
Patient count 1,045
Median and interquartile range (25th-75th percentile) of encounters per patient 52 (45 - 64)
Median and interquartile range (25th-75th percentile) of clinical features per patient 86 (64 - 109)
Median and interquartile range (25th-75th percentile) of event occurrences per patient 406 (286 - 570)
% of patients sharing Gastrointestinal disorders 0.4526
% of patients sharing Oncological conditions 0.2555
% of patients sharing Blood-related disorders 0.156
% of patients sharing Neurological system disorders 0.1359
5.4 Results
Cohort Selection & Data Extraction
We focus on phenotyping medically complex pediatric population. We model the last 2
years of records of each patient, so that the most recent clinical status is considered. For
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example, assume that the most recent record of a patient occurred at day x. We consider all
the medical events occurring within the [x-730, x] day range (2 years).
Formally, we define medically complex patients (MCP) as the patients who have Clin-
ical Risk Group (CRG) 5b, number of specialties 3, and total hospital charge ≥ $31, 027
(ranked as the top 5% annual total charge in the cohort) within 1-year windows. Out of
all MCP patients, we considered the ones having at least 40 encounters during the last 2
years of their records. This step ensures that we can study patients exhibiting some form
of temporal clinical feature evolution. This led to 1,045 pediatric patients with a total of
59,948 encounters. The maximum number of encounters per patient is 202 and the mean
is 57.4. In Table 5.1, we summarize the dataset statistics and the phenotype distribution
among patients.
We utilize the diagnoses, medications and procedures as the clinical features for each
patient. To enhance interpretability and clinical meaningfulness, we aggregate all the indi-
vidual medical codes to clinical categories. Their International Classification of Diseases
(ICD9) codes are summarized according to the flat (single-level) categorization of Clin-
ical Classification Software (CCS). [195] The provided Current Procedural Terminology
(CPT) [196] procedure codes are also summarized using the corresponding CCS catego-
rization for procedure coding. [195] Medications are provided in the internal form of cat-
egorization followed by the data provider, so no transformation was needed. As a result
of the summarization described, the number of diagnostic categories is 249, the number of
medication categories is 455 and the number of procedure categories is 156. Thus, the total
number of clinical features considered is 862.
We also filtered the CCS diagnostic and procedure categories, by removing the ones
that were too abstract or fragmented to provide direct clinical information, in accordance
with the medical experts guidelines. Thus, we removed the diagnostic categories: Residual
codes; unclassified and Other aftercare. We also removed the procedure categories: Other
diagnostic procedures (interview; evaluation; consultation) and Other therapeutic proce-
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Figure 5.3: Plotting the percentage of consistency diagnostic. We choose the solution pro-




We used the Matlab implementation of the PARAFAC2 algorithm designed for sparse in-
put, provided in [51]. We also utilized the core consistency diagnostic provided in the
N-way toolbox. [157] To increase our chances of avoiding local minima, for each target
rank (i.e., R phenotypes pursued), we run the PARAFAC2 fitting algorithm 20 times with
random initialization of factors, and also with the Singular Value Decomposition (SVD)-
based initialization suggested in [154]. Then, we choose the solution with the minimum
cost function error. [145]
Choosing the number of phenotypes automatically
In Figure 5.3, we provide both the percentage of consistency diagnostic for various target
ranks (i.e., phenotypes). As explained in the Materials and Methods Section, we pick
the solution with the highest target rank which still provides a well-specified model (i.e.,
consistency diagnostic above 90%). [171] Thus, for our experiment, the solution with 4
phenotypes is considered as the most suitable. The fact that there is a clear-cut among
the CORCONDIA values for solutions with R ≤ 4 (all above 90%) and those with R ≥
5 (all close to 0%) further boosts our confidence on the appropriateness of the solution
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picked. [171]
Discovery of phenotypes & temporal trends
First, we provide a clinical definition of each phenotype annotation, as provided by a med-
ical expert. This will aid in introducing the reader to the characteristics of each phenotype
and the specificity of the discovered contents to their annotation. Note that the phenotype
annotations were provided by a medical expert (Searles) after observing the associated
clinical features of each phenotype described in the output model (V matrix in particular).
1. Gastrointestinal disorders are disorders involving the gastrointestinal tract, namely
the esophagus, stomach, small intestine, large intestine and rectum, and the accessory
organs of digestion, such as the liver, gallbladder, and pancreas. These disorders
occur when the gastrointestinal tract does not function properly and may occur with
or without an underlying disease.
2. Oncological conditions refers to medical conditions resulting from tumors. There is
an extensive number of types of tumors and types of care for tumors.
3. Blood-related disorders are disorders, possibly diseases, of the blood, involving the
red blood cells, white blood cells (leukocytes), or platelets (thrombocytes); the tis-
sues in which these elements are formed such as the bone marrow, lymph nodes, and
spleen; or of bleeding and blood clotting.
4. Neurological system disorders are disorders of the nervous system. Structural, bio-
chemical or electrical abnormalities in the brain, spinal cord or other nerves can result
in a range of symptoms.
In Tables 5.2, 5.3, we provide the detailed phenotype definitions discovered by PARAFAC2.
The phenotype contents are ranked according to the value provided by the model for the
specific medical feature (V (i, r) value for the i-th feature expression as part of the r-th
phenotype). Thus, we expect that the higher-ranked medical categories of each phenotype
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Table 5.2: Gastrointestinal disorders & Oncological conditions phenotype definitions ex-
tracted by PARAFAC2.
Gastrointestinal disorders Oncological conditions
MED Analgesic/antipyretics non-salicylate MED Heparin and related preparations
MED Analgesics narcotics DIAG Maintenance chemotherapy; radiotherapy
MED Sodium/saline preparations PROC Cancer chemotherapy
MED Antihistamines - 1st generation MED Antiemetic/antivertigo agents
MED Antiemetic/antivertigo agents DIAG Leukemias
MED Potassium replacement DIAG Immunity disorders
MED Sedative-hypnotics non-barbiturate MED Sodium/saline preparations
MED Topical local anesthetics MED Topical local anesthetics
MED Laxatives and cathartics MED Antineoplastic - antimetabolites
MED Heparin and related preparations MED Antihistamines - 1st generation
MED Analgesics narcotic anesthetic adjunct agents MED General anesthetics injectable
MED Beta-adrenergic agents DIAG Cancer of brain and nervous system
MED Absorbable sulfonamide antibacterial agents PROC Laboratory - Chemistry and hematology
PROC Microscopic examination (bacterial smear; culture; toxicology) MED Analgesics narcotic anesthetic adjunct agents
DIAG Other gastrointestinal disorders MED Glucocorticoids
MED Iv solutions: dextrose-saline MED Iv solutions: dextrose-saline
MED General anesthetics injectable
DIAG Other nutritional; endocrine; and metabolic disorders
PROC Other laboratory
MED Topical preparations,antibacterials
are the ones exhibiting a higher recording frequency among the listed contents. We trun-
cate the medical categories with values lower than 0.05 and list up to 20 categories for each
phenotype. Overall, the listed phenotype definitions were endorsed by a medical expert as
homogeneous and descriptive of the corresponding phenotype annotation. A notable char-
acteristic of the phenotype definitions extracted is that neurological system disorders are
mainly characterized by a multiple related diagnoses and procedures, while gastrointesti-
nal disorders and oncological conditions are mainly characterized by medications. Apart
from different pathophysiological characteristics, this indicates that the phenotype defini-
tions vary w.r.t. the most frequently used modality as the means of treatment (medications
for gastrointestinal disorders and oncological conditions, as compared to procedures for
neurological system disorders).
In Figure 5.4, we are showcasing a representative example of a patient temporal sig-
nature alongside with the raw EHR for this patient. The temporal signature produced by
PARAFAC2 provides a succinct summary of the patients phenotypic temporal trends: as
can be verified by the raw EHR data, the temporal signature successfully captures the pe-
riod when cancer treatment is underway.
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Medical record events (days)
DIAG_Immunizations and screening for infectious disease
DIAG_Cancer of brain and nervous system
DIAG_Neoplasms of unspecified nature or uncertain behavior
DIAG_Maintenance chemotherapy; radiotherapy
DIAG_Immunity disorders
DIAG_Other nutritional; endocrine; and metabolic disorders




DIAG_Other ear and sense organ disorders
DIAG_Other nervous system disorders
DIAG_Other lower respiratory disease
DIAG_Esophageal disorders
DIAG_Other disorders of stomach and duodenum
DIAG_Other gastrointestinal disorders







MED_Nsaids, cyclooxygenase inhibitor - type
MED_Antiemetic/antivertigo agents
MED_Histamine h2-receptor inhibitors














MED_Absorbable sulfonamide antibacterial agents
MED_Heparin and related preparations
MED_General anesthetics injectable
MED_Cephalosporins - 3rd generation
MED_Anti-anxiety drugs









MED_Antineoplastic - alkylating agents
MED_Water
MED_Antihistamines - 1st generation
MED_Analgesic/antipyretics non-salicylate
PROC_Microscopic examination (bacterial smear; culture; toxicology)
PROC_Diagnostic physical therapy
PROC_Cancer chemotherapy
PROC_Prophylactic vaccinations and inoculations
PROC_Laboratory - Chemistry and hematology
PROC_Pathology
PROC_Other laboratory
Figure 5.4: Upper part: Temporal signature of phenotypes for a certain patient. Lower
part: Raw EHR information in the form of clinical categories, for the same patient.
PARAFAC2 successfully captures the period of the patient’s history where cancer treatment
is underway. It also captures the blood-related disorders’ phenotype due to the presence of
hematology lab tests throughout her history.
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Table 5.3: Blood-related conditions & Neurological system disorders phenotype definitions
extracted by PARAFAC2.
Blood-related disorders Neurological system disorders
PROC Laboratory - Chemistry and hematology PROC Physical therapy exercises; manipulation; and other procedures
PROC Other laboratory DIAG Rehabilitation care; fitting of prostheses; and adjustment of devices
PROC Microscopic examination (bacterial smear; culture; toxicology) DIAG Other nervous system disorders
DIAG Immunity disorders DIAG Other connective tissue disease
DIAG Chronic kidney disease PROC Other physical therapy and rehabilitation
DIAG Deficiency and other anemia DIAG Other nutritional; endocrine; and metabolic disorders
DIAG Other nutritional; endocrine; and metabolic disorders DIAG Paralysis
MED Heparin and related preparations DIAG Developmental disorders
DIAG Other liver diseases DIAG Other gastrointestinal disorders
DIAG Complication of device; implant or graft DIAG Epilepsy; convulsions
MED Immunosuppressives PROC Diagnostic physical therapy
MED Sodium/saline preparations
MED Analgesic/antipyretics non-salicylate
DIAG Sickle cell anemia
PROC Nonoperative urinary system measurements














Figure 5.5: tSNE visualization of patient representations learned by PARAFAC2. Each
point corresponds to a certain patient, mapped to the 2D space. Left Part: The color of
each point (patient) corresponds to the intensity of the “Oncological conditions” phenotype.
28% of the 375 patients belonging to the circled area are recorded to have deceased. On
the other hand, only 6.7% of the 670 rest of patients are reported to have deceased. Right
Part: The color and marker type for each point is decided based on the phenotype (vector
coordinate) with the maximum value for the corresponding patient.
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Identification of higher-risk patient subgroups
Now we assess whether PARAFAC2 can be used to extract meaningful patient subgroups,
by exploiting the learned patient phenotype indicators Sk, as described in the closing sub-
section of the Materials and Methods section.
We build a patient-by-phenotypes matrix W ∈ RK×R, where the k-th row W (k, :)
contains the diagonal of Sk. The largest variance among the columns of W corresponds to
the Oncological conditions phenotype; thus, we attempt to visualize the patient representa-
tions and examine whether there is clear distinction between lower and higher weights of
this phenotype. To visualize the representations, we used the well-known tSNE [194] soft-
ware, by reducing the 4-dimensional vectors to the 2-dimensional space. On top of that,
we color the marker corresponding to each patient with respect to the weight associated
with the Oncological conditions phenotype. In the left part of Figure 3, we present the
results of this experiment. The distinction between lower and higher values corresponding
to the second phenotype is clear enough, giving rise to two patient sub-groups. For each
one of the sub-groups, we calculate the relative mortality rates and identify significant sur-
vival variations (28% in the higher-risk group over 6.7% for the rest of patients). Thus, the
low-dimensional patient representations of PARAFAC2 are shown to distinguish between
higher and lower mortality risk patients. This hints that interpretable low-dimensional pa-
tient representations produced by PARAFAC2 may be useful for predictive modeling tasks
(e.g., mortality prediction). We elaborate on that in the Discussion Section.
Furthermore, in the right part of Figure 1, we showcase the same tSNE patient repre-
sentation described above. In this case, we color each patient based on the most-expressed
phenotype regarding her low-dimensional representation (for the k-th patient, we pick the
coordinate of the W (k, :) vector with the highest value). The patients having maximal
expression with respect to all but the Gastrointestinal disorders phenotype are closely clus-
tered together in the tSNE representation.
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5.5 Discussion
Raw EHR information (even in the form of clinical categories) is often too complex for clin-
ical providers to provide simple and intuitive understanding of patient phenotypes. This is
why manual phenotyping through chart review is considered a time-consuming and labo-
rious task. [38, 7] This highlights the importance of computational temporal phenotyping
towards health management of medically complex populations. Our proposed approach
leads to an interpretable model with uniqueness guarantees which is computed through an
algorithm that has been demonstrated to scale to hundreds of thousands of patients. [51]
For the reasons above, we believe that our approach is a promising candidate solution
for clinical deployment. The most appropriate use case in clinical practice is through inte-
gration in clinical decision support systems (CDSSs). Such systems are expected to lower
healthcare costs, improve efficiency and reduce patient inconvenience. [197] In particular,
our temporal phenotyping solution could support clinicians decisions, when no clear treat-
ment guidelines exist for their patients. [198, 4, 6] Exploiting EHR data to identify patients
with common phenotypes and temporal trends may guide clinicians towards interventions
that have been empirically demonstrated to be effective in similar populations. This is par-
ticularly important for populations such as the medically-complex children we focus on
in this work; due to the complex underlying pathophysiology, many medically-complex
patients may not precisely match textbook guidelines derived from gold standard evidence.
An immediate application of our computed phenotypes is towards interpretable pre-
dictive modeling. As showcased in the experiments, the learnt low-dimensional patient
representations (matrix Sk) can be utilized to identify significant mortality rate variations.
Thus, feeding them into a predictive modeling task is a promising research direction. The
key benefit of doing so as opposed to deploying a predictive model on the raw, noisy fea-
tures is improved interpretability: the features of the predictive model would be the R
validated phenotypes, thus interpreting the contribution of each one of them w.r.t. the out-
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come measure (e.g., mortality) is a much simpler process than considering all the possibly
noisy input features recorded. Previous literature [24] has demonstrated success on a simi-
lar methodology using the simpler PARAFAC tensor model, which cannot directly handle
the longitudinal nature of EHR data. Assessing whether the more flexible PARAFAC2
model used in this work could provide more accurate patient representations for predictive
modeling is an immediate next step of this work.
Another potential application of EHR-based computational phenotyping is exploiting
the computed phenotype definitions to identify eligible patients for recruitment in clinical
trials. [7] This is important as manual chart reviewing is impractical as a means to perform
EHR-based patient matching to trials. [199] This is particularly relevant for the medically-
complex children cohort we utilized in this study, since there may be multiple patients
undergoing unsuccessful treatments who may be benefited by participating in a clinical
trial.
A limitation of our approach is that a single medical expert (Searles) validated and
annotated the computed phenotype definitions. We plan to strengthen the clinical validation
of our results by onboarding more experts.
5.6 Conclusion
In this work, we tackle the challenge of temporal phenotyping of a medically complex
pediatric population. We report the discovery of four medically complex phenotypes and
representative examples of their temporal trends in different patients, which were endorsed
by a clinical expert. We also demonstrated the usefulness of exploiting the low-dimensional
patient representations produced by PARAFAC2, towards extracting subgroups of patients
with significant survival variations.
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CHAPTER 6
INTERPRETABLE TEMPORAL PHENOTYPING OF PRE-DIAGNOSTIC
HEART FAILURE VIA INTEGER-CONSTRAINED PARAFAC2
FACTORIZATION
Summary
Can distinct and interpretable pre-diagnostic heart failure (pre-HF) phenotypes be
identified from longitudinal EHRs in an efficient manner? In this Chapter, building
upon the results of Chapters 3 and 4, we propose the integer-constrained PARAFAC2
and apply that to extract concise, pre-HF phenotype definitions on HF patients from
Sutter Palo Alto Medical Foundation. We quantitatively demonstrate the increased
interpretability of integer-based phenotypes as compared to the real-valued model,
by evaluating both in terms of conciseness and feature overlap across different phe-
notypes.
Our goal is to extract interpretable phenotypes of pre-diagnostic heart failure (pre-HF)
from longitudinal electronic health records (EHRs) in an efficient manner. Identifying the
various stages and progress of pre-HF is important due to: a) the prevalence and compli-
cations associated with HF; b) the heterogeneity of HF subtypes and c) the potential of
developing adaptive treatment strategies based on a better understanding of pre-HF patient
progress. The EHRs provide a rich data source that can be used to study the temporal pro-
gression of pre-HF. Our aim is to do so in an efficient and interpretable manner which both
avoids the need for manual chart review and automatically provides concise and clinically-
meaningful groups of EHR features indicating each one of the phenotypes.
We analyze longitudinal EHR data of 2,577 HF patients from Sutter Palo Alto Med-
ical Foundation (Sutter-PAMF). We consider the diagnoses, medications and procedures
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recorded within a 2-year observation window ending 6 months before each patient met the
operational criteria of HF diagnosis (HFDx). We propose an integer-constrained version of
the PARAFAC2 tensor factorization to tackle the pre-HF temporal phenotyping challenge.
Through our proposed approach, we extract: a) computational phenotypes as groups of
features associated with integer scores indicating the features frequency, b) integer patient
representations indicating the level of presence of a phenotype in the corresponding pa-
tients records, and c) real-valued factors indicating when a phenotype occurred across the
patient history. We also describe how to extract the earliest occurrence of each phenotype
across all associated patients; the resulting insights may be impactful towards guiding the
design (e.g., length of prediction window) of predictive models based on the underlying
data. We guide the choice of the number of phenotypes via a stability-driven criterion,
promoting reproducible results when starting from multiple different initialization points.
We identified 16 phenotypes reflecting different clinical manifestations and healthcare
processes indicative of pre-HF patients. We quantitatively demonstrate the increased in-
terpretability of the resulting phenotypes based on integer constraints, as compared to the
corresponding real-valued model; to do so, we evaluate both in terms of model conciseness
and feature overlap across different phenotypes.
6.1 Introduction
Heart failure (HF) is a leading cause of morbidity and mortality. The lifetime risk in in-
dividuals aged 55 years and older is about one in five and the 5-year survival ranges from
2050% after first diagnosis. [200] At the same time, HF is a highly heterogeneous condi-
tion and gaining a concrete understanding of both its clinical characterization as well as
its trajectory over time remains an open challenge. [201, 202] Tackling this challenge is
important as it may allow for more targeted treatment development. [203]
Electronic health records (EHRs) provide a rich source of readily-available data that
can be used to study the temporal progression of HF. Focusing on identifying EHR-based
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phenotypes capturing the pre-diagnostic heart failure (pre-HF) progression is important
due to the following reasons: a) the phenotypes extracted may provide the foundations for
developing clinically actionable protocols of preventive care, and b) they may be further
exploited as succinct feature summarizations in downstream predictive tasks which utilize
EHR data (e.g., to perform early detection of HF in an interpretable manner).
Manually identifying pre-HF phenotypes through EHR chart review is time-consuming
and not scalable to the large patient cohorts available. [38] Computational rule-based ap-
proaches [165, 166] suffer from similar issues; they incur substantial burden on both med-
ical informatics and clinical experts in order to develop carefully-crafted feature sets and
possible ranges for each individual phenotype. As a result, it is extremely challenging to
scale these approaches for large number of patients and heterogeneous cohorts. [167]
Our goal is to extract phenotype candidates (i.e., patient groups exhibiting similar pre-
HF subtypes) along with information about the timing of phenotype occurrence across dif-
ferent patients without expert supervision. Our proposed methodology is based on tensor
factorization, which is a set of methods extracting the latent correlation structure in diverse
and multidimensional input data which can be naturally represented as a tensor (i.e., gener-
alization of matrix for higher orders). [11] Tensor factorization methods have the following
desirable properties towards our target task: a) multiple phenotypes can be simultaneously
derived from data without user supervision or domain expertise; b) diverse, high-order in-
teractions are captured, such as the ones occurring among patients, medical features and
patient encounters; c) concise phenotype criteria are generated as output, simplifying inter-
pretation of complex relationships; d) soft clusters of patients can be derived where patients
may have multiple phenotype assignments with different degrees of association.
Tensor factorization has been successfully applied and extended towards unsupervised
phenotyping with multiple proof-of-concept demonstrations (e.g., [24, 134, 48]). Recent
work based on tensor factorization has additionally tackled the challenge of extracting tim-
ing information of phenotype occurrence across different patients, [61, 51, 204] a task
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we call as unsupervised temporal phenotyping. [10] Still, the model weights capturing
feature associations to phenotypes and phenotype assignments to patients are dense and
real-valued. Factor density results in lengthy feature groups which share several features
among the phenotype candidates, thus making the model less interpretable (due to the lack
of conciseness) and less actionable (due to the limited discriminatory power among dif-
ferent phenotype candidates). Also, when the input data represent event occurrences (as
happens in this work), the non-negative factor weights extracted are direct indicators of
frequency, reflecting: a) how often does a phenotype occur in a patients records and b) how
often does a feature occur as part of a feature group across all associated patients. However,
real-valued factor elements may not be the most intuitive indicators of frequency-based re-
lationships and integer scores on a standardized scale may be more appropriate to describe
relative frequency relationships among factor elements.
To tackle the challenges described above, we propose the integer-constrained PARAFAC2
tensor factorization. Our proposed model inherits favorable properties from its real-valued
counterpart [58] for temporal phenotyping purposes: [61] a) it preserves model uniqueness
under mild assumptions, [59] thus avoiding rotational model ambiguities which would hin-
der interpretability, and b) it can naturally handle core properties of EHR data, such as
sparsity and variability of the number of encounters across different patients. Through
our approach, we extract: a) computational phenotypes as groups of features associated
with integer scores indicating the features frequency, b) integer patient representations in-
dicating the level of presence of a phenotype in the corresponding patients records, and c)
real-valued temporal signatures indicating the evolution of those phenotypes over time for
each patient. We also describe how to extract the time segment of earliest occurrence of
each phenotype across all associated patients. We guide the choice of the number of phe-
notypes via a stability-driven criterion, promoting reproducible results when starting from
different initial points.
To automatically identify pre-HF phenotypes, we consider 2,577 HF patients from Sut-
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ter Palo Alto Medical Foundation (Sutter-PAMF) and a 2-year observation window ending
6 months before each patient met the operational criteria of HF diagnosis (HFDx). [205]
We identified 16 clinically-meaningful phenotypes reflecting different clinical manifesta-
tions and healthcare processes indicative of pre-HF. Apart from the phenotypes clinical
validation, we empirically assessed their interpretability by using sparsity and feature over-
lap among different phenotypes as proxy measures. Through this experiment, we demon-
strate that our proposed approach achieves highly-interpretable solutions, as the integer
constraints imposed promote sparser and less overlapping phenotypes than the real-valued
model.
6.2 Related Work
Heart failure phenotyping There are several prior works investigating risk factors, signs
and symptoms derived based on EHR data analysis. Vijayakrishnan et al. examine the
prevalence of Framingham criteria in both HF case and control patients through unstruc-
tured clinical notes processing. [206] Shah et al. employ hierarchical clustering to dis-
tinguish between different subtypes of heart failure with preserved ejection fraction (HF-
pEF). [203] Uijl et al. investigate age- and sex-specific differences in prevalence among
incident HF patients. [200] Knorek et al. examine the use of loop diuretics as a clinical
predictor of HF in the period preceding its formal diagnosis. [207] Finally, there is a line
of supervised phenotyping approaches which tackle the early HF prediction challenge and
investigate several design choices related to this task, such as the machine learning method
to utilize and the minimum amount of training data needed. [205, 208, 110].
Overall, none of the aforementioned works automatically extracts interpretable feature
ensembles which can characterize a specific HF phenotype from EHR data without access
to gold-standard labels; they also do not focus on characterizing the temporal evolution of
pre-HF phenotypes.
Unsupervised temporal phenotyping Several prior works have tackled the challenge of
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unsupervised temporal phenotyping via a wide range of approaches, which we summarize
below. The most relevant ones to our work apply and extend the real-valued PARAFAC2
factorization for phenotyping purposes; [61, 51, 204] as we demonstrate in the experiments,
the phenotypes derived from the real-valued PARAFAC2 model are harder to interpret and
potentially less actionable than the ones derived from the proposed integer-constrained
counterpart.
Another category of approaches follows factorization-based temporal phenotyping. [209,
139, 177, 178] However, these works do not provide model uniqueness guarantees. As a
result, there may exist many arbitrarily rotated versions of a solution yielding the same ap-
proximation error and it is unclear to the practitioner which one of those solutions provides
the true latent factors.
Another approach to factorization-based phenotyping is to flatten the temporal mode by
aggregating clinical features over time so that different patients can be aligned for analysis
purposes. [24, 134, 48, 135, 210, 179, 126, 211, 212] However, such a pre-processing
ignores the temporal ordering of clinical events which is necessary to understand phenotype
progression.
Embedding-based approaches have also appeared in the recent literature which extend
the idea of word embeddings [185] to extract concept and visit [186], care event [213] and
patient [167] representations. Those works do not focus on extracting phenotype trajecto-
ries over time. Simpler clustering-based approaches have also been proposed [182], which
only provide with the patient clusters, without the corresponding phenotype definitions. In
the absence of those definitions, both tasks of validating and generalizing the result to dif-
ferent populations are challenging. Simpler clustering approaches may additionally require
pre-processing of input longitudinal data into segments so that those are comparable across
different patients. [183, 184].
Several probabilistic approaches have been proposed as well. [173, 175] focus on mod-
eling and forecasting continuous variables such as vital signs or uric acid concentration
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over time. As such, they are not tailored to handle the sparsity and irregularities present
in EHR high-dimensional discrete event sequences. In [8], the authors use a Markov Jump
Process to model the stage transitions of a certain disease. Unlike our proposed method,
their approach requires a pre-defined set of disease stages to be set (apart from the target
number of phenotypes and other additional input parameters). They also report practical
obstacles, such as the need to pre-process the input data into time windows to deal with
input EHR data sparsity, as well as the requirement to specify anchor features as a form of
supervision for every phenotype in order to achieve interpretable results. Neither of those
requirements is necessary for our method. In [174], the authors focus on extracting tem-
poral trajectories of individual input variables, rather than phenotypic trajectories, which
capture the evolution of clinically-meaningful groups of features. Static probabilistic phe-
notyping approaches have also been proposed (such as the UPhenome model [176]) which
fail to encode any temporality about the patient records.
Sequential pattern mining approaches have also appeared which capture a certain flow
of care provided based on individual features, rather than phenotype definitions based on
feature groups which evolve over time. [10, 187] Such pattern mining approaches also
fail to provide succinct computable patient representations which can be further utilized
in downstream predictive tasks. Finally, association analysis of structured codes and vi-
sualization of the resulting patterns has also been pursued. [214, 188, 215, 216] Those
approaches only provide a high-level understanding of code associations over time and do
not enable the extraction of precise phenotype definitions.
6.3 Materials and Methods
Data description We use data from Sutter Palo Alto Medical Foundation (Sutter-PAMF)
primary care patients. Sutter-PAMF has been using an Epic Systems Corporation EHR for
more than a decade. The EHR dataset contains documentation of care delivered in the out-
patient setting. We focus on extracting structured code information recorded as part of each
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encounter, medication order and procedure order for each patient. We utilize the following
types of available data in the EHR: the International Classification of Diseases (ICD-9)
diagnostic codes recorded for each encounter, [43] the therapeutic subclass information in
the form of the Anatomical Therapeutic Chemical Classification System (ATCCS) [112]
provided as part of the medication orders, and the Current Procedural Terminology (CPT)
codes provided as part of the procedure orders. For every medication and procedure order,
we utilize the target diagnosis information available and include the corresponding ICD-9
codes as part of the input data for each patient. Finally, since we target longitudinal mod-
eling, we make use of the date information for each recorded code. For this purpose, we
timestamp the codes recorded using the encounters contact date. In case that such date
information is not available (e.g., Pharmacy medication orders may not have a matching
encounter identifier), we use the order date information as timestamp.
Heart failure case patient definition We use the following operational criteria to define a
HF diagnosis (HFDx): [206]
1. Qualifying ICD-9 codes for HF appeared as an encounter diagnosis or as the indica-
tion for a medication order.
2. A minimum of three clinical encounters with qualifying diagnostic codes had to be
present within a year of each other. The HFDx date is considered to be the earliest of
those dates.
Input data formulation Each patient’s records are represented through a binary matrix
Xk ∈ {0, 1}Ik×J . Rows correspond to a sorted sequence of dates, in increasing order
from earliest to latest, on which a clinical event for the k-th patient was recorded. Columns
correspond to clinical features (illustrated in Figure 6.1)). Xk (i, j) = 1 corresponds to the
occurrence of the j-th feature on the i-th sequenced date of the k-th patient’s records. Cells
containing a value of zero reflect the absence of the corresponding event. Duplicate feature





























Figure 6.1: Input for our proposed approach: each patient’s records are represented through
a matrix where rows correspond to a sorted sequence of dates (from earliest to most recent)
on which a clinical event occurred for the k-th patient and columns correspond to the clini-
cal features monitored (common across all patients). Each one of those matrices is binary:
Xk(i, j) = 1 corresponds to the occurrence of the j-th feature on the i-th sequenced date
of the k-th patients records. Cells containing a value of zero reflect the absence of the
corresponding event.
as a target diagnosis in a medication order) is ignored.
Proposed model and interpretation We propose an integer-constrained version of the
PARAFAC2 model. [58] Considering Xk ∈ {0, 1}Ik×J ,k = {1, . . . , K} as input the
model takes the following form:
Xk ≈ Uk Sk VT
where Uk∈RIk×R, Sk∈{0, . . . , τ}R×R , V ∈{0, . . . , τ}J×R , Sk is diagonal and VT
is the transpose of V and τ is a small positive integer defined by the user. We illustrate the
output model factors in Figure 6.2. We define their interpretation as follows:
• V is the phenotype definition factor and is common across all K patients: the non-
zero elements of thej-th column V(:, j) reveal the clinical features associated with
the j-th phenotype. The integer constraints imposed on the feature weights enable
interpreting them as distinct levels of frequency. For example, in Figure 6.2, “Essen-
tial hypertension” is expected to be 5 times more frequent than the rest of features






























Figure 6.3: Scaled temporal signature extraction for each patient. Note that multiplying
each Uk with Sk re-scales and sparsifies the k-th temporal signature, due to the implicit
sparsity achieved through the integer constraints on Sk.
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this specific phenotype.
• Sk is the phenotype membership factor. Its non-zero elements along the diagonal
reveal the phenotypes expressed by the k-th patient. Similarly to the interpretation
of the phenotype definition factor, we can interpret integer weights as distinct levels
of phenotype frequency. For example, in Figure 6.2, the “Hypertension” phenotype
is expected to be 3 times more prevalent than the “Infectious disease” one in the k-th
patient’s records.
Apart from permitting a frequency-based interpretation, the integer constraints imposed on
the factors above implicitly achieve sparse solutions, further promoting interpretability.
• Uk corresponds to the temporal signature ; a positive element Uk(i, j) reflects
that phenotype j was expressed during the i-th sequenced date of records of the k-
th patient. We also define the scaled temporal signature asU′k := max(Uk Sk,
0), where max is taken element-wise (Figure 6.3). The benefit of considering such
a scaled version of Uk lies in scaling each Uk(:, j) column with the appropriate
integer phenotype membership weight Sk(j, j). Importantly, due to the implicit
sparsity achieved by representing Sk on a small integer scale ({0, . . . , τ}), several
columns of the resulting Uk Sk product will be completely zero, thus enhancing
interpretability. Finally, due to the fact that both the input as well as the phenotypes’
definition factor V are non-negative, we only consider the positive elements of the
Uk Sk.
Identifying earliest phenotype occurrence In this Section, we describe how to identify the
earliest time segment of occurrence of a pre-HF phenotype across all associated patients.
For example, we enable detecting which percentage of patients exhibit the hypertension
phenotype up to 2 years before the HF diagnosis date. This information may be useful in
guiding the design of predictive models based on the underlying data (e.g., by considering
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a prediction window such that phenotypes corresponding to well-known risk factors of HF
are captured for most associated patients).
We consider a split of our observation window into b time segments. Those do not have
to span an equal period of time and can vary depending on the disease or cohort under
consideration. For the needs of studying pre-HF phenotypes, we use b = 4 segments of 6
months each. Then, we consider the scaled temporal signature factor U′k := max(Uk Sk,
0), and normalize each j-th column by the maximum column value such that Uk (:, j) :=
U
′
k (:, j) ./max(U
′
k (:, j)) where ./ denotes elementwise division. Then, we consider as
earliest time segment of occurrence of phenotype j in the records of k-th patient as the
minimum index l for which Uk (i, j) > ρ, i ∈ Bk,l where Bk,l is a set storing the indices
of k-th patient corresponding to the l-th time segment and ρ is a user-defined threshold (we
empirically choose that to be equal to 0.5).
Proposed fitting algorithm The workhorse framework fitting the PARAFAC2 model is the
Alternating Least Squares (ALS). [59] This framework dictates optimizing a least squares
criterion in an alternating fashion, i.e., fixing a set of factors and solving for all others. The








subject to Sk being diagonal. In order to guarantee model uniqueness under mild assump-
tions, Harhsman imposed a cross-product invariance constraint which dictates that UTk Uk
is invariant ∀k ∈ {1, . . . , K} .. [58] In the context of our phenotyping application, this
implies that the correlations among different phenotypes are kept constant, across all pa-
tients. Uniqueness ensures that a factorization is pursuing the true latent factors, rather
than an arbitrary rotation of them. In the context of phenotyping, using unique models pro-
vide with greater license to interpret their output factors as indicative of the true underlying
phenotypes. [14, 20]
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Thus, the following ALS framework can be employed which iteratively solves for 2 sub-
problems until a convergence criterion is met:
1. Solving for Qk, by fixing the rest of factors, under the constraint thatQTk Qk= I.The
problem reduces to an Orthogonal Procrustes problem and can be optimally solved
through the Singular Value Decomposition. [109]
2. Solving for H Sk VT with Qk fixed. This step reduces to a CP factorization of a
tensor (i.e., multi-way array) Y ∈RR ×J ×K, whose k-th frontal slice isYk =QTk Xk ,
whereYk ∈RR ×J. [59] In order to impose integer constraints on Sk , V, we solve
this step through the recently-proposed SUSTain approach, which performs integer
tensor factorization. [48] Also, in order to exploit the sparse nature of input data,
we solve the bottleneck MTTKRP step of CP factorization through the SPARTan
approach. [51]
Choosing the number of phenotypes We use the stability-driven criterion proposed in [117]
in order to guide the choice of the target rank R (i.e., the number of phenotypes). Intu-
itively, this criterion promotes a target rank for which several runs with different initial
points return reproducible factors. We choose the phenotypes factor V as the factor under
assessment.
6.4 Results
Data processing The observation window considered for each patient is [-2.5 years, -6
months] before the HFDx date. A total of 69,817 unique encounters were processed.
A standard step towards improving interpretability and clinical meaningfulness is to
transform the codes occurring in the patient records to clinical categories. We transform
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the ICD-9 diagnostic codes to hierarchical Clinical Classifications Software (CCS) level-3
codes. [195] We omit the diagnostic category “Dx: Residual codes; unclassified; all E codes
[259. and 260.]” since it does not represent a concrete clinical category, but an aggregation
of residual diagnostic codes. We also group the normalized drug names (i.e., combining
all branded names and the generic name for a medication) based on therapeutic subclasses
using the Anatomical Therapeutic Chemical Classification System (ATCCS). [112] We
transform the CPT codes available to CCS procedure categories. [195]
Based on the data extraction described above, our initial cohort consisted of 3,362 pa-
tients described by 836 categories. We excluded clinical categories appearing in less than
1% of patients; thus, we excluded categories appearing in less than 34 patients. The num-
ber of excluded categories was 481. Due to filtering features, we had 4 patients left with
empty records, which we removed.
Since we are interested in studying the longitudinal nature of pre-HF phenotypes, we
also omitted patients having less than 10 distinct dates of events (Ik < 10). [205] 781
patients were omitted through this step.
We present summary statistics describing our input data in Table 6.1
Table 6.1: Summary statistics.
Summary statistics Value
Number of patients 2,577
Number of features 355
Number of diagnostic categories 178
Number of medication subclasses 119
Number of procedure categories 58
Number of event occurrences 257,013
Median (25th - 75th percentile) of distinct dates per patient 27 (17 - 44)
Median (25th - 75th percentile) of clinical features per patient 29 (18 - 42)
Median (25th - 75th percentile) of event occurrences per patient 75 (42 - 135)
Study design We used Matlab R2017b for the implementation, and utilized several func-
tionalities based on SPARTan [51] and SUSTain [48] methods. [217, 218] We also accredit
the N-way Toolbox [157] and the Tensor Toolbox [114], from where we have adapted some
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functionalities. We plan to open-source our implementations and make them publicly avail-
able post-acceptance.
We empirically observed that initializing the integer factors with a rounded version of
the real-valued model is less susceptible to local minima than random integer initialization.
Naively rounding real-valued solutions usually leads to poor model fit, due to blindly col-
lapsing all values < 0.5 to 0. We have designed a more sophisticated rounding approach
which first performs scaling to avoid such an issue; [48] we use this approach to initialize
our method.
We define the upper bound τ := 5 throughout our experiments, driven by discussions
with medical experts and similarity to several medical scoring systems.
We define the fit of a solution given a certain target rank R as the proportion of the total
sum of squares that is explained by theR-dimensional model. [59] Formally, we have:









We also define the phenotype sparsity measure as:
Sparsity(R) := 1 − nnz (V)
J R
,
where nnz(V) denotes the number of non-zero elements of the factor matrix V, and J R
is the product of its mode sizes. Sparse solutions are considered more interpretable; thus,
we prefer solutions where Sparsity(R) is close to 1.
We finally define the phenotype overlap as the percentage of phenotype pairs sharing at
least one common (overlapping) feature. For example, if V(i, k) and V(i, l) are both non-
zero for k 6= l, then the pair of phenotypes (k, l) shares i as an overlapping feature. Lower
values of overlap improve interpretability, as more distinct phenotypes can be extracted
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Integer-constrained PARAFAC2: Instability measure vs target rank
Figure 6.4: Guiding the choice of target rank for integer-constrained PARAFAC2. We re-
peat the experiments with 10 different initialization points for every target rank (R). The
instability measure gives lower values to more robust solutions, i.e., where different ini-
tialization points for the same target rank give highly-correlated phenotype factors (V), up
to column permutations. Domain knowledge suggests that there are more than 2 distinct
phenotypes for pre-HF; as a result, we choose the solution with R = 16.









We denote the upper-triangular (lower triangular is equivalent) part of the cross-product
VTV (excluding the main diagonal) as triu(VTV). We then count the number of non-
zero elements and normalize by the maximum number of phenotype pairs.
Choosing the number of phenotypes We provide the results guiding our choice of the
number of phenotypes in Figure 6.4. For each target rank R ∈ {2, . . . , 25} , we run
our proposed algorithm for 10 different initialization points. The instability measure gives
lower values to more robust solutions, for which different initial points for the same target
rank R give highly-correlated phenotype factorsV, up to column permutations. Domain
knowledge suggests that there are more than 2 distinct phenotypes describing the hetero-
geneity of pre-HF. Thus, we pick the solution with the second lowest instability measure,
achieved for R = 16.
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Table 6.2: 5 most prevalent phenotype definitions extracted via integer-constrained
PARAFAC2
Phenotype ID: 1 (Prevalence: 0.72) Feature score
Dx Essential hypertension [98.] 5
Med ACE Inhibitors 1
Med Beta Blockers Cardio-Selective 1
Med Calcium Channel Blockers 1
Phenotype ID: 13 (Prevalence: 0.59) Feature score
Dx Immunizations and screening for infectious disease [10.] 5
Proc Prophylactic vaccinations and inoculations 4
Dx Medical examination/evaluation [256.] 1
Dx Other screening for suspected conditions (not mental disorders or infectious
disease) [258.]
1
Dx Other upper respiratory disease [134.] 1
Phenotype ID: 4 (Prevalence: 0.56) Feature score
Dx Disorders of lipid metabolism [53.] 5
Med HMG CoA Reductase Inhibitors 2
Phenotype ID: 7 (Prevalence: 0.47) Feature score
Dx Other skin disorders [200.] 5
Proc Excision of skin lesion 3
Dx Allergic reactions [253.] 1
Dx Other and unspecified benign neoplasm [47.] 1
Dx Other mycoses 1
Dx Other non-epithelial cancer of skin [23.] 1
Proc Other non-OR therapeutic procedures on skin and breast 1
Phenotype ID: 14 (Prevalence: 0.45) Feature score
Dx Other and unspecified lower respiratory disease 5
Dx Chronic airway obstruction; not otherwise specified 1
Dx Other and unspecified asthma 1
Med Azithromycin 1
Med Cough/Cold/Allergy Combinations 1
Med Sympathomimetics 1
Proc Routine chest X-ray 1
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1 2 3 4 5 6 7 8 9 10 11 12 13
Sequence of dates with clinical events
Dx_Coronary atherosclerosis and other heart disease [101.]
Dx_Disorders of lipid metabolism [53.]
Dx_Diverticulosis and diverticulitis [146.]
Dx_Essential hypertension [98.]
Dx_Hemorrhoids [120.]
Dx_Immunizations and screening for infectious disease [10.]
Dx_Other and unspecified benign neoplasm [47.]
Dx_Other male genital disorders [166.]
Dx_Other screening for suspected conditions (not mental disorders or infectious disease) [258.]
Med_ACE Inhibitors












































































































































































Figure 6.5: Example of input data for a single patient. The x-axis corresponds to the
sequence of distinct dates of events and the y-axis corresponds to the diagnostic, medication
and procedure categories. A value of 1 for the corresponding (clinical category, date) pair
denotes that a clinical category was observed during that date in the patients records.
Phenotype discovery and clinical evaluation Table 6.2 provides the detailed definitions of
the 5 most prevalent pre-HF phenotype extracted. For each phenotype, we have computed
its prevalence (ranging within [0, 1]) across the HF cohort we examine. Prevalence is
computed by inspecting the integer phenotype membership factor Sk. We consider that the
k-th patient exhibits the j-th phenotype if Sk (j, j) > 0.
In Figure 6.6, we illustrate a heatmap of a scaled temporal signature for an example
patient. Rows correspond to phenotype annotations and columns to distinct dates of medi-
cal records. We only list phenotypes with some non-zero value across any column; only 4
phenotypes are relevant for this patient. We picked a patient with a small number of distinct
dates of events in order to facilitate validation by contrasting the result with the correspond-
ing patient’s input data (Figure 6.5). An example indicating the validity of the result is that
the third row – corresponding to the phenotype containing “Coronary atherosclerosis and
other heart disease [101.]” as a single feature – contains non-zero elements precisely during
126
1 2 3 4 5 6 7 8 9 10 11 12 13















































































Figure 6.6: Illustration of a scaled temporal signature (row-normalized by the maximum
row value) extracted via our proposed approach for the patient with input data shown in Fig-
ure 6.5. Rows correspond to phenotype definitions provided by a cardiologist and columns
correspond to dates of clinical event occurrence. Phenotypes with some non-zero element
in any date are only presented (i.e., only 4 phenotypes in total).
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Figure 6.7: Percentages of earliest phenotype occurrences for every phenotype extracted.
Each (i,j) cell corresponds to the percentage of patients developing the earliest occurrence
of i-th phenotype during the j-th time segment (out of patients eventually developing the
i-th phenotype during the observation window). For example, we remark that out of the
1864 patients developing Hypertension (phenotype identifier: 1), 1745 (94%) patients have
developed it at least 1 year before the HF diagnosis date (i.e., before the last-most time
segment we consider).
the dates of the corresponding diagnosis occurrence in the patient’s records (Figure 6.5).
Identifying earliest phenotype occurrence In Figure 6.7, we provide with the percentages
(each row sums to 100%) of earliest occurrence across all phenotypes and time segments.
For example, the cell (1, 1) indicates that 59.4% of hypertensive patients have developed
the Hypertension phenotype as early as 2 years before the HF diagnosis date.
There are potentially interesting insights revealed through this analysis which indicate
differences in phenotype progression and occurrence in the EHRs. For example, out of the
1,864 patients developing Hypertension (phenotype index 1), 1,745 (94%) patients have
developed it at least 1 year before the HF diagnosis date (i.e., before the last-most time
segment we consider). On the other hand, out of the 1,149 patients developing lower res-
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Figure 6.8: Comparing the proposed integer-constrained PARAFAC2 against its real-
valued counterpart in terms of the phenotype sparsity fit trade-off. We run the experiments
10 times for each value of R = 2, 3, , 25 and choose the solution achieving the best fit.
Sparsity reveals the amount of zero elements w.r.t. the total number of elements of the
models matrix V, indicating the phenotype definitions. Sparsity is key for ease of inter-
pretation; we remark that our proposed integer-constrained PARAFAC2 method achieves a
much sparser solution without incurring a significant loss in terms of model fit.
piratory system disorders (Phenotype ID: 14), 227 of them (19.8%) exhibit this phenotype
for the first time during the last-most time segment we consider.
We developed a simple validation method to test whether the earliest phenotype oc-
currence we extract as described in the “Materials and Methods” Section is not modeling
noise, instead of a true phenotype presence. If a detection of the j-th phenotype occurs
during the i-th sequenced date of the k-th patient’s records, then we assess whether any of
the features composing the j-th phenotype does occur during the i-th date of the k-th pa-
tient’s input data. Based on this validation method, we measure precision (i.e., how many
detections are relevant). Out of a total of 15,743 detections, 15,725 are relevant (precision:
99.9%).
Quantitative comparisons in terms of model fit and interpretability We quantitatively
compare the proposed integer-constrained PARAFAC2 approach against its real-valued
counterpart. [58, 61] We do so in terms of model fit and interpretability of the phenotypes’
definition factor V. Despite the fact that quantitatively measuring the interpretability of a
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Figure 6.9: Comparing the proposed integer-constrained PARAFAC2 against its real-
valued counterpart in terms of the phenotype overlap fit trade-off. We run the experiments
10 times for each value of R = 2, 3, , 25 and choose the solution achieving the best fit.
Overlap is defined as the percentage of phenotype pairs having at least one overlapping
feature (e.g., if V (i, k) and V (i, l) are both non-zero for k 6= l, then the pair of pheno-
types (k, l) shares i as an overlapping feature). It is crucial that phenotype overlap is low
for ease of interpretation; we remark that our proposed integer-constrained PARAFAC2
method achieves a much smaller value of feature overlap, without incurring a significant
loss in terms of model fit.
machine learning model remains an open challenge, there are standard measures which are
widely accepted as proxies for interpretability: a) model conciseness, which can be mea-
sured by assessing the model’s sparsity, and b) minimization of inter-component overlap,
in the sense that the different components captured (i.e., different columns of V) should
describe a wide range of latent concepts. The latter one is particularly relevant for pheno-
typing where different components should capture a wide range of clinical manifestations.
All measures of fit, sparsity and overlap are described in the “Study design” Section.
As shown in Figure 6.8, our integer-constrained approach implicitly (i.e., it does not di-
rectly optimize for sparsity) achieves a much sparser solution than its real-valued counter-
part across all different values of target rankR ∈ {2, . . . , 25}. It does so without incurring
a significant loss in terms of model fit (x-axis). In Figure 6.9, we also measure the pheno-
types’ definition V factor overlap. We remark that the real-valued PARAFAC2 model is
noisy in the sense that all phenotypes overlap with each other (i.e., overlap value of 1 across
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all values of target rank). We conclude that, in the absence of any arbitrary post-processing
(e.g., truncation of features with the lower-most k weights), the real-valued model does
not lead to easily-interpretable solutions. On the contrary, our integer-constrained model is
interpretable, without incurring a significant loss in terms of model fit.
6.5 Conclusion & Future Work
We proposed an integer-constrained PARAFAC2 tensor factorization to automatically iden-
tify pre-diagnostic phenotypes of heart failure patients through readily-available EHR data,
as well as extract information about their temporal evolution. We quantitatively demon-
strate the increased interpretability of the resulting phenotypes based on integer constraints,
as compared to the corresponding real-valued model; to do so, we evaluate both in terms of
model conciseness and feature overlap across different phenotypes. Potential future work
may be to constrain factors {Uk} with non-negative/integer constraints in order to further
improve interpretability. Utilizing the extracted low-rank integer patient representations as
features in a predictive model tackling the challenge of early HF prediction in an inter-
pretable manner is a direct next step of this work.
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CHAPTER 7
USING THE PARAFAC2 TENSOR FACTORIZATION ON EHR AUDIT DATA TO
UNDERSTAND PHYSICIAN DESKTOP WORK
Summary
In this Chapter, we explore how the EHR activity log file can be processed to derive
scalable and quantifiable physician-level workflow measures. To cope with the mas-
sive volume of log data, we apply PARAFAC2 (as implemented via the SPARTan
approach presented in Chapter 4) to identify clusters of audit log records that map
to meaningful representations of physician tasks. The discovered variants of notes’
access map to two known workflows for this task.
Background: Activity or audit log data are required for EHR privacy and security man-
agement but may also be useful for understanding desktop workflow.
Objective: We determined if the EHR audit log file, a rich source of complex time-stamped
data on desktop activities, could be processed to derive primary care provider (PCP) level
workflow measures.
Methods: We analyzed audit log data on 876 PCPs across 17,455 ambulatory care en-
counters that generated 578,394 time-stamped records. Each individual record represents
a user interaction (e.g., point and click) that reflects all or part of a specific activity (e.g.,
order entry access). No dictionary exists to define how to combine clusters of sequential
audit log records to represent identifiable PCP tasks. We determined if PARAFAC2 tensor
factorization could: 1) learn to identify audit log record clusters that specifically represent
defined PCP tasks; and 2) identify variation in how tasks are completed without the need
for ground-truth labels. To interpret the result, we used the following PARAFAC2 factors:
a matrix representing the task definitions and a matrix containing the frequency measure of
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each task for each encounter.
Results: PARAFAC2 automatically identified 4 clusters of audit log records that represent
4 common clinical encounter tasks: 1) medications’ access, 2) notes’ access, 3) order entry
access, and 4) diagnosis modification. PARAFAC2 also identified the most common vari-
ants in how PCPs accomplish these tasks. It discovered variation in how the notes’ access
task was done, including identification of 9 distinct variants of notes access that explained
77% of the input data variation for notes. The discovered variants mapped to two known
workflows for notes’ access and to two distinct PCP user groups who accessed notes by
either using the Visit Navigator or the Wrap-Up option.
Conclusions: Our results demonstrate that EHR audit log data can be rapidly processed to
create higher-level constructed features that represent time-stamped PCP tasks.
7.1 Introduction
Health care structure (e.g., facilities, staff, financing) defines the context for care processes.
In ambulatory care, in particular, an increasing share of provider and staff time are spent
at the desktop. [219] Log file data (also known as audit logs) may be used to reveal how
desktop work is done and the time required to do this work. [220, 221, 222] Log files, how-
ever, are voluminous and difficult to decipher. We determined whether tensor factorization
methods could be used to cluster log file records into groups that represent distinct PCP
tasks. If this were possible, then these records could be used for a diversity of applica-
tions that include but are not limited to workflow analysis, efficiency improvement efforts,
learning best practices for use of the EHR, and to better understand how work is done and
improved.
EHRs automatically generate time-stamped audit logs that track all interactions that a
user has with a patient’s record, as well as, other desktop activities (e.g., inbox). While
these data are created for privacy and security management they also document how users
do their desktop work when using the EHR. [223] But, audit log data are inordinately com-
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plex and are not organized into self-identifiable clusters that represent defined jobs or tasks.
In this context, we use the term “job” as defined by Ulwick [224] to refer to the underlying
goal of a sequence of actions being taken or tasks being completed. [223] For example,
making a medication order in the EHR may be a task associated with the overall “job” of
managing a patient’s medication use for a specific condition with the intention of optimiz-
ing outcomes. The log file documents the electronic action (making the order), whereas
the job is inferred from an overall ensemble of related actions (e.g., open the patient’s
medication list, search the medication database for the appropriate medication, select the
dose/quantity/pharmacy) that may be summed and expressed as a series of tasks. If tasks
can be readily identified, log files could be used to understand how desktop work is done,
including the time required to do specific desktop job (i.e. make diagnosis, medication
management, procedure order, progress note).
We determined if machine-learning methods could be used to interpret audit log data
and rapidly identify the most common types of clinical desktop tasks and to determine
variation in how these tasks are done.
7.2 Methods
Overview
In this study, we used Epic audit log records from face-to-face primary care encounters
to answer the following questions about what PCPs do during encounters [58, 59, 51] 1)
Can raw time-stamped audit log records be organized into clusters of records that represent
intuitively meaningful representations of tasks that PCPs do? 2) Can audit log records be
automatically organized and interpreted to determine variation in how a specific task is
done? For the latter, we specifically focused on progress notes because this work is done
for every encounter. Moreover, it is known that there are two dominant ways to use the Epic
EHR built-in interface features for this purpose. That is, clinical observation has confirmed
that are two distinct methods by which progress notes are accessed and documented. We
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Figure 7.1: Example of EHR audit log records corresponding to the opening of the pa-
tient record at the start of an encounter. Note that there may be multiple log records with
the same timestamp. Timestamps with no records are indicators of no computer related
interactions (e.g., doctor is viewing data on screen, talking to patient, etc).
wanted to determine if machine learning could detect these two distinct methods and the
ensemble of related tasks and also cluster PCPs by how progress notes were completed. To
this end, the methods section describes the source data, pre-processing of the source data
for use in modeling, and then the tensor factorization methods used to summarize audit log
records.
Source of Data & Data Extraction
Audit log data were extracted from Sutter Health’s Epic EHR data sources. Sutter Health is
a large not-for-profit health system that serves over 100 communities in northern California.
Sutter uses a single instance of the Epic Systems Corporation EHR.
Audit log files are very large even for a small number of encounters. We randomly se-
lected two working days in 2016 (Epic 2015) and extracted log records for ambulatory care
face-to-face encounters completed by 876 Primary Care Providers (PCPs). PCPs include
physician, nurse practitioner, and physician assistants. The two days of log files resulted in
578,394 time-stamped audit log records across 17,455 encounters. Each entry in the audit
log is time-stamped at a resolution of one-second, where two or more records occurring
less than one second apart will have the same time-stamp, but these records are sequen-
tially ordered as they occur. We restricted analysis to PCP face-to-face encounters that
had at least two time-stamped audit log records. This resulted in 16,613 input encounters
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Figure 7.2: Transformation of face-to-face encounter audit log records data into a binary
matrix. Each row of the matrix is a multi-hot vector encoding of the feature assembly
representing a potential PCP task; the row number reflects the chronological task ordering
during a single encounter. Each one of the columns corresponds to a feature defined as a
variant of a certain audit log record: if an audit log record occurs or co-occurs with the last
timestamp of a potential task, then this is marked as Terminal. Otherwise, it is marked as
Intermediate. Terminal features are in bold font.
Preprocessing of Raw Activity Log Data into Task and Feature Construction
We are interested in using tensor factorization to determine if a schema could be created
where clusters of log records could be automatically identified that correspond to discrete
tasks. To this end, log data were pre-processed by ordering them within provider, by date,
by encounter within date, and last, by the audit log record time stamp and sequence indica-
tor. Encounters that contained only one log record were removed. Figure 7.1 describes an
audit log sequence that begins with opening of the encounter visit navigator, where multiple
log records with the same timestamp means that they occurred during the same second.
Log records were further pre-processed to disassemble the contents of an encounter
(sequence of log records) into smaller log record sequences that may reflect common tasks
or parts of tasks done by PCPs. We refer to these discrete log record sequences as “potential
tasks” that are defined as follows: in the absence of an explicit signal indicating the end of a
task, we assume that sequential records that occurred on consecutive seconds (e.g., interval
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00:04-00:06 in Figure 2) and that are separated by a break of no activity (i.e., >1 second)
either before or after the sequence are considered to be part of the same potential task, but
not necessarily representing a complete task.
Log records co-occurring with the last timestamp of a potential task indicate actions
which occupy the user’s attention (e.g., reviewing data retrieved when an EHR features is
clicked), or that are consistently followed by a separate user activity (e.g., talking to the
patient) that does not involve desktop interactions. Accordingly, we define two variants
of audit log records which we call Intermediate (occurring before the last time stamp) and
Terminal (co-occurring with the final timestamp before a >1 second gap between potential
tasks) features. We annotate all records occurring during the n-th timestamp as Terminal
features and records occurring during the timestamps 1, . . . , n−1 as Intermediate features.
Also, duplicate features within the same potential task are removed. Such duplicates may
arise when we create the multi-hot vector encodings of potential tasks as in Figure 7.2,
when there may be multiple occurrences of a certain feature (e.g., I Visit Navigator template
loaded).
In sum, we transform each k-th ambulatory care encounter to a binary matrix Xk of
size IK × J , where Ikcorresponds to the number of potential tasks for the k-th encounter
and J denotes the total number of features derived from raw audit log records (Figure
3). Importantly, the number of potential tasks per encounter is not known in advance.
Finally, in the absence of labeled data, we do not know in advance whether a group of
log records represents a systematic way of accomplishing a PCP task. PARAFAC2 tensor
factorization [58] was used to address this challenge.
PARAFAC2 Factorization: Variation in How PCPs Complete Tasks We determined
whether the PARAFAC2 factorization [58] could identify tasks and variation in how tasks
are done. We selected the PARAFAC2 framework (i.e., model & factorization algorithm)
because it can effectively account for the folded structure of our intermediate data. That




















Figure 7.3: A visual representation of the collection of matrices created through our pro-
posed method of organizing raw activity log records into candidate physician tasks. Each
matrix corresponds to a single encounter. The rows correspond to candidate physician tasks
recorded (which can vary across encounters) and the columns to the features constructed




















Figure 7.4: PARAFAC2 factorization given an input collection of matrices (as in Fig-
ure 7.3). The chosen model can naturally handle a varying number of candidate tasks
across different encounters. The matrix V contains the most prevalent variation patterns of
the most common physician tasks.
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resents a sequence of records corresponding to underlying potential tasks, each of which
can ultimately be represented by an ensemble of features (i.e., audit data entries). Such a
folded structure can be concisely modeled by a multi-dimensional data array, containing a
matrix of sequenced potential tasks X features for each one of the PCP encounters; such
an array fits the expected input for the PARAFAC2 factorization. PARAFAC2 also offers
an easily-interpretable approach to dimensionality reduction, as noted below. Notably, in
contrast to other simpler multi-dimensional dimensionality reduction approaches (e.g., the
CP/PARAFAC decomposition [89]), PARAFAC2 does not require any ad-hoc alignment
of tasks among encounters. This is crucial because it is unrealistic to assume that all en-
counters will share the same number of potential tasks. PARAFAC2 also preserves model
uniqueness under mild assumptions, boosting reliability of model interpretation (we elab-
orate on that below) and also it natively handles input data sparsity, which is a by-product
of the fact that a few features will be observed for every potential task. Finally, specialized
algorithms have recently been developed [51] scaling up PARAFAC2 for sparse input data;
the use of scalable frameworks is crucial in order to cope with the voluminous nature of
log files.
The input data for this decomposition (Figure 7.4) are organized as a binary multi-way
array (tensor) of size Ik × J × K where K is the number of encounters. PARAFAC2
approximates a collection of matrices {Xk ∈ RIk×J} as:
Xk ≈ Uk Sk V T (7.1)
where k = 1, . . . , K,Uk ∈ RIk×R,Sk ∈ RR×R is diagonal and V ∈ RJ×R. R is a user-
defined parameter which denotes the number of tasks extracted from the model. We exploit
the following factors of the PARAFAC2 model: a) a matrix revealing the most representa-
tive variations of physician task definitions across all encounters (V matrix in the model),
and b) a matrix containing the frequency of each task extracted for each k-th encounter
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(Sk matrix in the model). The model can be extended so that non-negative constraints are
imposed on {Sk},V factors, [145] a constraint we employ to enhance interpretability.
Model and Algorithm PARAFAC2 preserves uniqueness of the model output by impos-
ing the constraint that the cross product UTkUkis invariant regardless of which k is in-
volved. [58] This implies that the correlations between the tasks extracted are constant for
all the encounters. [59] Preserving uniqueness means that the model is pursuing the actual
latent factors, rather than an arbitrary rotation of them, which boosts the reliability of the
model interpretation. [131]
The state-of-the-art framework for fitting the PARAFAC2 model uses Alternating Least
Squares (ALS). [59] This corresponds to optimizing a least-squares criterion, in an alternat-
ing fashion, where we solve for a subset of factors by fixing all others. Our input data are
inherently sparse, meaning that there are a few non-zero elements recorded as compared to
the total size of the input matrices. Thus, we use the algorithm proposed by Perros et al.,
which also follows the ALS framework, but is optimized for sparse datasets. [51, 61]
To avoid repetition, we refer the reader to the Section 5.3 regarding the details of deter-
mining the number of task definitions via utilizing the Core Consistency Diagnostic [171,
190]. To increase our chances of avoiding local minima in our experiments, we ran the
PARAFAC2 fitting algorithm 10 times for each target rank R (i.e., number of task defini-
tions pursued) using random initialization of factors and with the Singular Value Decom-
position (SVD)-based initialization suggested in [154]. Then, we chose the solution with
the minimum cost function error, among the ones achieving a diagnostic score of at least
90%. If the diagnostic score was lower than 90% for all 10 runs, then we simply picked the
result with the best diagnostic score.
On the other hand, we define the percentage of fit as the proportion of the total sum of
squares that is explained by the model: [59]
Fit (R) := 1−
∑K
k=1







A reasonable expectation is that as long as we increase the number of representative task
definitions pursued, the fit percentage will increase as we are providing the model with
more factors to describe data variation.
Proposed Model Interpretation Below, we summarize the proposed approach to interpret
the model parameters. Each one of the R columns of the V matrix of the model provides
a certain task definition to extract this definition, we order the weights of each column in
decreasing order and list the associated features. Due to the non-negativity constraints im-
posed on V , features associated with higher weights are expected to be more representative
of the corresponding task definition.
The diagonal Sk matrix in the model is representative of the frequency of each task
extracted for each k-th encounter. To estimate the task utilization for each user (i.e. clini-
cian), we propose to consider the mean of all the R-dimensional encounters for each user.
The resulting R-dimensional vector for each user can be used to identify variations among
the users, with respect to task utilization. To visually identify clusters of users with similar
utilization profiles, we use the tSNE [194] software, which can reduce the R-dimensional
vectors to the 2-dimensional space.
7.3 Results
For our experiments, we used the Matlab implementation of the PARAFAC2 algorithm
designed for sparse input, provided in [51]. Among a total of 84 features, derived as Inter-
mediate or Terminal variants of audit log records (refer to the Methods Section for details),
we excluded 36 that accounted for less than 1% of all feature occurrences across all the
encounters. This resulted in J = 48 unique features as input to the model. No significant
change in fit (less than 1%) was observed before and after excluding the 36 uncommon
features.
Figure 7.5 summarizes the percentages of fit and consistency diagnostic for various
target ranks (i.e., number of tasks). As suggested in [190], the final solution comprising
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Figure 7.5: The percentage of consistency diagnostic and fit. We choose the solution pro-
viding the highest fit (i.e., lowest error) and also providing a well-specified model reflected
by the consistency diagnostic (over 90 percent). Thus, the best solution for 5 task defini-
tions is selected.
Table 7.1: Task definitions discovered via PARAFAC2. The first part of each entry denotes
whether the feature corresponds to an activity log record that is an intermediate (I) or a
terminal one (T). The terminal activities are in bold font. Activities are listed in order
of frequency of occurrence as indicated by the PARAFAC2 model weights. Activities
associated with weights > 0.2 are listed.
Task Features
1. Medication Access
T Medications activity accessed
T Patient Encounter opened
I Visit Navigator template loaded
T Chief Complaint navigator section accessed
T PCP History accessed
I Data from related encounters accessed through VB
2. Note Access
T Notes activity and navigators accessed
T Patient Encounter opened
T Problem List activity accessed
3. Order Access
T Order Entry activity accessed
T Diagnosis association updated
4. Diagnosis Modification
T Visit diagnoses modified
T Patient Encounter opened
I Visit Navigator template loaded
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five tasks has the highest fit, as well as, a high consistency diagnostic (above 90%). Thus,
for our experiment, the solution with 5 tasks is considered the most suitable.
Table 7.1 presents the most common tasks discovered using PARAFAC2 in our first
experiment. The name assigned to each task was derived from the log record with highest
weight in each cluster. We have used the term “access” in Table 7.1 as a general term for
the cluster of EHR features accessed by the user; this does not imply that the task is a read-
only view of the EHR; the audit log source file does not record more granular activities,
such as keyboard typing, data entry, copy/paste activities, etc.
Discovery of most representative PCP tasks Without prior information, PARAFAC2
identified five groups of features accounting for 55% of the variation in activity log data
(Figure 7.5). One of those 5 groups contained intermediate features as the ones having
the largest frequency of occurrence and thus was excluded from our result. For each of
the remaining 4 discovered task definitions, we list the identified features, in order of fre-
quency as indicated by the PARAFAC2 model weights, and also indicate whether they are
intermediate (I) or terminal (T). We annotate each one of the feature groups according to
their most frequent terminal feature (e.g., we consider the first feature group in Table 7.1 to
reveal the most common variation pattern of completing the Medication access task).
Variation in Notes Access Task We further determined whether PARAFAC2 could be
used to extract variation in activity log records that correspond to Notes Access (Table 7.1)
with the intention of detecting differences among physicians in how notes are accessed and
done.
Beginning with the 17,455 unique input encounters, we only retained tasks that con-
tained the T Notes activity and navigators accessed feature, indicating the inclusion of
Notes access as a terminal activity. We then follow the same pre-processing strategy
as above, by excluding very infrequent features (< 1% of the total feature frequency,
N=14,659) and excluding 51 encounters that contained a single activity.
Figure 7.6 summarizes the percentages of fit and consistency diagnostic for various
143
Figure 7.6: Plotting the percentage of consistency diagnostic and fit for the Notes activity
access. We choose the solution providing the highest fit (i.e., lowest error) and also provid-
ing a well-specified model reflected by the consistency diagnostic (over 90 percent). Thus,
the best solution for 9 notes access variation patterns is selected. Note that for illustration
purposes, we have set the values of consistency diagnostic less than zero to zero.
target ranks (i.e., number of pursued notes access variation patterns). We extracted 9 dis-
tinct patterns associated with the notes access task that explained approximately 77% of
the input data variation.
We examined whether the 9 notes access pattern variants were specific to physician
groups using the pattern utilization indicator model factor (Sk in Figure 7.4). This factor
describes the pattern utilization of each k-th encounter for all R variation patterns extracted.
To estimate the pattern utilization for each user (i.e. clinician), we simply estimate the mean
of all the R-dimensional encounters for each user. We used the tSNE [194] software to
visualize user representations, by reducing the 9-dimensional vectors to the 2-dimensional
space.
Figure 7.7 shows a clear separation of clinicians into two distinct groups (denoted as
Groups A and B on the left and bottom right part of Figure 7.7 respectively). We separately















Figure 7.7: tSNE visualization of the PCP patterns for Notes access. Each point in the 2-D
space corresponds to a PCPs relative position with respect to her pattern of utilization. The
key conclusion is that there do exist 2 distinct clouds of points corresponding to 2 groups
of primary care providers, based on the 9 variation patterns of notes access. Individual
axes can be safely ignored, as tSNE only preserves neighborhood information between
data points.
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Groups A and B were distinct in that the 6th variation pattern is the least used by group
A (4%), but is often used by group B (29%). The common activities for group B clinicians
is SmartSets activitity selected, which corresponds to a Wrap-Up tag in the EHR that is
available to directly access notes before closing a patient encounter in the EHR.
Group B clinicians rarely used the patterns 2, 5, and 7 (Figure 7.7). A common activity
of those patterns is the loading of the Visit Navigator, which is used by 30% of group B
clinicians, and only 0.5% of group A clinicians. The latter corresponds to use of the Visit
Navigator tag to access progress note in the EHR.
Finally, we independently worked with an EPIC expert and asked for a demonstration
of ways to access clinic notes. For each approach that was demonstrated we recorded the
underlying log record sequence of EPIC interface tags. Two dominant approaches to access
clinic notes were identified, one via the “Visit navigator” tag and one via “Wrap-Up” tag.
7.4 Discussion
Electronic health records (EHR) data are increasingly used to understand the relation be-
tween the care that was delivered and the change in patient outcomes. But, workflow
improvement efforts have a different focus, attempting to increase efficiency and effective-
ness of work processes within and between encounters and to monitor progress towards
efficiency. [225] Clinical data, alone, are usually insufficient to understand whether work-
flow efforts like “Lean process improvement” is working and, importantly, to understand
how it is working. In fact, a common criticism of healthcare workflow improvement work
is that it lacks scientific measurement principles supported by readily accessible contin-
ual data. Audit log data may be useful in providing a scientific foundation for workflow
management. Clinic practice workflow improvements (e.g., Lean principles) have not con-
sistently translated into sustainable efficiency improvements. [226] In part, this may be
because workflow efforts in health care lack a systematic and scalable approach to quanti-
fying processes before and after a workflow improvement are implemented. [219, 227]
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How work gets done has been described by Ulwick [224] and Christensen [228] as
fundamentally important to understanding how to innovate in ways that have a high proba-
bility of success. [228, 229] While these methods have been used in a diversity of business
sectors, little work has been done in healthcare. The volume and availability of audit log
files offers a means to understand how healthcare is delivered by PCPs and others and to
understand how work actually gets done. Access to this high-resolution data may offer a
means to accelerate innovations to making healthcare work easier and more effective.
Audit log file data have not been widely used to understand care processes. Adler-
Milstein et al. examined the impact of EHR platform usage on PCP productivity. [230] Tai-
Seale et al. analyzed the time allocation patterns of PCPs between seeing patients and using
the EHR platform. [231] Hirsch et al. used audit log file data to better understand clinical
workflow practices and the corresponding patient experience. [223] Hribar et al. exploited
the audit log file to calculate timings of clinical workflows. [232] Wetterneck et al. present
a PCP task list derived from human observations of encounters; such an approach though
has limited scalability due to the laborious nature of manual encounter observations. [233]
None of these previous studies used audit log data to reveal PCP tasks and to understand
how tasks get done (e.g., workflow variation patterns), nor to enable classification of EHR
users based on their EHR access variation patterns to complete clinical tasks. Our work is a
first step towards exploiting audit logs to understand PCP work processes. To this end, we
applied advanced machine learning methods to identify the most common tasks that PCPs
do during office encounter, as well as, common variants of those tasks. Our work opens
the possibility of developing scalable quantitative measurement tools to both understand
clinical tasks and the time required for these tasks.
One logical next step to this work is to link the task variation patterns with PCPs to
clinical efficiency measures (e.g. minimal time spending in specific EHR area): given
identification of user EHR utilization patterns to complete tasks, we could then estimate
which group is more efficient in term of time spent in the tasks and timely completeness
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of encounter documentation. This type of work could offer rapid means of improving
how EHRs could be more effectively used by PCPs, as well as, identifying EHR tasks
that are a challenge to complete or too time-consuming, as priority candidates for vendor
improvements.
Audit log data metrics could also be linked with clinical outcomes for defined patient
segments that vary by disease burden to study variation in clinical processes and demands.
In so doing, it may be possible to identify optimal approaches to use of the EHR for patient
subgroups. For example, patients with severe or complicated conditions require much more
time and effort by the PCPs during the encounter than less severe patients. Examination
of audit logs for encounters of patients who are very demanding may reveal specialized
workflows that facilitate the PCP’s use of the EHR and an increase in the volume of work
done with less effort.
Understanding audit log data is in its infancy. Our work and that of others is only
beginning to reveal the potential power of these data. Our preliminary use of PARAFAC2
revealed only five tasks. These were the most common. Future work will likely involve
an iterative process where the most common tasks are identified and documented. Once
these tasks are identified, the audit log records for these known, common tasks can be
eliminated so that less common tasks can be revealed. To this end, we recently eliminated
the audit log records associated with these first five tasks and then applied PARAFAC2
to the remaining log records. Not surprising, a new set of tasks were identified. While
we partially demonstrated this methodology by focusing on the Notes’ access variation
patterns, a systematic application of this idea is an important future direction to pursue in
ultimately creating an ontology that could be used to represent the content of audit log data.
7.5 Limitations
There are several limitations to the current work. We did not consider the frequency of
features within a task in each of our experiments. Duplicate features may represent ˜5% of
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consecutive activities. Retaining repeated features may increase the variation of patterns,
but it does not impact the identification of features that were used to represent a pattern
variation. The current task variation patterns captured ˜55% of EHR audit log record vari-
ation; We have not investigated the remaining 45% of variation, other than to note that
iterative application of PARAFAC2 reveals new tasks. As we have noted, removal of the
audit log records associated with these common tasks with re-application of PARAFAC2 to
the remaining log records identifies less common tasks. In addition to the four well-defined
clinical tasks we have identified, in-basket work (i.e. managing patient phone call, order
results, order authorization, emails with patients or other PCPs, referral, etc.) accounts
for 10-15% of PCP time. But, in-basket work is often done in fragments where individ-
ual tasks are interspersed among others. This makes it difficult to dissect these tasks from
log records. Future work on iterative extraction of tasks may reveal the details of how in-
basket work is done as a step towards reducing the growing demand that this work imposes
on PCPs.
In the absence of a signal or dictionary indicating the end of a task, we adopted the
simplifying assumption that all log records that are separated by less than a second are
part of the same potential task. While we acknowledge this simplification, we argue that
our approach fully utilizes log records at the available time-stamped resolution (i.e. one-
second) and is robust to the two scenarios that may occur from this assumption. First,
records grouped together may not belong to the same potential task. For example, in Fig-
ure 7.2, it is possible that “Visit Navigator template loaded” is an irrelevant log record to
the second potential task (timestamps 00:04-00:06). Still, PARAFAC2 would still capture
the (I Patient Encounter Opened, T Notes activity and navigators accessed) task if this was
prevalent in other encounters, whether or not it had the same timestamp as other features in
the set. Second, groups of records that should be collectively considered to indicate a single
task may be assigned to two different tasks by the model. For example, in Figure 7.2, it is
possible that both of the potential tasks we extracted should actually be grouped together
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to form a single task. Still, PARAFAC2 would capture more granular tasks if log records
composed to the tasks are commonly clustered together in other encounters.
Finally, clinical validation is needed to ensure that the labels we have applied to each
identified task indeed map to what a PCP is trying to accomplish following the correspond-
ing log record sequence. However, we believe that assigning the label based on the log
record with the highest weight (thus, indicating the most frequent record), as we did, is the
most reasonable data-driven way to label each task.
7.6 Conclusions
Our application of PARAFAC2 to audit log data offers an analytic approach that can facil-
itate the creation of ontologies or libraries that describe how healthcare work is done. We
believe this is a critical step towards creating innovations that successfully equip PCPs and
others to get more done with less effort and with a better experience.
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CHAPTER 8
CONCLUSION AND FUTURE WORK
In this dissertation, we demonstrate how tensor factorization can be applied and extended to
tackle several important problems in healthcare (unsupervised EHR-based phenotyping and
automating understanding of physician desktop work) and biomedicine (drug-perturbed,
tissue-specific gene expression prediction). In the following of this Chapter, we specify
future work directions focusing on EHR-based phenotyping, which is a central topic of this
dissertation.
Downstream healthcare tasks. Most of unsupervised phenotyping research (including
the Chapters 3, 4, 5, 6 presented as part of this dissertation) has focused on extracting
clinically-meaningful phenotype definitions. Utilizing the computed patient representa-
tions and phenotype definitions for downstream healthcare tasks is a ripe target for future
work. The low-rank patient representations computed can be used as features for predictive
modeling (e.g., towards early detection of heart failure which can provide with actionable
insights regarding treatment development and management [234]). A predictive model
based on the low-rank patient representations would provide a more clinically-meaningful,
thus interpretable, result as it would utilize a small set of higher-level validated features
indicating concrete patient phenotypes, as opposed to a large set of raw and noisy input
features. Previous work [24] has demonstrated proof-of-concept success towards inter-
pretable predictive modeling by collapsing the patient history to aggregate indicators of
medical code records. A next step is to assess whether modeling the longitudinal evolution
of patient records (as in Chapters 4, 5, 6) could provide patient representations with higher
predictive power. Utilizing the results of unsupervised phenotyping to identify similar pa-
tients and inform clinicians in the absence of gold-standard evidence is an additional target
for future work. Most of recent research towards this direction has focused on rule-based
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phenotypes [6], which are limited by the substantial expert supervision required to create
and maintain them.
Robust unsupervised phenotyping. Patients with the same named disease may differ in
the number or density of medical events, due to differences in disease severity, ability to
self-manage, interest in self-managing, poor access to care and other reasons. In essence,
there may be outlier patients (e.g., with many more encounter records than others) which
could obfuscate the patient phenotypes discovered. Prior work [235] tackles the challenge
of robust tensor factorization for the CP tensor model. Developing robust unsupervised
phenotyping methods which can handle the longitudinal evolution of patient data (e.g., via
the PARAFAC2 model) is a target for future work.
Incorporating additional EHR data domains. Finally, our work has been mostly focus-
ing on utilizing structured code information from the EHR. Including clinical text as well
as continuous values such as lab test information is an additional target for future work.
Modeling continuous lab values is particularly challenging for tensor-based approaches, as
this would render the result harder to interpret than with categorical input data.
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